|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein; Deoxycytidine inhibits the reaction [[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein]
|
CTD |
PMID:9297556 PMID:9403342 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
ISO
|
CYP1A1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]
|
CTD |
PMID:21907773 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions
|
ISO
|
CYP1A2 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP1A2 protein promotes the reaction [Estrone binds to Deoxyguanosine]
|
CTD |
PMID:21907773 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
multiple interactions
|
ISO
|
CYP1B1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]
|
CTD |
PMID:21907773 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions
|
ISO
|
CYP3A4 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP3A4 protein promotes the reaction [Estrone binds to Deoxyguanosine]
|
CTD |
PMID:21907773 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Mgmt
|
O-6-methylguanine-DNA methyltransferase
|
decreases activity
|
ISO
|
Deoxyguanosine analog results in decreased activity of MGMT protein
|
CTD |
PMID:17880193 |
|
NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482
|
|
|
G
|
Tymp
|
thymidine phosphorylase
|
increases abundance
|
ISO
|
TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate
|
CTD |
PMID:11103787 |
|
NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003
|
|
|
G
|
Tymp
|
thymidine phosphorylase
|
increases abundance
|
ISO
|
TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate
|
CTD |
PMID:11103787 |
|
NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003
|
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
multiple interactions
|
ISO
|
[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]
|
CTD |
PMID:35101544 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Nat2
|
N-acetyltransferase 2
|
multiple interactions
|
ISO
|
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]
|
CTD |
PMID:20545351 |
|
NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions
|
ISO
|
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
|
CTD |
PMID:20545351 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
P2ry1
|
purinergic receptor P2Y1
|
decreases activity
|
ISO
|
Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein
|
CTD |
PMID:22273509 |
|
NCBI chr 2:147,391,661...147,397,870
Ensembl chr 2:147,390,681...147,398,027
|
|
G
|
Sult1a1
|
sulfotransferase family 1A member 1
|
multiple interactions increases sulfation
|
ISO
|
2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein] SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate
|
CTD |
PMID:11425650 PMID:16601080 PMID:20545351 |
|
NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131
|
|
G
|
Sult2a1
|
sulfotransferase family 2A member 1
|
multiple interactions
|
ISO
|
[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol]
|
CTD |
PMID:15483193 |
|
NCBI chr 1:84,582,011...84,639,001
|
|
|
G
|
Adora3
|
adenosine A3 receptor
|
multiple interactions
|
EXP ISO
|
2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]]; 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein] [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Dizocilpine Maleate; [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Scopolamine; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein
|
CTD |
PMID:12672554 PMID:15452191 PMID:19966059 |
|
NCBI chr 2:196,077,042...196,080,686
Ensembl chr 2:196,077,042...196,080,686
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:16116186 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Birc3
|
baculoviral IAP repeat-containing 3
|
decreases expression decreases response to substance
|
ISO
|
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of BIRC3 mRNA BIRC3 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine
|
CTD |
PMID:16088125 |
|
NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
decreases response to substance
|
ISO
|
BIRC5 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine
|
CTD |
PMID:16088125 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
EXP
|
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of FOS mRNA]
|
CTD |
PMID:15452191 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Il12a
|
interleukin 12A
|
multiple interactions
|
ISO
|
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]
|
CTD |
PMID:16116186 |
|
NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997
|
|
G
|
Il12b
|
interleukin 12B
|
multiple interactions
|
ISO
|
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; Wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]
|
CTD |
PMID:16116186 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
G
|
Naip6
|
NLR family, apoptosis inhibitory protein 6
|
decreases response to substance decreases expression
|
ISO
|
NAIP protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of NAIP mRNA
|
CTD |
PMID:16088125 |
|
NCBI chr 2:33,241,520...33,293,184
Ensembl chr 2:33,241,521...33,276,859
|
|
G
|
Nppa
|
natriuretic peptide A
|
multiple interactions
|
EXP
|
2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]
|
CTD |
PMID:15452191 PMID:19966059 |
|
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493
|
|
G
|
Rgs2
|
regulator of G-protein signaling 2
|
multiple interactions
|
EXP
|
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of RGS2 mRNA]
|
CTD |
PMID:15452191 |
|
NCBI chr13:58,350,063...58,352,666
Ensembl chr13:58,349,163...58,352,697
|
|
G
|
Slc9a1
|
solute carrier family 9 member A1
|
multiple interactions
|
EXP
|
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of SLC9A1 protein]
|
CTD |
PMID:15452191 |
|
NCBI chr 5:150,859,412...150,913,525
Ensembl chr 5:150,860,228...150,913,517
|
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
decreases expression
|
ISO
|
5'-S-methyl-5'-thioadenosine decreases expression of Acta2 mRNA in Mdr2-/- mouse liver and liver myofibroblasts
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Adora2b
|
adenosine A2B receptor
|
multiple interactions
|
ISO
|
5'-S-methyl-5'-thioadenosine enhances the reaction [lipopolysaccharide increases expression of Adora2b mRNA in mouse liver myofibroblasts]
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
decreases phosphorylation multiple interactions
|
ISO
|
5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein IL7 protein inhibits the reaction [5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein]
|
CTD |
PMID:31712395 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
decreases expression
|
ISO
|
5'-S-methyl-5'-thioadenosine decreases expression of Ccl2 mRNA in Mdr2-/- mouse liver and myofibroblasts
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccnd1
|
cyclin D1
|
decreases expression
|
ISO
|
5'-S-methyl-5'-thioadenosine decreases expression of cyclin-D1 mRNA in Mdr2-/- mouse liver myofibroblasts
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
decreases expression
|
ISO
|
5'-methylthioadenosine results in decreased expression of COL1A1 mRNA 5'-S-methyl-5'-thioadenosine decreases expression of Col1a1 mRNA in Mdr2-/- mouse liver and liver myofibroblasts
|
CTD RGD |
PMID:15983038 PMID:21209952 |
RGD:153297773 |
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Col1a2
|
collagen type I alpha 2 chain
|
decreases expression
|
ISO
|
5'-methylthioadenosine results in decreased expression of COL1A2 mRNA
|
CTD |
PMID:15983038 |
|
NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995
|
|
G
|
Idh2
|
isocitrate dehydrogenase (NADP(+)) 2
|
increases abundance multiple interactions
|
ISO
|
IDH2 protein mutant form results in increased abundance of 5'-methylthioadenosine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 5'-methylthioadenosine]
|
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions decreases secretion
|
ISO
|
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IFNG mRNA] 5'-methylthioadenosine results in decreased secretion of IFNG protein
|
CTD |
PMID:17080400 PMID:31712395 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Ifnl1
|
interferon, lambda 1
|
multiple interactions
|
ISO
|
5'-methylthioadenosine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of IFNL1 mRNA]
|
CTD |
PMID:37611859 |
|
NCBI chr 1:92,926,184...92,927,830
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL1B mRNA]
|
CTD |
PMID:17080400 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il2
|
interleukin 2
|
multiple interactions decreases secretion
|
ISO
|
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL2 mRNA] 5'-methylthioadenosine results in decreased secretion of IL2 protein
|
CTD |
PMID:17080400 PMID:31712395 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672
|
|
G
|
Il33
|
interleukin 33
|
multiple interactions
|
ISO
|
5'-methylthioadenosine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of IL33 mRNA]
|
CTD |
PMID:37545493 |
|
NCBI chr 1:237,115,478...237,149,897
Ensembl chr 1:237,115,572...237,150,901
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions decreases expression
|
ISO
|
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL6 mRNA] 5'-S-methyl-5'-thioadenosine decreases expression of Il6 mRNA in Mdr2-/- mouse liver
|
CTD RGD |
PMID:17080400 PMID:21209952 |
RGD:153297773 |
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Il7
|
interleukin 7
|
multiple interactions
|
ISO
|
IL7 protein inhibits the reaction [5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein]
|
CTD |
PMID:31712395 |
|
NCBI chr 2:96,142,523...96,186,282
Ensembl chr 2:96,142,092...96,187,389
|
|
G
|
Jund
|
JunD proto-oncogene, AP-1 transcription factor subunit
|
decreases expression
|
ISO
|
5'-S-methyl-5'-thioadenosine decreases expression of JunD protein in Mdr2-/- mouse liver myofibroblasts
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,764,985...18,782,148
|
|
G
|
Ltb
|
lymphotoxin beta
|
multiple interactions
|
ISO
|
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of LTB mRNA]
|
CTD |
PMID:17080400 |
|
NCBI chr20:3,632,209...3,634,054
Ensembl chr20:3,632,210...3,634,054
|
|
G
|
Mdm4
|
MDM4 regulator of p53
|
multiple interactions
|
ISO
|
5'-methylthioadenosine affects the splicing of and affects the expression of MDM4 mRNA alternative form
|
CTD |
PMID:31712395 |
|
NCBI chr13:46,922,236...47,068,241
Ensembl chr13:46,958,298...47,026,372
|
|
G
|
Mki67
|
marker of proliferation Ki-67
|
decreases expression
|
ISO
|
5'-S-methyl-5'-thioadenosine decreases expression of Ki-67 protein in Mdr2-/- mouse liver
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593
|
|
G
|
Mmp13
|
matrix metallopeptidase 13
|
decreases expression
|
ISO
|
5'-S-methyl-5'-thioadenosine decreases expression of MMP13 mRNA in Mdr2-/- mouse liver
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
decreases phosphorylation
|
ISO
|
5'-methylthioadenosine results in decreased phosphorylation of MTOR protein
|
CTD |
PMID:31712395 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
decreases expression
|
ISO
|
5'-S-methyl-5'-thioadenosine decreases expression of iNOS mRNA in Mdr2-/- mouse liver
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Rps6
|
ribosomal protein S6
|
decreases phosphorylation
|
ISO
|
5'-methylthioadenosine results in decreased phosphorylation of RPS6 protein
|
CTD |
PMID:31712395 |
|
NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
decreases expression
|
ISO
|
5'-S-methyl-5'-thioadenosine decreases expression of Tgfb1 mRNA in Mdr2-/- mouse liver myofibroblasts
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tgfb2
|
transforming growth factor, beta 2
|
decreases expression
|
ISO
|
5'-S-methyl-5'-thioadenosine decreases expression of Tgfb2 mRNA in Mdr2-/- mouse liver and myofibroblasts
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856
|
|
G
|
Tnc
|
tenascin C
|
decreases expression
|
ISO
|
5'-S-methyl-5'-thioadenosine decreases expression of tenascin-C mRNA in Mdr2-/- mouse liver
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:82,391,340...82,476,131
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
5'-S-methyl-5'-thioadenosine inhibits the reaction [lipopolysaccharide increases expression of Tnf-alpha mRNA and protein in mouse liver myofibroblasts]
|
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression
|
ISO
|
5'-methylthioadenosine results in increased expression of TP53 protein
|
CTD |
PMID:31712395 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
|
G
|
Acan
|
aggrecan
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of ACAN mRNA
|
CTD |
PMID:39531065 |
|
NCBI chr 1:142,390,951...142,453,779
Ensembl chr 1:142,390,951...142,453,779
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
ISO
|
Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]
|
CTD |
PMID:22841775 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Adamts1
|
ADAM metallopeptidase with thrombospondin type 1 motif, 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of ADAMTS1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390
|
|
G
|
Adrb1
|
adrenoceptor beta 1
|
affects expression
|
ISO
|
Azacitidine affects the expression of ADRB1 mRNA
|
CTD |
PMID:19002953 |
|
NCBI chr 1:265,777,103...265,780,114
Ensembl chr 1:265,766,079...265,849,237
|
|
G
|
Adrb2
|
adrenoceptor beta 2
|
affects expression multiple interactions
|
ISO
|
Azacitidine affects the expression of ADRB2 mRNA Azacitidine inhibits the reaction [Particulate Matter results in decreased expression of ADRB2 mRNA]
|
CTD |
PMID:19002953 PMID:30986742 |
|
NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803
|
|
G
|
Afp
|
alpha-fetoprotein
|
increases expression
|
ISO
|
Azacitidine results in increased expression of AFP mRNA
|
CTD |
PMID:27590069 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649
|
|
G
|
Aggf1
|
angiogenic factor with G patch and FHA domains 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of AGGF1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 2:28,354,073...28,380,794
Ensembl chr 2:28,354,073...28,380,759
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
increases expression multiple interactions
|
ISO
|
Azacitidine results in increased expression of AHR mRNA [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]
|
CTD |
PMID:12927368 PMID:17682057 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Ak5
|
adenylate kinase 5
|
increases expression
|
ISO
|
Azacitidine results in increased expression of AK5 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:244,057,240...244,241,372
Ensembl chr 2:244,057,240...244,241,366
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
Azacitidine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:22841775 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Alad
|
aminolevulinate dehydratase
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of ALAD mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 5:80,977,562...80,987,901
Ensembl chr 5:80,977,562...80,988,041
|
|
G
|
Alb
|
albumin
|
decreases expression increases expression
|
ISO
|
Azacitidine results in decreased expression of ALB protein Azacitidine results in increased expression of ALB mRNA
|
CTD |
PMID:27590069 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
Aldh3a1
|
aldehyde dehydrogenase 3 family, member A1
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]]
|
CTD |
PMID:17682057 |
|
NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151
|
|
G
|
Andpro
|
androgen regulated protein
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CST4 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 3:157,171,739...157,178,262
Ensembl chr 3:157,171,740...157,178,104
|
|
G
|
Anxa1
|
annexin A1
|
decreases expression
|
EXP
|
Azacitidine results in decreased expression of ANXA1 protein
|
CTD |
PMID:17105402 |
|
NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831
|
|
G
|
App
|
amyloid beta precursor protein
|
decreases methylation multiple interactions
|
ISO
|
Azacitidine results in decreased methylation of APP promoter Azacitidine results in increased expression of and results in increased cleavage of APP protein; Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]
|
CTD |
PMID:19635394 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
G
|
Aqp5
|
aquaporin 5
|
decreases methylation increases expression multiple interactions
|
ISO
|
Azacitidine results in decreased methylation of AQP5 promoter Azacitidine results in increased expression of AQP5 protein [Azacitidine results in decreased methylation of AQP5 promoter] which results in increased expression of AQP5 mRNA; Azacitidine promotes the reaction [SP1 protein binds to AQP5 promoter]
|
CTD |
PMID:17198683 |
|
NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:132,601,059...132,605,062
|
|
G
|
Aqp9
|
aquaporin 9
|
multiple interactions increases expression
|
ISO
|
[Azacitidine results in increased expression of AQP9 mRNA] which results in increased uptake of arsenic trioxide; HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA]
|
CTD |
PMID:25953102 |
|
NCBI chr 8:80,678,027...80,718,273
Ensembl chr 8:80,678,030...80,717,240
|
|
G
|
Ar
|
androgen receptor
|
multiple interactions increases expression
|
ISO
|
[Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to bicalutamide; [Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to Dihydrotestosterone
|
CTD |
PMID:18324645 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467
|
|
G
|
Arhgap35
|
Rho GTPase activating protein 35
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ARHGAP35 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:86,330,566...86,447,414
Ensembl chr 1:86,330,566...86,447,414
|
|
G
|
Arhgef2
|
Rho/Rac guanine nucleotide exchange factor 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of ARHGEF2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:176,358,904...176,417,646
|
|
G
|
Art1
|
ADP-ribosyltransferase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ART1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:165,890,032...165,899,154
Ensembl chr 1:165,890,086...165,899,146
|
|
G
|
Asb2
|
ankyrin repeat and SOCS box-containing 2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ASB2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 6:128,239,550...128,275,833
Ensembl chr 6:128,239,552...128,266,321
|
|
G
|
Atp2b1
|
ATPase plasma membrane Ca2+ transporting 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of ATP2B1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:35,622,461...35,731,904
|
|
G
|
Atp6v0c
|
ATPase H+ transporting V0 subunit C
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ATP6V0C mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr10:13,700,764...13,707,147
Ensembl chr10:13,700,764...13,706,245
|
|
G
|
Aurka
|
aurora kinase A
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of AURKA mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771
|
|
G
|
Bad
|
BCL2-associated agonist of cell death
|
increases expression multiple interactions
|
EXP
|
Azacitidine results in increased expression of BAD mRNA [Azacitidine co-treated with entinostat] results in increased expression of BAD mRNA
|
CTD |
PMID:21224363 |
|
NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034
|
|
G
|
Bak1
|
BCL2-antagonist/killer 1
|
multiple interactions increases expression
|
EXP
|
[Azacitidine co-treated with entinostat] results in increased expression of BAK1 mRNA Azacitidine results in increased expression of BAK1 mRNA
|
CTD |
PMID:21224363 |
|
NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions increases expression
|
ISO
|
Bleomycin inhibits the reaction [Azacitidine results in increased expression of BAX mRNA]
|
CTD |
PMID:32278510 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcat1
|
branched chain amino acid transaminase 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of BCAT1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:179,695,662...179,777,288
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions decreases expression
|
ISO
|
Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 mRNA]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 protein] Azacitidine results in decreased expression of BCL2 mRNA; Azacitidine results in decreased expression of BCL2 protein
|
CTD |
PMID:32278510 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
multiple interactions affects expression
|
ISO
|
[metacept-1 co-treated with Azacitidine] results in decreased expression of BCL2L1 [Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein
|
CTD |
PMID:18443271 PMID:19148494 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
G
|
Bcl2l13
|
Bcl2-like 13
|
increases expression
|
ISO
|
Azacitidine results in increased expression of BCL2L13 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:155,728,284...155,785,058
Ensembl chr 4:155,728,284...155,781,158
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
increases expression decreases methylation multiple interactions
|
ISO
|
Azacitidine results in increased expression of BDNF mRNA Azacitidine results in decreased methylation of BDNF promoter Tetrodotoxin inhibits the reaction [Azacitidine results in decreased methylation of BDNF promoter]; Tetrodotoxin inhibits the reaction [Azacitidine results in increased expression of BDNF mRNA]
|
CTD |
PMID:18184782 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Bglap
|
bone gamma-carboxyglutamate protein
|
decreases expression increases expression
|
EXP ISO
|
Azacitidine results in decreased expression of BGLAP protein Azacitidine results in increased expression of OCN mRNA
|
CTD |
PMID:18037191 PMID:39531065 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318
|
|
G
|
Bicd1
|
BICD cargo adaptor 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of BICD1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:184,208,891...184,362,840
Ensembl chr 4:184,210,363...184,357,391
|
|
G
|
Bik
|
BCL2-interacting killer
|
multiple interactions increases expression
|
EXP
|
[Azacitidine co-treated with entinostat] results in increased expression of BIK mRNA Azacitidine results in increased expression of BIK mRNA
|
CTD |
PMID:21224363 |
|
NCBI chr 7:116,552,303...116,571,317
Ensembl chr 7:116,552,303...116,571,317
|
|
G
|
Bmp15
|
bone morphogenetic protein 15
|
increases expression
|
ISO
|
Azacitidine results in increased expression of BMP15 mRNA
|
CTD |
PMID:23395740 |
|
NCBI chr X:18,840,943...18,846,006
Ensembl chr X:18,840,829...18,847,438
|
|
G
|
Bnip3
|
BCL2 interacting protein 3
|
increases expression
|
ISO
|
Azacitidine results in increased expression of BNIP3 mRNA
|
CTD |
PMID:25446377 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962
|
|
G
|
Bok
|
BCL2 family apoptosis regulator BOK
|
multiple interactions increases expression
|
EXP
|
[Azacitidine co-treated with entinostat] results in increased expression of BOK mRNA Azacitidine results in increased expression of BOK mRNA
|
CTD |
PMID:21224363 |
|
NCBI chr 9:101,670,729...101,681,834
Ensembl chr 9:101,670,625...101,681,833
|
|
G
|
Bub1b
|
BUB1 mitotic checkpoint serine/threonine kinase B
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of BUB1B mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796
|
|
G
|
C17h6orf62
|
similar to human chromosome 6 open reading frame 62
|
increases expression
|
ISO
|
Azacitidine results in increased expression of C6ORF62 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr17:40,684,236...40,695,874
Ensembl chr17:40,684,236...40,704,043
|
|
G
|
C3ar1
|
complement C3a receptor 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of C3AR1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 4:157,747,419...157,756,609
Ensembl chr 4:157,746,089...157,776,323
|
|
G
|
Calca
|
calcitonin-related polypeptide alpha
|
decreases methylation
|
ISO
|
Azacitidine results in decreased methylation of CALCA promoter
|
CTD |
PMID:19299654 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529
|
|
G
|
Cald1
|
caldesmon 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CALD1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:64,232,906...64,414,085
Ensembl chr 4:64,233,171...64,414,085
|
|
G
|
Calhm2
|
calcium homeostasis modulator family member 2
|
increases expression multiple interactions
|
ISO
|
Azacitidine results in increased expression of CALHM2 mRNA Cisplatin affects the reaction [Azacitidine results in increased expression of CALHM2 mRNA]
|
CTD |
PMID:36336710 |
|
NCBI chr 1:255,963,661...255,969,387
Ensembl chr 1:255,963,663...255,969,387
|
|
G
|
Casp3
|
caspase 3
|
affects expression increases activity increases expression multiple interactions
|
ISO
|
Azacitidine affects the expression of CASP3 protein 5-azacytidine co-treated with doxorubicin increases activity of CASP3 protein in lung cancer cells Azacitidine results in increased expression of CASP3 mRNA [metacept-1 co-treated with Azacitidine] results in increased expression of CASP3
|
CTD RGD |
PMID:18443271 PMID:19148494 PMID:23395740 PMID:24356455 |
RGD:153344603 |
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CASP8 mRNA
|
CTD |
PMID:18082045 PMID:23395740 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CASP9 mRNA
|
CTD |
PMID:23395740 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Ccna1
|
cyclin A1
|
multiple interactions decreases expression
|
ISO
|
Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter]; Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]; Azacitidine promotes the reaction [H4C16 protein modified form binds to CCNA1 promoter] Azacitidine results in decreased expression of CCNA1 mRNA
|
CTD |
PMID:17698632 |
|
NCBI chr 2:141,383,352...141,428,205
Ensembl chr 2:141,382,468...141,393,300
|
|
G
|
Ccna2
|
cyclin A2
|
multiple interactions decreases expression
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of CCNA2 mRNA Azacitidine results in decreased expression of CCNA2 mRNA
|
CTD |
PMID:18720364 PMID:20823114 |
|
NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701
|
|
G
|
Ccnb1
|
cyclin B1
|
multiple interactions increases expression
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of CCNB1 mRNA Azacitidine results in increased expression of CCNB1 protein
|
CTD |
PMID:18720364 PMID:20607034 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
G
|
Ccnd1
|
cyclin D1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CCND1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Ccnd2
|
cyclin D2
|
affects methylation multiple interactions
|
ISO
|
Azacitidine affects the methylation of CCND2 promoter [Azacitidine affects the methylation of CCND2 promoter] which affects the expression of CCND2 mRNA
|
CTD |
PMID:17016690 |
|
NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:161,653,048...161,680,301 Ensembl chr 4:161,653,048...161,680,301
|
|
G
|
Ccng2
|
cyclin G2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of CCNG2 mRNA
|
CTD |
PMID:21245298 |
|
NCBI chr14:15,088,694...15,097,190
Ensembl chr14:15,088,695...15,096,206
|
|
G
|
Cd274
|
CD274 molecule
|
multiple interactions
|
ISO
|
Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]
|
CTD |
PMID:32894642 |
|
NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:236,496,463...236,549,951
|
|
G
|
Cdc20
|
cell division cycle 20
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of CDC20 mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799
|
|
G
|
Cdc42bpa
|
CDC42 binding protein kinase alpha
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of CDC42BPA mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr13:94,215,359...94,435,681
Ensembl chr13:94,215,959...94,435,681
|
|
G
|
Cdh1
|
cadherin 1
|
decreases methylation increases expression
|
ISO
|
Azacitidine results in decreased methylation of CDH1 promoter Azacitidine results in increased expression of CDH1 mRNA
|
CTD |
PMID:17520682 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Cdh2
|
cadherin 2
|
increases expression
|
EXP
|
Azacitidine results in increased expression of CDH2 mRNA
|
CTD |
PMID:18037191 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288
|
|
G
|
Cdk1
|
cyclin-dependent kinase 1
|
multiple interactions increases expression
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of CDK1 mRNA Azacitidine analog results in increased expression of CDK1 protein
|
CTD |
PMID:18324645 PMID:18720364 |
|
NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455
|
|
G
|
Cdk2
|
cyclin dependent kinase 2
|
decreases expression
|
ISO
|
Azacitidine analog results in decreased expression of CDK2 protein
|
CTD |
PMID:18324645 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878
|
|
G
|
Cdk4
|
cyclin-dependent kinase 4
|
decreases expression
|
ISO
|
Azacitidine analog results in decreased expression of CDK4 protein
|
CTD |
PMID:18324645 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression multiple interactions
|
ISO EXP
|
Azacitidine analog results in increased expression of CDKN1A protein; Azacitidine results in increased expression of CDKN1A mRNA [Azacitidine co-treated with entinostat] results in increased expression of CDKN1A mRNA; Azacitidine inhibits the reaction [potassium bromate results in increased expression of CDKN1A protein] [metacept-1 co-treated with Azacitidine] results in increased expression of CDKN1A
|
CTD |
PMID:18324645 PMID:19148494 PMID:20823114 PMID:21224363 PMID:25015661 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cdkn1c
|
cyclin-dependent kinase inhibitor 1C
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CDKN1C mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 1:208,084,801...208,087,680
Ensembl chr 1:208,084,787...208,087,498
|
|
G
|
Cdkn2a
|
cyclin-dependent kinase inhibitor 2A
|
multiple interactions decreases methylation affects methylation increases expression
|
EXP ISO
|
[Azacitidine co-treated with entinostat] results in decreased methylation of CDKN2A gene; [Azacitidine co-treated with entinostat] results in increased expression of CDKN2A mRNA Azacitidine inhibits the reaction [Particulate Matter results in increased methylation of CDKN2A promoter] Hydroxyurea inhibits the reaction [Azacitidine results in decreased methylation of CDKN2A gene] Azacitidine affects the methylation of CDKN2A gene Azacitidine results in increased expression of CDKN2A mRNA
|
CTD |
PMID:17686055 PMID:18443271 PMID:21224363 PMID:22355787 |
|
NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248
|
|
G
|
Cdkn2b
|
cyclin-dependent kinase inhibitor 2B
|
decreases methylation multiple interactions affects response to substance
|
ISO
|
Azacitidine results in decreased methylation of CDKN2B promoter [metacept-1 co-treated with Azacitidine] results in increased expression of CDKN2B CDKN2B promoter modified form affects the susceptibility to Azacitidine
|
CTD |
PMID:17611569 PMID:19148494 PMID:19194470 |
|
NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:109,114,322...109,134,855
|
|
G
|
Cebpa
|
CCAAT/enhancer binding protein alpha
|
decreases methylation increases expression
|
ISO
|
Azacitidine results in decreased methylation of CEBPA promoter Azacitidine results in increased expression of CEBPA mRNA
|
CTD |
PMID:19194470 PMID:27590069 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309
|
|
G
|
Cenpa
|
centromere protein A
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of CENPA mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 6:31,420,062...31,431,703
|
|
G
|
Cenpf
|
centromere protein F
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of CENPF mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr13:103,715,344...103,760,931
Ensembl chr13:103,715,344...103,760,886
|
|
G
|
Cenpo
|
centromere protein O
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CENPO mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 6:32,923,127...32,937,879
Ensembl chr 6:32,908,025...32,937,853
|
|
G
|
Chat
|
choline O-acetyltransferase
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CHAT mRNA; Azacitidine results in increased expression of CHAT protein
|
CTD |
PMID:19151599 |
|
NCBI chr16:7,663,665...7,723,416
Ensembl chr16:7,663,665...7,723,416
|
|
G
|
Chga
|
chromogranin A
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of CHGA protein
|
CTD |
PMID:20607034 |
|
NCBI chr 6:127,460,895...127,472,238
Ensembl chr 6:127,460,854...127,472,237
|
|
G
|
Chit1
|
chitinase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CHIT1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr13:48,117,886...48,165,645
Ensembl chr13:48,145,893...48,165,639
|
|
G
|
Chrm1
|
cholinergic receptor, muscarinic 1
|
affects expression
|
ISO
|
Azacitidine affects the expression of CHRM1 mRNA
|
CTD |
PMID:19002953 |
|
NCBI chr 1:214,996,180...215,012,136
Ensembl chr 1:214,995,872...215,020,602
|
|
G
|
Chrm2
|
cholinergic receptor, muscarinic 2
|
affects expression
|
ISO
|
Azacitidine affects the expression of CHRM2 mRNA
|
CTD |
PMID:19002953 |
|
NCBI chr 4:65,981,136...66,116,128
Ensembl chr 4:65,981,006...66,126,464
|
|
G
|
Chst14
|
carbohydrate sulfotransferase 14
|
increases expression
|
EXP
|
Azacitidine results in increased expression of CHST14 mRNA
|
CTD |
PMID:27415467 |
|
NCBI chr 3:126,370,348...126,372,405
Ensembl chr 3:126,370,348...126,372,777
|
|
G
|
Ciita
|
class II, major histocompatibility complex, transactivator
|
multiple interactions increases expression
|
ISO
|
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA] Azacitidine results in increased expression of CIITA mRNA
|
CTD |
PMID:18829986 PMID:20823114 |
|
NCBI chr10:5,646,854...5,694,393
Ensembl chr10:5,647,085...5,694,342
|
|
G
|
Cldn10
|
claudin 10
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of CLDN10 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr15:102,269,858...102,361,589
Ensembl chr15:102,269,858...102,361,589
|
|
G
|
Cldn6
|
claudin 6
|
increases expression decreases methylation multiple interactions
|
ISO
|
Azacitidine results in increased expression of CLDN6 mRNA Azacitidine results in decreased methylation of CLDN6 promoter [trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN6 promoter
|
CTD |
PMID:18661270 |
|
NCBI chr10:13,213,837...13,218,578
Ensembl chr10:13,213,956...13,218,581
|
|
G
|
Cldn7
|
claudin 7
|
multiple interactions decreases expression
|
ISO
|
Cisplatin affects the reaction [Azacitidine results in decreased expression of CLDN7 mRNA]
|
CTD |
PMID:36336710 |
|
NCBI chr10:55,188,670...55,190,871
Ensembl chr10:55,188,684...55,190,905
|
|
G
|
Cldn8
|
claudin 8
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CLDN8 mRNA
|
CTD |
PMID:18661270 |
|
NCBI chr11:41,362,081...41,364,330
|
|
G
|
Cldn9
|
claudin 9
|
decreases methylation multiple interactions increases expression
|
ISO
|
Azacitidine results in decreased methylation of CLDN9 promoter [trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN9 promoter Azacitidine results in increased expression of CLDN9 mRNA
|
CTD |
PMID:18661270 |
|
NCBI chr10:13,218,728...13,220,159
Ensembl chr10:13,218,729...13,220,178
|
|
G
|
Cnnm2
|
cyclin and CBS domain divalent metal cation transport mediator 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of CNNM2 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 1:255,585,063...255,709,455
Ensembl chr 1:255,585,095...255,704,849
|
|
G
|
Col14a1
|
collagen type XIV alpha 1 chain
|
increases expression
|
ISO
|
Azacitidine results in increased expression of COL14A1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:88,611,828...88,826,938
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
ISO
|
Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]
|
CTD |
PMID:22841775 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Col6a3
|
collagen type VI alpha 3 chain
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of COL6A3 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990
|
|
G
|
Col9a3
|
collagen type IX alpha 3 chain
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of COL9A3 mRNA
|
CTD |
PMID:18033690 |
|
NCBI chr 3:188,089,337...188,112,034
Ensembl chr 3:188,089,403...188,112,270
|
|
G
|
Cox6a2
|
cytochrome c oxidase subunit 6A2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of COX6A2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:192,218,970...192,221,188
Ensembl chr 1:192,218,970...192,219,716
|
|
G
|
Cpe
|
carboxypeptidase E
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CPE mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr16:29,796,707...29,908,647
Ensembl chr16:29,796,689...29,909,524
|
|
G
|
Cplx1
|
complexin 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CPLX1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr14:1,329,073...1,360,781
Ensembl chr14:1,329,032...1,360,769
|
|
G
|
Creb1
|
cAMP responsive element binding protein 1
|
multiple interactions
|
ISO
|
Azacitidine promotes the reaction [CREB1 protein modified form binds to PPP2CA promoter]
|
CTD |
PMID:19155497 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339
|
|
G
|
Creb3l4
|
cAMP responsive element binding protein 3-like 4
|
increases expression
|
EXP
|
Azacitidine results in increased expression of CREB3L4 mRNA
|
CTD |
PMID:27415467 |
|
NCBI chr 2:177,987,981...177,994,568
Ensembl chr 2:177,987,981...177,993,485
|
|
G
|
Crem
|
cAMP responsive element modulator
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of CREM mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr17:58,932,011...59,001,160
Ensembl chr17:58,934,147...59,001,160
|
|
G
|
Cryaa
|
crystallin, alpha A
|
increases expression
|
EXP
|
Azacitidine results in increased expression of CRYAA protein
|
CTD |
PMID:17105402 |
|
NCBI chr20:9,784,872...9,788,656
Ensembl chr20:9,784,857...9,788,654
|
|
G
|
Cryab
|
crystallin, alpha B
|
increases expression
|
EXP
|
Azacitidine results in increased expression of CRYAB protein
|
CTD |
PMID:17105402 |
|
NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528
|
|
G
|
Csf1
|
colony stimulating factor 1
|
increases expression
|
EXP
|
Azacitidine results in increased expression of CSF1 mRNA
|
CTD |
PMID:17156202 |
|
NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468
|
|
G
|
Csn1s1
|
casein alpha s1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CSN1S1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr14:20,622,858...20,638,849
|
|
G
|
Cst3
|
cystatin C
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CST3 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 3:156,790,061...156,794,116
Ensembl chr 3:156,790,079...156,793,937
|
|
G
|
Cxcl12
|
C-X-C motif chemokine ligand 12
|
decreases methylation increases expression
|
ISO
|
Azacitidine results in decreased methylation of CXCL12 promoter Azacitidine results in increased expression of CXCL12 mRNA; Azacitidine results in increased expression of CXCL12 protein
|
CTD |
PMID:19748759 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions increases expression
|
ISO
|
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] Azacitidine results in increased expression of CYP1A1 mRNA
|
CTD |
PMID:11281733 PMID:12927368 PMID:17682057 PMID:27590069 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions increases expression
|
ISO
|
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA] Azacitidine results in increased expression of CYP1A2 mRNA
|
CTD |
PMID:12927368 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
multiple interactions increases expression
|
ISO
|
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] Azacitidine results in increased expression of CYP1B1 mRNA
|
CTD |
PMID:12927368 PMID:27590069 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CYP3A4 mRNA
|
CTD |
PMID:27590069 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyth1
|
cytohesin 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of CYTH1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr10:103,901,376...103,984,496
Ensembl chr10:103,864,804...103,984,383
|
|
G
|
Dapk1
|
death associated protein kinase 1
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of DAPK1 promoter
|
CTD |
PMID:17557868 |
|
NCBI chr17:3,935,826...4,096,858
Ensembl chr17:3,935,625...4,096,581
|
|
G
|
Dcn
|
decorin
|
multiple interactions decreases expression
|
ISO
|
Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein] Azacitidine results in decreased expression of DCN mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926
|
|
G
|
Des
|
desmin
|
increases expression multiple interactions
|
EXP ISO
|
Azacitidine results in increased expression of DES mRNA; Azacitidine results in increased expression of DES protein [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA
|
CTD |
PMID:18037191 PMID:20823114 |
|
NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:84,298,447...84,307,347
|
|
G
|
Dhx9
|
DExH-box helicase 9
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of DHX9 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr13:68,152,813...68,189,580
Ensembl chr13:68,152,813...68,189,546
|
|
G
|
Dio2
|
iodothyronine deiodinase 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of DIO2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594
|
|
G
|
Dlk1
|
delta like non-canonical Notch ligand 1
|
decreases methylation
|
ISO
|
Azacitidine results in decreased methylation of DLK1 promoter
|
CTD |
PMID:19194470 |
|
NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:134,192,518...134,200,529
|
|
G
|
Dlx5
|
distal-less homeobox 5
|
increases expression
|
ISO
|
Azacitidine results in increased expression of DLX5 mRNA
|
CTD |
PMID:17085970 |
|
NCBI chr 4:35,965,579...35,969,973
Ensembl chr 4:35,965,579...35,969,845
|
|
G
|
Dlx6
|
distal-less homeobox 6
|
increases expression
|
ISO
|
Azacitidine results in increased expression of DLX6 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:35,951,005...35,956,354
Ensembl chr 4:35,951,005...35,956,354
|
|
G
|
Dnmt1
|
DNA methyltransferase 1
|
multiple interactions decreases expression
|
ISO EXP
|
[SLC28A1 protein results in increased uptake of Azacitidine] which results in decreased expression of DNMT1 protein; Arsenic Trioxide promotes the reaction [Azacitidine results in decreased expression of DNMT1 protein]; Azacitidine inhibits the reaction [DNMT1 protein binds to MIR497 promoter] Azacitidine results in decreased expression of DNMT1 mRNA [Azacitidine co-treated with entinostat] results in decreased expression of DNMT1 protein; [Cisplatin co-treated with Azacitidine] results in decreased expression of DNMT1 protein
|
CTD |
PMID:19139132 PMID:19723570 PMID:21224363 PMID:28901456 PMID:35066776 PMID:39331569 More...
|
|
NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119
|
|
G
|
Dnmt3a
|
DNA methyltransferase 3 alpha
|
multiple interactions decreases expression
|
ISO
|
Azacitidine inhibits the reaction [DNMT3A protein binds to MIR497 promoter] Azacitidine results in decreased expression of DNMT3A mRNA
|
CTD |
PMID:35066776 PMID:39331569 |
|
NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970
|
|
G
|
Dnmt3b
|
DNA methyltransferase 3 beta
|
multiple interactions decreases expression
|
ISO
|
Azacitidine inhibits the reaction [DNMT3B protein binds to MIR497 promoter] Azacitidine results in decreased expression of DNMT3B mRNA
|
CTD |
PMID:35066776 PMID:39331569 |
|
NCBI chr 3:162,590,777...162,629,313
Ensembl chr 3:162,604,037...162,629,313
|
|
G
|
Dpyd
|
dihydropyrimidine dehydrogenase
|
decreases methylation multiple interactions decreases response to substance
|
ISO
|
Azacitidine results in decreased methylation of DPYD promoter [Azacitidine results in decreased methylation of DPYD promoter] which results in increased expression of DPYD mRNA DPYD protein results in decreased susceptibility to Azacitidine
|
CTD |
PMID:15501990 |
|
NCBI chr 2:209,293,902...210,159,777
Ensembl chr 2:209,293,929...210,159,778
|
|
G
|
Dusp1
|
dual specificity phosphatase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of DUSP1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644
|
|
G
|
Dusp6
|
dual specificity phosphatase 6
|
increases expression
|
ISO
|
Azacitidine results in increased expression of DUSP6 mRNA
|
CTD |
PMID:21245298 |
|
NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833
|
|
G
|
E2f1
|
E2F transcription factor 1
|
multiple interactions
|
ISO
|
E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]
|
CTD |
PMID:19451745 |
|
NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563
|
|
G
|
Eef1a1
|
eukaryotic translation elongation factor 1 alpha 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of EEF1A1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 8:88,221,839...88,225,688
Ensembl chr 8:88,221,843...88,225,072
|
|
G
|
Efna3
|
ephrin A3
|
increases expression
|
ISO
|
Azacitidine results in increased expression of EFNA3 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:177,026,928...177,035,838
Ensembl chr 2:177,026,933...177,044,843
|
|
G
|
Egr2
|
early growth response 2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of EGR2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748
|
|
G
|
Eno2
|
enolase 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of ENO2 protein
|
CTD |
PMID:20607034 |
|
NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220
|
|
G
|
Entpd1
|
ectonucleoside triphosphate diphosphohydrolase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ENTPD1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:249,374,810...249,502,310
Ensembl chr 1:249,374,836...249,502,317
|
|
G
|
Esr1
|
estrogen receptor 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ESR1 protein
|
CTD |
PMID:22558281 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
G
|
Ets1
|
ETS proto-oncogene 1, transcription factor
|
multiple interactions
|
ISO
|
Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL4 promoter]
|
CTD |
PMID:18945643 |
|
NCBI chr 8:39,303,936...39,426,022
Ensembl chr 8:39,303,925...39,426,021
|
|
G
|
Eya1
|
EYA transcriptional coactivator and phosphatase 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of EYA1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:9,646,591...9,884,614
|
|
G
|
Fads2
|
fatty acid desaturase 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of FADS2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066
|
|
G
|
Fam8a1
|
family with sequence similarity 8, member A1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of FAM8A1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr17:18,232,834...18,241,736
Ensembl chr17:18,232,834...18,241,703
|
|
G
|
Faslg
|
Fas ligand
|
increases response to substance
|
ISO
|
Azacitidine results in increased susceptibility to FASLG protein
|
CTD |
PMID:18829727 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
Fbln1
|
fibulin 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of FBLN1 mRNA
|
CTD |
PMID:21245298 |
|
NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:118,190,478...118,269,965
|
|
G
|
Fen1
|
flap structure-specific endonuclease 1
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of FEN1 mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 1:216,270,016...216,274,873
Ensembl chr 1:216,269,163...216,275,016
|
|
G
|
Fgf7
|
fibroblast growth factor 7
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of FGF7 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 3:133,734,557...133,786,678
Ensembl chr 3:133,734,673...133,786,328
|
|
G
|
Filip1l
|
filamin A interacting protein 1-like
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of FILIP1L mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr11:56,403,467...56,646,422
Ensembl chr11:56,410,582...56,646,402
|
|
G
|
Foxo1
|
forkhead box O1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419
|
|
G
|
Foxp3
|
forkhead box P3
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with TGFB1 protein] results in increased expression of FOXP3 protein; [Azacitidine results in decreased methylation of FOXP3 gene] which results in increased expression of FOXP3 protein
|
CTD |
PMID:18493985 |
|
NCBI chr X:17,580,380...17,601,181
Ensembl chr X:17,580,380...17,595,894
|
|
G
|
Ftl1
|
ferritin light chain 1
|
decreases expression
|
EXP
|
Azacitidine results in decreased expression of FTL1 protein
|
CTD |
PMID:17105402 |
|
NCBI chr 1:105,072,858...105,074,705
Ensembl chr X:45,399,355...45,399,915 Ensembl chr 2:45,399,355...45,399,915 Ensembl chr 1:45,399,355...45,399,915
|
|
G
|
Fyn
|
FYN proto-oncogene, Src family tyrosine kinase
|
increases expression
|
ISO
|
Azacitidine results in increased expression of FYN mRNA
|
CTD |
PMID:21245298 |
|
NCBI chr20:44,322,635...44,514,498
Ensembl chr20:44,322,361...44,515,479
|
|
G
|
Gabrb1
|
gamma-aminobutyric acid type A receptor subunit beta1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of GABRB1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr14:36,434,339...36,917,920
Ensembl chr14:36,434,352...36,902,893
|
|
G
|
Gadd45a
|
growth arrest and DNA-damage-inducible, alpha
|
decreases methylation multiple interactions increases expression
|
ISO
|
Azacitidine results in decreased methylation of GADD45A promoter [Azacitidine results in increased expression of GADD45A protein] which results in increased susceptibility to docetaxel Azacitidine results in increased expression of GADD45A mRNA; Azacitidine results in increased expression of GADD45A protein
|
CTD |
PMID:19190346 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807
|
|
G
|
Gadd45b
|
growth arrest and DNA-damage-inducible, beta
|
multiple interactions
|
ISO
|
Azacitidine promotes the reaction [Depsipeptides results in increased expression of GADD45B]
|
CTD |
PMID:18225533 |
|
NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718
|
|
G
|
Gata4
|
GATA binding protein 4
|
increases expression
|
EXP
|
Azacitidine results in increased expression of GATA4 mRNA; Azacitidine results in increased expression of GATA4 protein
|
CTD |
PMID:18037191 |
|
NCBI chr15:41,635,572...41,707,252
Ensembl chr15:41,635,572...41,681,609
|
|
G
|
Gbp2
|
guanylate binding protein 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of GBP2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:234,008,590...234,021,810
|
|
G
|
Gcnt2
|
glucosaminyl (N-acetyl) transferase 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of GCNT2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr17:24,002,592...24,107,339
Ensembl chr17:24,002,597...24,106,989
|
|
G
|
Gdf9
|
growth differentiation factor 9
|
increases expression
|
ISO
|
Azacitidine results in increased expression of GDF9 mRNA
|
CTD |
PMID:23395740 |
|
NCBI chr10:38,090,021...38,100,801
Ensembl chr10:38,089,878...38,100,797
|
|
G
|
Gja1
|
gap junction protein, alpha 1
|
increases expression decreases expression
|
EXP ISO
|
Azacitidine results in increased expression of GJA1 protein Azacitidine results in decreased expression of GJA1 mRNA
|
CTD |
PMID:18037191 PMID:20823114 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689
|
|
G
|
Glb1
|
galactosidase, beta 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of GLB1 protein
|
CTD |
PMID:39531065 |
|
NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:122,963,718...123,036,326
|
|
G
|
Gng7
|
G protein subunit gamma 7
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of GNG7 promoter
|
CTD |
PMID:18219292 |
|
NCBI chr 7:9,348,148...9,411,924
Ensembl chr 7:9,348,218...9,411,923
|
|
G
|
Gpkow
|
G patch domain and KOW motifs
|
increases expression
|
ISO
|
Azacitidine results in increased expression of GPKOW mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr X:17,463,521...17,478,298
Ensembl chr X:17,463,525...17,478,298
|
|
G
|
Gpnmb
|
glycoprotein nmb
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of GPNMB mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:79,341,128...79,362,366
Ensembl chr 4:79,341,021...79,380,240
|
|
G
|
Gpx3
|
glutathione peroxidase 3
|
increases expression
|
ISO
|
5-azacytidine increases expression of GPX3 mRNA in epithelial cells of stomach
|
RGD |
PMID:16229808 |
RGD:151665354 |
NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,529,448...39,537,405
|
|
G
|
Grin2b
|
glutamate ionotropic receptor NMDA type subunit 2B
|
decreases methylation
|
ISO
|
Azacitidine results in decreased methylation of GRIN2B gene
|
CTD |
PMID:18618247 |
|
NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:170,322,617...170,773,570
|
|
G
|
Guk1
|
guanylate kinase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of GUK1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr10:44,471,075...44,488,332
Ensembl chr10:44,471,085...44,479,355
|
|
G
|
Gzmb
|
granzyme B
|
multiple interactions
|
ISO
|
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein]
|
CTD |
PMID:19394699 |
|
NCBI chr15:34,459,007...34,462,469
Ensembl chr15:34,459,007...34,462,469
|
|
G
|
H1f0
|
H1.0 linker histone
|
increases expression
|
ISO
|
Azacitidine results in increased expression of H1-0 protein
|
CTD |
PMID:16006241 |
|
NCBI chr 7:112,473,280...112,475,140
Ensembl chr 7:112,473,222...112,475,006
|
|
G
|
H2ax
|
H2A.X variant histone
|
increases expression multiple interactions
|
ISO EXP
|
Azacitidine results in increased expression of H2AX protein Azacitidine inhibits the reaction [potassium bromate results in increased phosphorylation of H2AX protein]
|
CTD |
PMID:17991895 PMID:25015661 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
H3f4
|
H3.4 histone, cluster member
|
multiple interactions
|
ISO
|
Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]
|
CTD |
PMID:17698632 |
|
NCBI chr10:44,240,282...44,240,842
|
|
G
|
Hgd
|
homogentisate 1, 2-dioxygenase
|
increases expression
|
ISO
|
Azacitidine results in increased expression of HGD mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr11:76,592,202...76,643,776
Ensembl chr11:76,592,204...76,643,767
|
|
G
|
Hgf
|
hepatocyte growth factor
|
increases expression
|
ISO
|
Azacitidine results in increased expression of HGF mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851
|
|
G
|
Hhex
|
hematopoietically expressed homeobox
|
increases expression
|
ISO
|
Azacitidine results in increased expression of HHEX mRNA
|
CTD |
PMID:27590069 |
|
NCBI chr 1:244,602,945...244,608,532
Ensembl chr 1:244,602,825...244,608,604
|
|
G
|
Hmga1
|
high mobility group AT-hook 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of HMGA1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr20:5,612,902...5,620,596
Ensembl chr20:5,613,471...5,620,593
|
|
G
|
Hmga2
|
high mobility group AT-hook 2
|
increases expression multiple interactions
|
ISO
|
Azacitidine results in increased expression of HMGA2 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of HMGA2 mRNA]
|
CTD |
PMID:21245298 |
|
NCBI chr 7:57,762,710...57,884,555
Ensembl chr 7:57,765,675...57,880,341
|
|
G
|
Hmgb1
|
high mobility group box 1
|
decreases expression multiple interactions
|
ISO
|
Azacitidine results in decreased expression of HMGB1 mRNA Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of HMGB1 mRNA]
|
CTD |
PMID:32278510 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327 Ensembl chr12:39,039,050...39,041,327
|
|
G
|
Hnf1a
|
HNF1 homeobox A
|
decreases methylation multiple interactions increases expression
|
ISO
|
Azacitidine results in decreased methylation of HNF1A promoter HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA] Azacitidine results in increased expression of HNF1A mRNA; Azacitidine results in increased expression of HNF1A protein
|
CTD |
PMID:25953102 |
|
NCBI chr12:47,299,171...47,333,457
Ensembl chr12:47,306,245...47,332,755
|
|
G
|
Hnf4a
|
hepatocyte nuclear factor 4, alpha
|
increases expression
|
ISO
|
Azacitidine results in increased expression of HNF4A mRNA
|
CTD |
PMID:27590069 |
|
NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:172,606,220...172,667,758
|
|
G
|
Hoxa1
|
homeobox A1
|
multiple interactions increases expression
|
ISO
|
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA] Azacitidine results in increased expression of HOXA1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:82,586,505...82,589,209
Ensembl chr 4:82,586,505...82,589,209
|
|
G
|
Hpgd
|
15-hydroxyprostaglandin dehydrogenase
|
decreases methylation multiple interactions increases expression
|
ISO
|
Azacitidine results in decreased methylation of HPGD gene trichostatin A promotes the reaction [Azacitidine results in increased expression of HPGD mRNA]
|
CTD |
PMID:19584167 |
|
NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831
|
|
G
|
Hsd3b1
|
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1
|
affects expression
|
ISO
|
Azacitidine affects the expression of HSD3B1 mRNA
|
CTD |
PMID:18033690 |
|
NCBI chr 2:188,858,574...188,864,694
|
|
G
|
Hsf1
|
heat shock transcription factor 1
|
decreases activity
|
ISO
|
Azacitidine results in decreased activity of HSF1 protein
|
CTD |
PMID:34170685 |
|
NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665
|
|
G
|
Hspa6l-ps1
|
heat shock protein family A (Hsp70) member 6 like, pseudogene 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of HSPA6 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr13:85,805,911...85,807,052
|
|
G
|
Id1
|
inhibitor of DNA binding 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ID1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685
|
|
G
|
Id3
|
inhibitor of DNA binding 3
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ID3 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:153,630,498...153,657,856
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]; [Azacitidine results in increased expression of KIR2DL4 protein] which results in increased secretion of IFNG protein
|
CTD |
PMID:18829986 PMID:18945643 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Igfbp1
|
insulin-like growth factor binding protein 1
|
multiple interactions increases expression
|
ISO
|
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein] Azacitidine results in increased expression of IGFBP1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344
|
|
G
|
Igfbp4
|
insulin-like growth factor binding protein 4
|
increases expression
|
ISO
|
Azacitidine results in increased expression of IGFBP4 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr10:84,491,471...84,503,487
Ensembl chr10:84,485,775...84,503,473
|
|
G
|
Il12b
|
interleukin 12B
|
increases expression
|
ISO
|
Azacitidine results in increased expression of IL12B mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
G
|
Il1b
|
interleukin 1 beta
|
increases expression multiple interactions
|
EXP ISO
|
Azacitidine results in increased expression of IL1B mRNA Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]
|
CTD |
PMID:17156202 PMID:32894642 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il2
|
interleukin 2
|
multiple interactions
|
ISO
|
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein]; Azacitidine inhibits the reaction [IL2 protein results in increased secretion of PRF1 protein]
|
CTD |
PMID:19394699 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672
|
|
G
|
Il4
|
interleukin 4
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of IL4 promoter
|
CTD |
PMID:18158872 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549
|
|
G
|
Il6
|
interleukin 6
|
affects secretion affects methylation
|
ISO
|
Azacitidine affects the secretion of IL6 protein Azacitidine affects the methylation of IL6 promoter
|
CTD |
PMID:18158872 PMID:18443271 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Il6r
|
interleukin 6 receptor
|
affects expression multiple interactions
|
ISO
|
[Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein; Azacitidine affects the expression of IL6R mRNA [Azacitidine affects the expression of IL6R protein] which affects the phosphorylation of STAT3 protein
|
CTD |
PMID:18443271 |
|
NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221
|
|
G
|
Isca1
|
iron-sulfur cluster assembly 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ISCA1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr17:4,910,816...4,923,478
Ensembl chr17:4,910,795...4,923,476
|
|
G
|
Itgb1
|
integrin subunit beta 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of ITGB1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269
|
|
G
|
Itgb2
|
integrin subunit beta 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of ITGB2 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr20:11,061,009...11,097,242
Ensembl chr20:11,058,492...11,097,182
|
|
G
|
Itprid2
|
ITPR interacting domain containing 2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ITPRID2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 3:84,943,572...84,980,993
Ensembl chr 3:84,939,808...84,980,899
|
|
G
|
Kdr
|
kinase insert domain receptor
|
increases expression
|
EXP
|
Azacitidine results in increased expression of KDR mRNA
|
CTD |
PMID:18037191 |
|
NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192
|
|
G
|
Kif2c
|
kinesin family member 2C
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of KIF2C mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 5:135,873,925...135,899,267
Ensembl chr 5:135,873,925...135,899,212
|
|
G
|
Kir3dl1
|
killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1
|
increases expression decreases methylation
|
ISO
|
Azacitidine results in increased expression of KIR3DL1 mRNA; Azacitidine results in increased expression of KIR3DL1 protein Azacitidine results in decreased methylation of KIR3DL1 promoter
|
CTD |
PMID:18945643 PMID:19394699 |
|
NCBI chr 1:78,756,035...78,796,961
Ensembl chr 1:78,757,394...78,796,715
|
|
G
|
Klf6
|
KLF transcription factor 6
|
increases expression multiple interactions
|
ISO
|
Azacitidine results in increased expression of KLF6 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of KLF6 mRNA]
|
CTD |
PMID:21245298 |
|
NCBI chr17:69,449,483...69,458,478
Ensembl chr17:69,441,493...69,498,601
|
|
G
|
Klk1c10
|
kallikrein 1-related peptidase C10
|
increases expression
|
ISO
|
Azacitidine analog results in increased expression of KLK3 protein
|
CTD |
PMID:18324645 |
|
NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586
|
|
G
|
Krt19
|
keratin 19
|
increases expression
|
ISO
|
Azacitidine results in increased expression of KRT19 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr10:85,576,235...85,580,952
Ensembl chr10:85,576,235...85,580,952
|
|
G
|
Krt32
|
keratin 32
|
increases expression
|
ISO
|
Azacitidine results in increased expression of KRT32 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr10:85,513,951...85,520,978
Ensembl chr10:85,513,951...85,520,978
|
|
G
|
Krt8
|
keratin 8
|
multiple interactions increases expression
|
ISO
|
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA] Azacitidine results in increased expression of KRT8 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403
|
|
G
|
Lama1
|
laminin subunit alpha 1
|
affects localization
|
ISO
|
Azacitidine affects the localization of LAMA1 protein
|
CTD |
PMID:18033690 |
|
NCBI chr 9:115,139,548...115,263,620
Ensembl chr 9:115,139,548...115,264,251
|
|
G
|
Lamb2
|
laminin subunit beta 2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of LAMB2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 8:118,056,899...118,069,090
Ensembl chr 8:118,056,935...118,069,090
|
|
G
|
Ldhb
|
lactate dehydrogenase B
|
increases expression
|
ISO
|
Azacitidine results in increased expression of LDHB mRNA
|
CTD |
PMID:23437403 |
|
NCBI chr 4:177,159,389...177,177,408
Ensembl chr 4:177,159,392...177,177,408
|
|
G
|
Lims1
|
LIM zinc finger domain containing 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of LIMS1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr20:26,851,364...26,961,607
Ensembl chr20:26,852,996...26,961,606
|
|
G
|
Litaf
|
lipopolysaccharide-induced TNF factor
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of LITAF mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr10:5,163,258...5,199,930
Ensembl chr10:5,163,242...5,199,930
|
|
G
|
Ltb4r
|
leukotriene B4 receptor
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of LTB4R mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr15:33,233,120...33,235,636
Ensembl chr15:33,232,820...33,235,637
|
|
G
|
Lyz2
|
lysozyme 2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of LYZ mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011
|
|
G
|
Mad1l1
|
mitotic arrest deficient 1 like 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of MAD1L1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr12:19,434,782...19,744,574
Ensembl chr12:19,434,746...19,744,567
|
|
G
|
Mafb
|
MAF bZIP transcription factor B
|
increases expression multiple interactions
|
ISO
|
Azacitidine results in increased expression of MAFB mRNA Cisplatin affects the reaction [Azacitidine results in increased expression of MAFB mRNA]
|
CTD |
PMID:36336710 |
|
NCBI chr 3:169,417,890...169,419,810
Ensembl chr 3:169,416,945...169,419,975
|
|
G
|
Map1a
|
microtubule-associated protein 1A
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of MAP1A mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 3:128,716,907...128,736,638
Ensembl chr 3:128,716,940...128,740,159
|
|
G
|
Map2k5
|
mitogen activated protein kinase kinase 5
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of MAP2K5 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 8:72,520,616...72,748,395
Ensembl chr 8:72,520,617...72,747,373
|
|
G
|
Mapt
|
microtubule-associated protein tau
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of MAPT protein
|
CTD |
PMID:16930453 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108
|
|
G
|
Mcl1
|
MCL1 apoptosis regulator, BCL2 family member
|
decreases expression
|
ISO
|
5-azacytidine decreases expression of MCL1 protein in lung cancer cells
|
RGD |
PMID:24356455 |
RGD:153344603 |
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782
|
|
G
|
Mcm5
|
minichromosome maintenance complex component 5
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of MCM5 mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,488,813...13,517,758
|
|
G
|
Mdc1
|
mediator of DNA damage checkpoint 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of MDC1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr20:2,898,496...2,914,960
Ensembl chr20:2,900,308...2,914,960
|
|
G
|
Mdm2
|
MDM2 proto-oncogene
|
increases expression
|
ISO
|
Azacitidine results in increased expression of MDM2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
G
|
Mecp2
|
methyl CpG binding protein 2
|
multiple interactions
|
ISO
|
Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter]
|
CTD |
PMID:17698632 |
|
NCBI chr X:156,932,481...156,995,981
Ensembl chr X:156,941,234...156,943,560
|
|
G
|
Mef2a
|
myocyte enhancer factor 2a
|
increases expression affects expression
|
ISO
|
Azacitidine results in increased expression of MEF2A Azacitidine affects the expression of MEF2A protein
|
CTD |
PMID:12094073 PMID:19002953 |
|
NCBI chr 1:130,258,083...130,392,819
Ensembl chr 1:130,260,339...130,392,162
|
|
G
|
Mef2d
|
myocyte enhancer factor 2D
|
affects expression increases expression
|
ISO
|
Azacitidine affects the expression of MEF2D protein Azacitidine results in increased expression of MEF2D
|
CTD |
PMID:12094073 PMID:19002953 |
|
NCBI chr 2:175,904,332...175,933,451
Ensembl chr 2:175,903,959...175,930,760
|
|
G
|
Megf6
|
multiple EGF-like-domains 6
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of MEGF6 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 5:170,020,699...170,121,557
Ensembl chr 5:170,020,778...170,121,554
|
|
G
|
Mesd
|
mesoderm development LRP chaperone
|
decreases expression
|
EXP
|
Azacitidine results in decreased expression of MESD protein
|
CTD |
PMID:17105402 |
|
NCBI chr 1:147,275,904...147,289,134
Ensembl chr 1:147,275,396...147,289,134
|
|
G
|
Mfap2
|
microfibril associated protein 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of MFAP2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 5:158,595,121...158,603,283
Ensembl chr 5:158,597,512...158,610,656
|
|
G
|
Mfge8
|
milk fat globule EGF and factor V/VIII domain containing
|
affects expression
|
ISO
|
Azacitidine affects the expression of MFGE8 mRNA
|
CTD |
PMID:18033690 |
|
NCBI chr 1:142,474,027...142,489,431
Ensembl chr 1:142,474,028...142,489,431
|
|
G
|
Mgmt
|
O-6-methylguanine-DNA methyltransferase
|
increases expression decreases methylation
|
ISO
|
Azacitidine results in increased expression of MGMT mRNA Azacitidine results in decreased methylation of MGMT protein
|
CTD |
PMID:7511991 PMID:12807730 |
|
NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482
|
|
G
|
Mir193a
|
microRNA 193a
|
increases expression
|
ISO
|
5-azacytidine increases expression of MIR193A in liver cells 5-azacytidine increases expression of MIR193a RNA in lung cancer cells
|
RGD |
PMID:28036298 PMID:24356455 |
RGD:153344564, RGD:153344603 |
NCBI chr10:65,170,306...65,170,417
|
|
G
|
Mir23b
|
microRNA 23b
|
increases expression
|
ISO
|
5-azacytidine increases expression of MIR23B miRNA in liver cells
|
RGD |
PMID:28036298 |
RGD:153344564 |
NCBI chr17:1,819,386...1,819,482
|
|
G
|
Mir497
|
microRNA 497
|
increases expression multiple interactions decreases methylation
|
ISO
|
Azacitidine results in increased expression of MIR497 mRNA Azacitidine inhibits the reaction [DNMT1 protein binds to MIR497 promoter]; Azacitidine inhibits the reaction [DNMT3A protein binds to MIR497 promoter]; Azacitidine inhibits the reaction [DNMT3B protein binds to MIR497 promoter] Azacitidine results in decreased methylation of MIR497 promoter
|
CTD |
PMID:35066776 |
|
NCBI chr10:55,450,171...55,450,239
Ensembl chr10:55,450,162...55,450,241
|
|
G
|
Mir9-3
|
microRNA 9-3
|
increases expression
|
ISO
|
5-azacytidine increases expression of MIR9-3 in lung cancer cells
|
RGD |
PMID:24356455 |
RGD:153344603 |
NCBI chr 1:142,849,400...142,849,489
|
|
G
|
Mki67
|
marker of proliferation Ki-67
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of MKI67 mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593
|
|
G
|
Mmp1
|
matrix metallopeptidase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of MMP1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
ISO
|
metacept-1 inhibits the reaction [Azacitidine results in increased expression of MMP9]
|
CTD |
PMID:19148494 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Morf4l2
|
mortality factor 4 like 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of MORF4L2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr X:104,874,850...104,885,946
Ensembl chr X:104,852,693...104,892,855
|
|
G
|
Mov10l1
|
Mov10 like RNA helicase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of MOV10L1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 7:121,949,743...122,015,042
Ensembl chr 7:121,949,822...122,015,042
|
|
G
|
Msrb2
|
methionine sulfoxide reductase B2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of MSRB2 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr17:86,882,750...86,908,392
Ensembl chr17:86,882,394...86,908,391
|
|
G
|
Mthfd2
|
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of MTHFD2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:117,368,835...117,380,350
|
|
G
|
Mtrex
|
Mtr4 exosome RNA helicase
|
increases expression
|
ISO
|
Azacitidine results in increased expression of MTREX mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:46,233,528...46,293,827
Ensembl chr 2:46,194,647...46,293,827
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
decreases expression multiple interactions
|
ISO
|
Azacitidine analog results in decreased expression of MYC mRNA MYC protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; MYC protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]
|
CTD |
PMID:18045574 PMID:19451745 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Myf5
|
myogenic factor 5
|
increases expression
|
ISO
|
Azacitidine results in increased expression of MYF5 mRNA
|
CTD |
PMID:18938140 |
|
NCBI chr 7:44,689,407...44,692,638
Ensembl chr 7:44,689,407...44,692,638
|
|
G
|
Myh7
|
myosin heavy chain 7
|
increases expression
|
EXP
|
Azacitidine results in increased expression of MYH7 mRNA; Azacitidine results in increased expression of MYH7 protein
|
CTD |
PMID:17105402 |
|
NCBI chr15:32,416,525...32,439,851
Ensembl chr15:32,416,527...32,438,194
|
|
G
|
Myl2
|
myosin light chain 2
|
increases expression
|
EXP
|
Azacitidine results in increased expression of MYL2 mRNA
|
CTD |
PMID:17105402 |
|
NCBI chr12:40,114,964...40,126,236
Ensembl chr12:40,114,958...40,129,149
|
|
G
|
Myod1
|
myogenic differentiation 1
|
increases expression
|
EXP ISO
|
Azacitidine results in increased expression of MYOD1 mRNA
|
CTD |
PMID:18037191 PMID:18938140 |
|
NCBI chr 1:106,021,161...106,023,871
Ensembl chr 1:106,021,161...106,023,871
|
|
G
|
Myog
|
myogenin
|
increases expression
|
ISO
|
Azacitidine results in increased expression of MYOG mRNA
|
CTD |
PMID:18938140 |
|
NCBI chr13:48,297,476...48,300,065
Ensembl chr13:48,297,235...48,300,065
|
|
G
|
Ncam1
|
neural cell adhesion molecule 1
|
increases expression
|
EXP
|
Azacitidine results in increased expression of NCAM1 mRNA
|
CTD |
PMID:18037191 |
|
NCBI chr 8:58,762,088...59,062,131
Ensembl chr 8:58,762,116...59,061,971
|
|
G
|
Nefl
|
neurofilament light chain
|
increases expression
|
ISO
|
Azacitidine results in increased expression of NEFL mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515
|
|
G
|
Nfatc1
|
nuclear factor of activated T-cells 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of NFATC1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr18:76,321,386...76,430,997
Ensembl chr18:76,321,386...76,430,990
|
|
G
|
Niban1
|
niban apoptosis regulator 1
|
increases expression multiple interactions
|
ISO
|
Azacitidine results in increased expression of NIBAN1 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of NIBAN1 mRNA]
|
CTD |
PMID:21245298 |
|
NCBI chr13:66,224,219...66,377,728
Ensembl chr13:66,224,021...66,377,724
|
|
G
|
Nkx2-5
|
NK2 homeobox 5
|
increases expression
|
ISO
|
Azacitidine results in increased expression of NKX2-5 mRNA
|
CTD |
PMID:18557828 |
|
NCBI chr10:16,844,888...16,851,458
Ensembl chr10:16,848,582...16,851,452
|
|
G
|
Nlgn3
|
neuroligin 3
|
increases expression
|
ISO
|
Azacitidine results in increased expression of NLGN3 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr X:70,469,251...70,497,380
Ensembl chr X:70,469,457...70,497,379
|
|
G
|
Nme2
|
NME/NM23 nucleoside diphosphate kinase 2
|
increases expression
|
EXP
|
Azacitidine results in increased expression of NME2 protein
|
CTD |
PMID:17105402 |
|
NCBI chr10:79,394,999...79,400,418
Ensembl chr20:11,179,066...11,179,497 Ensembl chr10:11,179,066...11,179,497
|
|
G
|
Nmi
|
N-myc (and STAT) interactor
|
increases expression
|
ISO
|
Azacitidine results in increased expression of NMI mRNA
|
CTD |
PMID:21245298 |
|
NCBI chr 3:56,824,778...56,848,891
Ensembl chr 3:56,811,314...56,848,717
|
|
G
|
Nnt
|
nicotinamide nucleotide transhydrogenase
|
increases expression
|
ISO
|
Azacitidine results in increased expression of NNT mRNA; Azacitidine results in increased expression of NNT protein
|
CTD |
PMID:36336710 |
|
NCBI chr 2:53,144,157...53,237,857
Ensembl chr 2:53,144,160...53,237,310
|
|
G
|
Nom1
|
nucleolar protein with MIF4G domain 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of NOM1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:6,562,931...6,586,093
Ensembl chr 4:6,567,836...6,585,036
|
|
G
|
Nphp1
|
nephrocystin 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of NPHP1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 3:135,413,927...135,469,505
Ensembl chr 3:135,413,927...135,469,505
|
|
G
|
Nppa
|
natriuretic peptide A
|
increases expression
|
ISO
|
Azacitidine results in increased expression of NPPA
|
CTD |
PMID:15005238 |
|
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493
|
|
G
|
Nppb
|
natriuretic peptide B
|
increases expression
|
ISO
|
Azacitidine results in increased expression of NPPB
|
CTD |
PMID:15005238 |
|
NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]]
|
CTD |
PMID:17682057 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Nr4a1
|
nuclear receptor subfamily 4, group A, member 1
|
multiple interactions
|
ISO
|
[metacept-1 co-treated with Azacitidine] results in increased expression of NR4A1
|
CTD |
PMID:19148494 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041
|
|
G
|
Nrip1
|
nuclear receptor interacting protein 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of NRIP1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr11:28,382,835...28,466,483
Ensembl chr11:28,378,878...28,467,353
|
|
G
|
Nrn1
|
neuritin 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of NRN1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr17:28,335,426...28,344,354
Ensembl chr17:28,334,616...28,344,354
|
|
G
|
Nt5e
|
5' nucleotidase, ecto
|
increases expression
|
ISO
|
Azacitidine results in increased expression of NT5E mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645
|
|
G
|
Nts
|
neurotensin
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of NTS mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 7:39,451,484...39,460,888
Ensembl chr 7:39,451,073...39,460,961
|
|
G
|
Nusap1
|
nucleolar and spindle associated protein 1
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of NUSAP1 mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 3:127,057,220...127,092,779
Ensembl chr 3:127,057,265...127,087,237
|
|
G
|
Nxt2
|
nuclear transport factor 2-like export factor 2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of NXT2 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr X:110,652,434...110,659,738
Ensembl chr X:110,652,434...110,659,737
|
|
G
|
Ocln
|
occludin
|
increases expression
|
ISO
|
Azacitidine results in increased expression of OCLN mRNA
|
CTD |
PMID:18661270 |
|
NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411
|
|
G
|
Ogfrl1
|
opioid growth factor receptor-like 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of OGFRL1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 9:33,320,501...33,338,742
Ensembl chr 9:33,324,392...33,339,237
|
|
G
|
Ogg1
|
8-oxoguanine DNA glycosylase
|
decreases expression decreases methylation
|
ISO
|
Azacitidine results in decreased expression of OGG1 protein Azacitidine results in decreased methylation of OGG1 promoter
|
CTD |
PMID:22064374 |
|
NCBI chr 4:148,030,237...148,037,599
Ensembl chr 4:148,030,349...148,037,604
|
|
G
|
Or8b8
|
olfactory receptor family 8 subfamily B member 8
|
increases expression
|
ISO
|
Azacitidine results in increased expression of OR8B8 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 8:45,882,321...45,883,253
Ensembl chr 8:45,882,321...45,883,253
|
|
G
|
Oxr1
|
oxidation resistance 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of OXR1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 7:74,413,609...74,850,487
Ensembl chr 7:74,413,590...74,850,487
|
|
G
|
Oxtr
|
oxytocin receptor
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of OXTR mRNA
|
CTD |
PMID:21245298 |
|
NCBI chr 4:147,154,374...147,171,723
Ensembl chr 4:147,154,374...147,170,750
|
|
G
|
P4hb
|
prolyl 4-hydroxylase subunit beta
|
increases expression
|
EXP ISO
|
Azacitidine results in increased expression of P4HB protein Azacitidine results in increased expression of P4HB mRNA
|
CTD |
PMID:17105402 PMID:20823114 |
|
NCBI chr10:106,335,300...106,346,911
Ensembl chr10:106,335,300...106,346,911
|
|
G
|
Paep
|
progestagen associated endometrial protein
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of PAEP mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 3:28,929,252...28,932,592
|
|
G
|
Pak1
|
p21 (RAC1) activated kinase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PAK1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:161,522,399...161,637,623
Ensembl chr 1:161,491,847...161,637,612
|
|
G
|
Pank3
|
pantothenate kinase 3
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of PANK3 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr10:20,733,191...20,757,017
Ensembl chr10:20,733,127...20,757,015
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage multiple interactions
|
ISO
|
Azacitidine results in increased cleavage of PARP1 protein Bleomycin inhibits the reaction [Azacitidine results in increased cleavage of PARP1 protein]
|
CTD |
PMID:32278510 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pax4
|
paired box 4
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PAX4 mRNA
|
CTD |
PMID:18949370 |
|
NCBI chr 4:58,023,873...58,032,265
Ensembl chr 4:58,023,914...58,028,858
|
|
G
|
Pcdh18
|
protocadherin 18
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of PCDH18 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:135,982,929...135,996,917
Ensembl chr 2:135,983,144...135,996,826
|
|
G
|
Pcdha1
|
protocadherin alpha 1
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of PCDHA1 promoter
|
CTD |
PMID:18204046 |
|
Ensembl chr18:28,855,256...29,120,227
|
|
G
|
Pcdha10
|
protocadherin alpha 10
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of PCDHA10 promoter
|
CTD |
PMID:18204046 |
|
|
|
G
|
Pcdha11
|
protocadherin alpha 11
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of PCDHA11 promoter
|
CTD |
PMID:18204046 |
|
|
|
G
|
Pcdha12
|
protocadherin alpha 12
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of PCDHA12 promoter
|
CTD |
PMID:18204046 |
|
Ensembl chr18:28,855,256...29,120,227
|
|
G
|
Pcdha2
|
protocadherin alpha 2
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of PCDHA2 promoter
|
CTD |
PMID:18204046 |
|
|
|
G
|
Pcdha3
|
protocadherin alpha 3
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of PCDHA3 promoter
|
CTD |
PMID:18204046 |
|
|
|
G
|
Pcdha4
|
protocadherin alpha 4
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of PCDHA4 promoter
|
CTD |
PMID:18204046 |
|
NCBI chr18:28,688,274...29,120,227
Ensembl chr18:28,855,256...29,120,227
|
|
G
|
Pcdha5
|
protocadherin alpha 5
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of PCDHA5 promoter
|
CTD |
PMID:18204046 |
|
|
|
G
|
Pcdha6
|
protocadherin alpha 6
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of PCDHA6 promoter
|
CTD |
PMID:18204046 |
|
Ensembl chr18:28,855,256...29,120,227
|
|
G
|
Pcdha7
|
protocadherin alpha 7
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of PCDHA7 promoter
|
CTD |
PMID:18204046 |
|
|
|
G
|
Pcdha9
|
protocadherin alpha 9
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of PCDHA8 promoter; Azacitidine affects the methylation of PCDHA9 promoter
|
CTD |
PMID:18204046 |
|
|
|
G
|
Pcdhb20
|
protocadherin beta 20
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of PCDHB14 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr18:29,485,888...29,489,282
Ensembl chr18:29,454,999...29,489,427
|
|
G
|
Pcdhb5
|
protocadherin beta 5
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of PCDHB4 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr18:29,302,466...29,305,048
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
decreases expression multiple interactions
|
EXP
|
Azacitidine results in decreased expression of PCNA protein [Cisplatin co-treated with Azacitidine] results in decreased expression of PCNA protein
|
CTD |
PMID:19723570 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pdk1
|
pyruvate dehydrogenase kinase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PDK1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145
|
|
G
|
Pdk4
|
pyruvate dehydrogenase kinase 4
|
increases expression decreases methylation
|
ISO
|
Azacitidine results in increased expression of PDK4 protein Azacitidine results in decreased methylation of PDK4 promoter
|
CTD |
PMID:28003426 |
|
NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:34,556,330...34,568,381
|
|
G
|
Pecam1
|
platelet and endothelial cell adhesion molecule 1
|
increases expression
|
EXP
|
Azacitidine results in increased expression of PECAM1 mRNA
|
CTD |
PMID:18037191 |
|
NCBI chr10:92,090,263...92,152,002
Ensembl chr10:92,090,235...92,151,839
|
|
G
|
Pfn1
|
profilin 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PFN1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr10:55,863,882...55,866,587
Ensembl chr10:55,863,881...55,868,611
|
|
G
|
Phactr2
|
phosphatase and actin regulator 2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PHACTR2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:9,411,412...9,680,648
Ensembl chr 1:9,418,085...9,680,583
|
|
G
|
Pip5k1a
|
phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of PIP5K1A mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 2:185,317,319...185,361,859
Ensembl chr 2:185,317,319...185,360,476
|
|
G
|
Pitpnc1
|
phosphatidylinositol transfer protein, cytoplasmic 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of PITPNC1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr10:92,663,260...92,928,616
Ensembl chr10:92,663,260...92,928,344
|
|
G
|
Pitx3
|
paired-like homeodomain 3
|
increases expression
|
EXP
|
Azacitidine results in increased expression of PITX3 mRNA
|
CTD |
PMID:27415467 |
|
NCBI chr 1:254,942,550...254,955,325
Ensembl chr 1:254,942,608...254,955,336
|
|
G
|
Pja1
|
praja ring finger ubiquitin ligase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PJA1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr X:68,621,101...68,626,001
Ensembl chr X:68,620,084...68,638,407
|
|
G
|
Pkd2l1
|
polycystin 2 like 1, transient receptor potential cation channel
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PKD2L1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:252,982,096...253,019,235
Ensembl chr 1:252,982,096...253,023,359
|
|
G
|
Pkm
|
pyruvate kinase M1/2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PKM mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396
|
|
G
|
Plcb1
|
phospholipase C beta 1
|
decreases methylation decreases response to substance increases response to substance increases expression
|
ISO
|
Azacitidine results in decreased methylation of PLCB1 promoter PLCB1 promoter modified form results in decreased susceptibility to Azacitidine PLCB1 mRNA results in increased susceptibility to Azacitidine; PLCB1 protein results in increased susceptibility to Azacitidine Azacitidine results in increased expression of PLCB1 mRNA; Azacitidine results in increased expression of PLCB1 protein
|
CTD |
PMID:19805378 |
|
NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:142,513,033...143,225,646
|
|
G
|
Plpp1
|
phospholipid phosphatase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PLPP1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 2:46,172,202...46,233,632
Ensembl chr 2:46,172,197...46,234,676
|
|
G
|
Pls3
|
plastin 3
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of PLS3 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr X:116,401,247...116,495,898
Ensembl chr X:116,401,293...116,495,893
|
|
G
|
Pml
|
PML nuclear body scaffold
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PML mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:67,523,164...67,576,083
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
decreases methylation increases expression
|
ISO
|
Azacitidine results in decreased methylation of PPARG promoter Azacitidine results in increased expression of PPARG mRNA
|
CTD |
PMID:19589179 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Ppp2ca
|
protein phosphatase 2 catalytic subunit alpha
|
multiple interactions increases expression decreases methylation
|
ISO
|
Azacitidine promotes the reaction [CREB1 protein modified form binds to PPP2CA promoter] Azacitidine results in increased expression of PPP2CA mRNA Azacitidine results in decreased methylation of PPP2CA promoter
|
CTD |
PMID:19155497 |
|
NCBI chr10:36,856,534...36,878,789
|
|
G
|
Prdx4
|
peroxiredoxin 4
|
decreases expression
|
EXP
|
Azacitidine results in decreased expression of PRDX4 protein
|
CTD |
PMID:17105402 |
|
NCBI chr X:43,876,374...43,893,815
Ensembl chr X:43,876,417...43,893,812
|
|
G
|
Prf1
|
perforin 1
|
multiple interactions
|
ISO
|
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of PRF1 protein]
|
CTD |
PMID:19394699 |
|
NCBI chr20:29,789,040...29,794,550
Ensembl chr20:29,788,972...29,795,124
|
|
G
|
Prl
|
prolactin
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein
|
CTD |
PMID:20823114 |
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217
|
|
G
|
Prom1
|
prominin 1
|
increases expression
|
EXP
|
Azacitidine results in increased expression of PROM1 mRNA
|
CTD |
PMID:18037191 |
|
NCBI chr14:71,202,303...71,307,008
Ensembl chr14:71,202,336...71,307,002
|
|
G
|
Prss12
|
serine protease 12
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of PRSS12 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:214,308,695...214,368,679
Ensembl chr 2:214,308,774...214,369,941
|
|
G
|
Psen1
|
presenilin 1
|
decreases methylation multiple interactions
|
ISO
|
Azacitidine results in decreased methylation of PSEN1 promoter Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter]
|
CTD |
PMID:19635394 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189
|
|
G
|
Pten
|
phosphatase and tensin homolog
|
multiple interactions
|
ISO
|
Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased methylation of PTEN promoter]
|
CTD |
PMID:22841775 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330
|
|
G
|
Pthlh
|
parathyroid hormone-like hormone
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of PTHLH mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:181,919,400...181,930,454
|
|
G
|
Ptpa
|
protein phosphatase 2 phosphatase activator
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PTPA mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 3:34,087,637...34,118,100
Ensembl chr 3:34,087,575...34,162,772
|
|
G
|
Ptprc
|
protein tyrosine phosphatase, receptor type, C
|
increases expression
|
ISO
|
Azacitidine results in increased expression of PTPRC mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr13:52,147,717...52,259,810
Ensembl chr13:52,147,717...52,259,746
|
|
G
|
Ptpro
|
protein tyrosine phosphatase, receptor type, O
|
increases expression
|
EXP
|
Azacitidine results in increased expression of PTPRO mRNA
|
CTD |
PMID:14508512 |
|
NCBI chr 4:171,895,104...172,105,911
Ensembl chr 4:171,895,232...172,105,903
|
|
G
|
Rab13
|
RAB13, member RAS oncogene family
|
decreases methylation
|
ISO
|
Azacitidine results in decreased methylation of RAB13 promoter
|
CTD |
PMID:19194470 |
|
NCBI chr 2:177,972,535...177,977,679
Ensembl chr 2:177,972,372...177,977,684
|
|
G
|
Rab1b
|
RAB1B, member RAS oncogene family
|
increases expression
|
ISO
|
Azacitidine results in increased expression of RAB1B mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:211,835,133...211,843,408
Ensembl chr 1:211,835,073...211,843,337 Ensembl chr X:211,835,073...211,843,337
|
|
G
|
Racgap1
|
Rac GTPase-activating protein 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of RACGAP1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 7:132,629,789...132,659,738
Ensembl chr 7:132,620,595...132,659,738
|
|
G
|
Ranbp2
|
RAN binding protein 2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of RANBP2 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr20:26,984,520...27,036,573
Ensembl chr20:26,985,275...27,036,571
|
|
G
|
Rasa3
|
RAS p21 protein activator 3
|
increases expression
|
ISO
|
Azacitidine results in increased expression of RASA3 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr16:82,557,556...82,671,527
Ensembl chr16:82,557,428...82,672,984
|
|
G
|
Rcn1
|
reticulocalbin 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of RCN1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 3:112,295,838...112,310,082
Ensembl chr 3:112,295,838...112,310,082
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
affects localization decreases expression
|
ISO
|
Azacitidine affects the localization of RELA protein 5-azacytidine decreases expression of RELA protein in lung cancer cells
|
CTD RGD |
PMID:18443271 PMID:24356455 |
RGD:153344603 |
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Ret
|
ret proto-oncogene
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of RET mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556
|
|
G
|
Rfc3
|
replication factor C subunit 3
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of RFC3 mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr12:5,836,546...5,847,331
Ensembl chr12:5,836,553...5,847,340
|
|
G
|
Rhob
|
ras homolog family member B
|
multiple interactions
|
ISO
|
[trichostatin A co-treated with Azacitidine] results in increased expression of RHOB protein; Azacitidine promotes the reaction [trichostatin A results in increased expression of RHOB mRNA]
|
CTD |
PMID:18047684 |
|
NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:37,075,015...37,112,772
|
|
G
|
Rin1
|
Ras and Rab interactor 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of RIN1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:211,785,107...211,789,755
Ensembl chr 1:211,784,943...211,791,368
|
|
G
|
Rpl4
|
ribosomal protein L4
|
increases expression
|
EXP
|
Azacitidine results in increased expression of RPL4 mRNA
|
CTD |
PMID:9813173 |
|
NCBI chr 8:73,566,477...73,571,600
Ensembl chr 8:73,566,466...73,571,788
|
|
G
|
Rpp21
|
ribonuclease P/MRP subunit p21
|
increases expression
|
ISO
|
Azacitidine results in increased expression of RPP21 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr20:1,986,225...2,025,308
Ensembl chr20:2,023,186...2,025,308
|
|
G
|
Rps6
|
ribosomal protein S6
|
decreases phosphorylation
|
ISO
|
Azacitidine results in decreased phosphorylation of RPS6 protein
|
CTD |
PMID:21245298 |
|
NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566
|
|
G
|
Rpsa
|
ribosomal protein SA
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of RPSA mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 8:128,728,761...128,732,736
Ensembl chr 8:128,728,862...128,732,737
|
|
G
|
Rrm2
|
ribonucleotide reductase regulatory subunit M2
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of RRM2 mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370
|
|
G
|
Rrm2b
|
ribonucleotide reductase regulatory TP53 inducible subunit M2B
|
increases expression
|
ISO
|
Azacitidine results in increased expression of RRM2B mRNA
|
CTD |
PMID:19010910 |
|
NCBI chr 7:70,962,008...70,993,726
Ensembl chr 7:70,965,590...70,993,670
|
|
G
|
RT1-Da
|
RT1 class II, locus Da
|
multiple interactions
|
ISO
|
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein
|
CTD |
PMID:18829986 |
|
NCBI chr20:4,515,393...4,520,387
Ensembl chr20:4,513,908...4,520,383
|
|
G
|
Runx1
|
RUNX family transcription factor 1
|
multiple interactions
|
ISO
|
Azacitidine promotes the reaction [RUNX1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [RUNX1 protein binds to KIR2DL4 promoter]
|
CTD |
PMID:18945643 |
|
NCBI chr11:45,325,778...45,560,300
Ensembl chr11:45,329,044...45,564,925
|
|
G
|
Runx2
|
RUNX family transcription factor 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of RUNX2 mRNA
|
CTD |
PMID:39531065 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027
|
|
G
|
Runx3
|
RUNX family transcription factor 3
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of RUNX3 gene
|
CTD |
PMID:18058463 |
|
NCBI chr 5:152,644,270...152,702,835
Ensembl chr 5:152,644,270...152,702,835
|
|
G
|
S100a14
|
S100 calcium binding protein A14
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of S100A14 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:178,305,976...178,308,004
Ensembl chr 2:178,306,025...178,307,999
|
|
G
|
S100a9
|
S100 calcium binding protein A9
|
increases expression
|
ISO
|
Azacitidine results in increased expression of S100A9 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:178,487,941...178,490,870
|
|
G
|
Sall4
|
spalt-like transcription factor 4
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of SALL4 promoter
|
CTD |
PMID:17546590 |
|
NCBI chr 3:177,891,705...177,909,743
Ensembl chr 3:177,891,705...177,909,743
|
|
G
|
Scamp4
|
secretory carrier membrane protein 4
|
increases expression
|
ISO
|
Azacitidine results in increased expression of SCAMP4 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 7:9,752,193...9,764,614
Ensembl chr 7:9,752,193...9,778,736
|
|
G
|
Sdcbp
|
syndecan binding protein
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of SDCBP mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 5:24,245,279...24,314,712
Ensembl chr 5:24,245,033...24,326,197
|
|
G
|
Sema3a
|
semaphorin 3A
|
increases expression
|
ISO
|
Azacitidine results in increased expression of SEMA3A mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 4:22,239,418...22,709,907
Ensembl chr 4:22,245,322...22,535,774
|
|
G
|
Sema6c
|
semaphorin 6C
|
increases expression
|
ISO
|
Azacitidine results in increased expression of SEMA6C mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:185,422,636...185,436,237
Ensembl chr 2:185,422,639...185,448,689
|
|
G
|
Senp3
|
SUMO specific peptidase 3
|
increases expression
|
ISO
|
Azacitidine results in increased expression of SENP3 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr10:54,889,445...54,898,359
Ensembl chr10:54,888,847...54,898,227
|
|
G
|
Six2
|
SIX homeobox 2
|
decreases expression multiple interactions
|
ISO
|
Azacitidine results in decreased expression of SIX2 mRNA Cisplatin affects the reaction [Azacitidine results in decreased expression of SIX2 mRNA]
|
CTD |
PMID:36336710 |
|
NCBI chr 6:14,727,756...14,734,219
Ensembl chr 6:14,727,859...14,731,941
|
|
G
|
Slbp
|
stem-loop histone mRNA binding protein
|
multiple interactions
|
ISO
|
Azacitidine inhibits the reaction [sodium arsenite results in decreased expression of SLBP mRNA]
|
CTD |
PMID:25266719 |
|
NCBI chr14:81,295,479...81,306,446
Ensembl chr14:81,296,223...81,306,447
|
|
G
|
Slc28a1
|
solute carrier family 28 member 1
|
increases response to substance multiple interactions increases uptake
|
ISO
|
SLC28A1 protein results in increased susceptibility to Azacitidine [SLC28A1 protein results in increased uptake of Azacitidine] which results in decreased expression of DNMT1 protein; Sodium affects the reaction [SLC28A1 protein results in increased uptake of Azacitidine]
|
CTD |
PMID:19139132 |
|
NCBI chr 1:144,490,453...144,532,025
Ensembl chr 1:144,490,623...144,531,544
|
|
G
|
Slc29a2
|
solute carrier family 29 member 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of SLC29A2 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 1:211,756,588...211,764,561
Ensembl chr 1:211,757,000...211,764,560
|
|
G
|
Slc5a5
|
solute carrier family 5 member 5
|
multiple interactions increases expression
|
ISO
|
[Azacitidine co-treated with Butyrates] affects the expression of SLC5A5 mRNA Azacitidine results in increased expression of SLC5A5 mRNA
|
CTD |
PMID:16954431 PMID:17164311 |
|
NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691
|
|
G
|
Snu13
|
small nuclear ribonucleoprotein 13
|
increases expression
|
ISO
|
Azacitidine results in increased expression of SNU13 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 7:115,445,415...115,451,008
Ensembl chr 1:269,702,002...269,703,004 Ensembl chr 7:269,702,002...269,703,004
|
|
G
|
Socs3
|
suppressor of cytokine signaling 3
|
affects expression
|
ISO
|
Azacitidine affects the expression of SOCS3 protein
|
CTD |
PMID:18443271 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825
|
|
G
|
Sox13
|
SRY-box transcription factor 13
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of SOX13 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr13:47,383,145...47,427,572
Ensembl chr13:47,383,145...47,435,663
|
|
G
|
Sox2
|
SRY-box transcription factor 2
|
increases expression
|
EXP
|
Azacitidine results in increased expression of SOX2 mRNA
|
CTD |
PMID:27415467 |
|
NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350
|
|
G
|
Sox8
|
SRY-box transcription factor 8
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of SOX8 mRNA
|
CTD |
PMID:18033690 |
|
NCBI chr10:15,089,357...15,094,345
Ensembl chr10:15,089,357...15,094,345
|
|
G
|
Sox9
|
SRY-box transcription factor 9
|
affects expression increases expression
|
ISO
|
Azacitidine affects the expression of SOX9 mRNA Azacitidine results in increased expression of SOX9 mRNA
|
CTD |
PMID:18033690 PMID:39531065 |
|
NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250
|
|
G
|
Sp1
|
Sp1 transcription factor
|
multiple interactions decreases expression
|
ISO
|
Azacitidine promotes the reaction [SP1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [SP1 protein binds to KIR2DL4 promoter] Azacitidine results in decreased expression of SP1 mRNA Azacitidine promotes the reaction [SP1 protein binds to AQP5 promoter]
|
CTD |
PMID:17198683 PMID:18945643 PMID:20823114 |
|
NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513
|
|
G
|
Sp7
|
Sp7 transcription factor
|
increases expression
|
ISO
|
Azacitidine results in increased expression of SP7 mRNA
|
CTD |
PMID:17085970 |
|
NCBI chr 7:135,363,193...135,373,376
Ensembl chr 7:135,363,199...135,373,559
|
|
G
|
Spag5
|
sperm associated antigen 5
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of SPAG5 mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr10:63,693,300...63,714,813
Ensembl chr10:63,696,466...63,714,811
|
|
G
|
Srpx
|
sushi-repeat-containing protein, X-linked
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of SRPX mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr X:15,349,498...15,420,389
Ensembl chr X:15,349,440...15,420,392
|
|
G
|
Srsf7
|
serine and arginine rich splicing factor 7
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of SRSF7 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 6:20,564,035...20,571,205
Ensembl chr 6:20,564,044...20,571,212
|
|
G
|
Ssx2ip
|
SSX family member 2 interacting protein
|
increases expression
|
ISO
|
Azacitidine results in increased expression of SSX2IP mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:237,958,286...237,991,026
Ensembl chr 2:237,958,465...237,991,017
|
|
G
|
St3gal6
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 6
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ST3GAL6 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr11:55,530,120...55,590,950
Ensembl chr11:55,530,248...55,598,720
|
|
G
|
St8sia2
|
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of ST8SIA2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 1:137,172,354...137,247,796
Ensembl chr 1:137,172,354...137,247,792
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions
|
ISO
|
[Azacitidine affects the expression of IL6R protein] which affects the phosphorylation of STAT3 protein
|
CTD |
PMID:18443271 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Stc2
|
stanniocalcin 2
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of STC2 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr10:16,755,508...16,765,275
Ensembl chr10:16,755,267...16,767,447
|
|
G
|
Stk38
|
serine/threonine kinase 38
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of STK38 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr20:7,035,923...7,070,657
Ensembl chr20:7,035,933...7,069,711
|
|
G
|
Sulf1
|
sulfatase 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of SULF1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 5:11,145,950...11,308,622
Ensembl chr 5:11,145,950...11,308,643
|
|
G
|
Sult1c2a
|
sulfotransferase family 1C member 2A
|
increases expression
|
ISO
|
Azacitidine results in increased expression of SULT1C2 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 9:7,075,873...7,103,316
Ensembl chr 9:7,066,905...7,244,132
|
|
G
|
Tat
|
tyrosine aminotransferase
|
increases expression
|
ISO
|
Azacitidine results in increased expression of TAT mRNA
|
CTD |
PMID:27590069 |
|
NCBI chr19:54,856,604...54,867,168
Ensembl chr19:54,856,563...54,867,482
|
|
G
|
Tbc1d4
|
TBC1 domain family, member 4
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of TBC1D4 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr15:84,670,756...84,848,876
Ensembl chr15:84,670,756...84,848,693
|
|
G
|
Tcea1
|
transcription elongation factor A1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of TCEA1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 5:19,414,351...19,466,629
Ensembl chr15:12,831,339...12,834,156 Ensembl chr 5:12,831,339...12,834,156
|
|
G
|
Tecpr2
|
tectonin beta-propeller repeat containing 2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of TECPR2 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 6:135,720,765...135,823,187
Ensembl chr 6:135,720,656...135,823,187
|
|
G
|
Tek
|
TEK receptor tyrosine kinase
|
increases expression
|
EXP
|
Azacitidine results in increased expression of TEK mRNA
|
CTD |
PMID:18037191 |
|
NCBI chr 5:114,722,815...114,849,535
Ensembl chr 5:114,723,006...114,849,991
|
|
G
|
Tert
|
telomerase reverse transcriptase
|
decreases expression multiple interactions decreases methylation decreases activity
|
ISO
|
Azacitidine analog results in decreased expression of TERT mRNA; Azacitidine results in decreased expression of TERT mRNA E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]; MYC protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; MYC protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA] Azacitidine results in decreased methylation of TERT promoter
|
CTD |
PMID:18045574 PMID:19451745 |
|
NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111
|
|
G
|
Tfe3
|
transcription factor binding to IGHM enhancer 3
|
increases expression
|
ISO
|
Azacitidine results in increased expression of TFE3 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr X:17,401,466...17,414,829
Ensembl chr X:17,401,466...17,414,685
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with TGFB1 protein] results in increased expression of FOXP3 protein Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased methylation of PTEN promoter]; Azacitidine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:18493985 PMID:22841775 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Thumpd1
|
THUMP domain containing 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of THUMPD1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 1:183,510,242...183,516,282
Ensembl chr 1:183,431,657...183,516,282
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of TIMP1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tjp1
|
tight junction protein 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of TJP1 mRNA
|
CTD |
PMID:18661270 |
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158
|
|
G
|
Tmed3
|
transmembrane p24 trafficking protein 3
|
increases expression
|
ISO
|
Azacitidine results in increased expression of TMED3 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 8:99,121,361...99,129,653
Ensembl chr 8:99,121,361...99,129,215
|
|
G
|
Tmpo
|
thymopoietin
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of TMPO mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 7:27,529,977...27,554,980
Ensembl chr 7:27,529,978...27,554,937
|
|
G
|
Tnc
|
tenascin C
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of TNC mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:82,391,340...82,476,131
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression increases response to substance
|
EXP ISO
|
Azacitidine results in increased expression of TNF mRNA Azacitidine results in increased susceptibility to TNF protein
|
CTD |
PMID:17156202 PMID:18829727 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfsf10
|
TNF superfamily member 10
|
increases response to substance
|
ISO
|
Azacitidine results in increased susceptibility to TNFSF10 protein
|
CTD |
PMID:18829727 |
|
NCBI chr 2:112,136,550...112,155,903
|
|
G
|
Tnni3
|
troponin I3, cardiac type
|
increases expression
|
EXP
|
Azacitidine results in increased expression of TNNI3 protein
|
CTD |
PMID:17105402 |
|
NCBI chr 1:78,342,571...78,346,255
Ensembl chr 1:78,342,592...78,346,253
|
|
G
|
Tnnt2
|
troponin T2, cardiac type
|
increases expression
|
EXP
|
Azacitidine results in increased expression of TNNT2 protein
|
CTD |
PMID:22496879 |
|
NCBI chr13:49,819,123...49,837,125
Ensembl chr13:49,822,304...49,837,125
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of TOP2A mRNA; [Curcumin co-treated with Azacitidine] results in decreased expression of TOP2A mRNA
|
CTD |
PMID:18348204 PMID:18720364 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
G
|
Tp53
|
tumor protein p53
|
affects activity increases expression
|
ISO EXP
|
Azacitidine affects the activity of TP53 protein Azacitidine results in increased expression of TP53 mRNA; Azacitidine results in increased expression of TP53 protein
|
CTD |
PMID:16427046 PMID:35435491 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tp73
|
tumor protein p73
|
multiple interactions
|
ISO
|
TP73 protein promotes the reaction [Azacitidine results in increased expression of HMGA2 mRNA]; TP73 protein promotes the reaction [Azacitidine results in increased expression of KLF6 mRNA]; TP73 protein promotes the reaction [Azacitidine results in increased expression of NIBAN1 mRNA]
|
CTD |
PMID:21245298 |
|
NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:169,903,801...169,963,552
|
|
G
|
Tpd52
|
tumor protein D52
|
increases expression
|
EXP
|
Azacitidine results in increased expression of TPD52 mRNA
|
CTD |
PMID:27415467 |
|
NCBI chr 2:94,642,514...94,723,442
Ensembl chr 2:94,642,585...94,724,241
|
|
G
|
Tpm2
|
tropomyosin 2
|
increases expression
|
ISO
|
Azacitidine results in increased expression of TPM2 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 5:62,566,712...62,576,066
Ensembl chr 5:62,566,652...62,575,726
|
|
G
|
Tpo
|
thyroid peroxidase
|
increases expression
|
ISO
|
Azacitidine results in increased expression of TPO mRNA
|
CTD |
PMID:17679169 |
|
NCBI chr 6:52,425,998...52,495,793
Ensembl chr 6:52,426,010...52,495,793
|
|
G
|
Tpsg1
|
tryptase gamma 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of TPSG1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr10:14,889,838...14,895,605
Ensembl chr10:14,890,734...14,894,786
|
|
G
|
Trh
|
thyrotropin releasing hormone
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of TRH mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 4:126,299,236...126,301,762
Ensembl chr 4:126,299,236...126,301,762
|
|
G
|
Trib1
|
tribbles pseudokinase 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of TRIB1 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 7:93,096,001...93,102,547
Ensembl chr 7:93,095,973...93,117,480
|
|
G
|
Trim8
|
tripartite motif-containing 8
|
increases expression
|
ISO
|
Azacitidine results in increased expression of TRIM8 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 1:255,311,039...255,325,937
Ensembl chr 1:255,310,457...255,325,937
|
|
G
|
Tsc1
|
TSC complex subunit 1
|
multiple interactions
|
ISO
|
[Azacitidine affects the methylation of TSC1 promoter] which affects the expression of TSC1 mRNA
|
CTD |
PMID:18538015 |
|
NCBI chr 3:32,367,434...32,416,565
Ensembl chr 3:32,367,670...32,416,568
|
|
G
|
Tsc2
|
TSC complex subunit 2
|
decreases methylation multiple interactions increases expression
|
ISO
|
Azacitidine results in decreased methylation of TSC2 promoter [Azacitidine affects the methylation of TSC2 promoter] which affects the expression of TSC2 mRNA Azacitidine results in increased expression of TSC2 mRNA
|
CTD |
PMID:18538015 PMID:19250671 |
|
NCBI chr10:14,125,679...14,160,317
Ensembl chr10:14,125,680...14,160,600
|
|
G
|
Tshr
|
thyroid stimulating hormone receptor
|
increases expression
|
ISO
|
Azacitidine results in increased expression of TSHR mRNA
|
CTD |
PMID:17679169 |
|
NCBI chr 6:116,072,321...116,206,009
Ensembl chr 6:116,072,281...116,206,010
|
|
G
|
Tspan32
|
tetraspanin 32
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of TSPAN32 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 1:207,619,566...207,633,885
Ensembl chr 1:207,619,567...207,656,946
|
|
G
|
Ttk
|
Ttk protein kinase
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of TTK mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 8:93,632,678...93,672,664
Ensembl chr 8:93,634,319...93,672,664
|
|
G
|
Ube2c
|
ubiquitin-conjugating enzyme E2C
|
multiple interactions
|
ISO
|
[Azacitidine co-treated with Thalidomide] affects the expression of UBE2C mRNA
|
CTD |
PMID:18720364 |
|
NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:173,925,934...173,932,678
|
|
G
|
Uhmk1
|
U2AF homology motif kinase 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of UHMK1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr13:84,929,418...84,949,194
Ensembl chr13:84,922,829...84,949,061
|
|
G
|
Ush2a
|
usherin
|
increases expression
|
ISO
|
Azacitidine results in increased expression of USH2A mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr13:102,368,783...103,035,230
Ensembl chr13:102,368,783...103,035,217
|
|
G
|
Ushbp1
|
USH1 protein network component harmonin binding protein 1
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of USHBP1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr16:18,091,311...18,101,927
Ensembl chr16:18,091,316...18,101,867
|
|
G
|
Vim
|
vimentin
|
decreases expression increases expression multiple interactions
|
EXP ISO
|
Azacitidine results in decreased expression of VIM protein Azacitidine results in increased expression of VIM mRNA; Azacitidine results in increased expression of VIM protein [Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein
|
CTD |
PMID:17105402 PMID:20823114 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746
|
|
G
|
Wdr47
|
WD repeat domain 47
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of WDR47 mRNA
|
CTD |
PMID:19194470 |
|
NCBI chr 2:198,914,977...198,975,844
Ensembl chr 2:198,914,940...198,975,841
|
|
G
|
Wnt10b
|
Wnt family member 10B
|
increases expression
|
EXP
|
Azacitidine results in increased expression of WNT10B mRNA
|
CTD |
PMID:27415467 |
|
NCBI chr 7:131,801,046...131,806,850
Ensembl chr 7:131,801,046...131,806,850
|
|
G
|
Wnt5a
|
Wnt family member 5A
|
increases expression
|
ISO
|
Azacitidine results in increased expression of WNT5A mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,703,665...3,724,860
|
|
G
|
Wwtr1
|
WW domain containing transcription regulator 1
|
increases expression
|
ISO
|
Azacitidine results in increased expression of WWTR1 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 2:143,801,181...143,916,941
Ensembl chr 2:143,801,181...143,991,950
|
|
G
|
Xaf1
|
XIAP associated factor 1
|
decreases expression decreases methylation increases expression
|
ISO
|
Azacitidine results in decreased expression of XAF1 mRNA alternative form Azacitidine results in decreased methylation of XAF1 promoter Azacitidine results in increased expression of XAF1 mRNA; Azacitidine results in increased expression of XAF1 protein
|
CTD |
PMID:19077051 PMID:19549372 |
|
NCBI chr10:57,415,935...57,428,348
Ensembl chr10:57,415,658...57,428,349
|
|
G
|
Zfp189
|
zinc finger protein 189
|
decreases expression
|
ISO
|
Azacitidine results in decreased expression of ZNF189 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr 5:68,668,225...68,679,606
Ensembl chr 5:68,668,244...68,679,812
|
|
G
|
Zfp64
|
zinc finger protein 64
|
affects methylation
|
ISO
|
Azacitidine affects the methylation of ZFP64 promoter
|
CTD |
PMID:17546590 |
|
NCBI chr 3:178,085,604...178,114,557
Ensembl chr 3:178,085,605...178,114,557
|
|
G
|
Zp3
|
zona pellucida glycoprotein 3
|
increases expression
|
ISO
|
Azacitidine results in increased expression of ZP3 mRNA
|
CTD |
PMID:20823114 |
|
NCBI chr12:26,327,161...26,334,126
Ensembl chr12:26,327,161...26,334,126
|
|
|
G
|
Hsd17b2
|
hydroxysteroid (17-beta) dehydrogenase 2
|
affects binding
|
ISO
|
acetoacetyl CoA binds to HSD17B2 protein
|
CTD |
PMID:25526675 |
|
NCBI chr19:62,662,320...62,733,944
Ensembl chr19:62,662,098...62,733,943
|
|
|
G
|
Acly
|
ATP citrate lyase
|
increases abundance affects abundance
|
ISO
|
ACLY protein results in increased abundance of Acetyl Coenzyme A ACLY protein affects the abundance of Acetyl Coenzyme A
|
CTD |
PMID:28077572 PMID:36933457 |
|
NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631
|
|
G
|
App
|
amyloid beta precursor protein
|
affects localization increases secretion multiple interactions
|
ISO
|
APP protein affects the localization of Acetyl Coenzyme A Acetyl Coenzyme A results in increased secretion of APP protein modified form Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form] IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A]
|
CTD |
PMID:16122837 PMID:22906069 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
G
|
Crat
|
carnitine O-acetyltransferase
|
decreases activity
|
EXP
|
Acetyl Coenzyme A deficiency results in decreased activity of CRAT protein
|
CTD |
PMID:8075222 |
|
NCBI chr 3:34,073,504...34,087,099
Ensembl chr 3:34,073,506...34,087,099
|
|
G
|
Ercc6
|
ERCC excision repair 6, chromatin remodeling factor
|
decreases abundance multiple interactions
|
ISO
|
ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]
|
CTD |
PMID:25440059 |
|
NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895
|
|
G
|
G6pc1
|
glucose-6-phosphatase catalytic subunit 1
|
multiple interactions
|
ISO
|
[Fluoxetine results in decreased expression of G6PC1 protein] which results in increased abundance of Acetyl Coenzyme A
|
CTD |
PMID:33179799 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A]
|
CTD |
PMID:16122837 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Kat2b
|
lysine acetyltransferase 2B
|
affects binding
|
ISO
|
Acetyl Coenzyme A binds to KAT2B protein
|
CTD |
PMID:28077572 |
|
NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616
|
|
G
|
Metrnl
|
meteorin-like, glial cell differentiation regulator
|
multiple interactions
|
ISO
|
METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Acetyl Coenzyme A]
|
CTD |
PMID:30213948 |
|
NCBI chr10:107,462,148...107,476,143
Ensembl chr10:107,462,109...107,476,135
|
|
G
|
Nat1
|
N-acetyltransferase 1
|
multiple interactions affects binding
|
ISO
|
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein] Acetyl Coenzyme A binds to NAT1 protein
|
CTD |
PMID:20545351 PMID:22835378 |
|
NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527
|
|
G
|
Nat2
|
N-acetyltransferase 2
|
multiple interactions
|
ISO
|
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]
|
CTD |
PMID:20545351 |
|
NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions
|
ISO
|
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
|
CTD |
PMID:20545351 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
|
G
|
Echs1
|
enoyl-CoA hydratase, short chain 1
|
increases abundance
|
ISO
|
ECHS1 gene mutant form results in increased abundance of acryloyl-coenzyme A
|
CTD |
PMID:25125611 |
|
NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506
|
|
G
|
Hibch
|
3-hydroxyisobutyryl-CoA hydrolase
|
increases abundance
|
ISO
|
HIBCH gene mutant form results in increased abundance of acryloyl-coenzyme A
|
CTD |
PMID:25125611 |
|
NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:56,082,091...56,161,886
|
|
|
G
|
Ada
|
adenosine deaminase
|
decreases metabolic processing increases metabolic processing
|
ISO
|
ADA alternative form results in decreased metabolism of Adenosine ADA protein results in increased metabolism of Adenosine
|
CTD |
PMID:16221767 |
|
NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293
|
|
G
|
Adora1
|
adenosine A1 receptor
|
multiple interactions affects binding
|
ISO EXP
|
Adenosine analog binds to and affects the activity of ADORA1 protein; Adenosine analog binds to and results in decreased activity of ADORA1 protein; PD 81723 affects the reaction [Adenosine analog binds to and affects the activity of ADORA1 protein]; VUF 5455 affects the reaction [Adenosine analog binds to and affects the activity of ADORA1 protein] [lead acetate results in increased expression of ADORA1 protein] which results in increased abundance of Adenosine; Adenosine analog binds to and results in increased activity of ADORA1 protein Adenosine binds to ADORA1 protein
|
CTD |
PMID:10649980 PMID:11520205 PMID:18404447 PMID:20571079 PMID:20932874 |
|
NCBI chr13:48,210,922...48,247,826
Ensembl chr13:48,213,273...48,247,190
|
|
G
|
Adora2a
|
adenosine A2a receptor
|
multiple interactions affects binding
|
ISO
|
Adenosine analog binds to and results in decreased activity of ADORA2A protein; Adenosine promotes the reaction [Lipopolysaccharides results in increased expression of ADORA2A mRNA] Adenosine binds to ADORA2A protein
|
CTD |
PMID:18404447 PMID:20067761 |
|
NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,270...13,332,802
|
|
G
|
Adora2b
|
adenosine A2B receptor
|
affects response to substance
|
ISO
|
ADORA2B protein affects the susceptibility to Adenosine
|
CTD |
PMID:16920807 |
|
NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091
|
|
G
|
Adora3
|
adenosine A3 receptor
|
multiple interactions increases expression affects binding
|
ISO
|
Adenosine analog binds to and affects the activity of ADORA3 protein; Adenosine analog binds to and results in decreased activity of ADORA3 protein; Adenosine analog binds to and results in increased activity of ADORA3 protein; PD 81723 affects the reaction [Adenosine analog binds to and affects the activity of ADORA3 protein]; VUF 5455 affects the reaction [Adenosine analog binds to and affects the activity of ADORA3 protein] Adenosine results in increased expression of ADORA3 mRNA Adenosine binds to ADORA3 protein
|
CTD |
PMID:11520205 PMID:18404447 PMID:20067761 PMID:20571079 |
|
NCBI chr 2:196,077,042...196,080,686
Ensembl chr 2:196,077,042...196,080,686
|
|
G
|
Alpi
|
alkaline phosphatase, intestinal
|
multiple interactions
|
ISO
|
Adenosine inhibits the reaction [Methotrexate results in increased activity of ALPI protein]
|
CTD |
PMID:16598758 |
|
NCBI chr 9:95,221,314...95,224,780
Ensembl chr 9:95,221,314...95,224,780
|
|
G
|
Ampd2
|
adenosine monophosphate deaminase 2
|
multiple interactions
|
ISO
|
[tofacitinib results in decreased expression of AMPD2 protein] which affects the abundance of Adenosine
|
CTD |
PMID:25496463 |
|
NCBI chr 2:198,395,767...198,408,514
Ensembl chr 2:198,395,768...198,408,796
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases localization multiple interactions
|
ISO
|
Adenosine results in increased localization of BAX protein Thymidine inhibits the reaction [Adenosine results in increased localization of BAX protein]
|
CTD |
PMID:11570579 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
decreases expression multiple interactions
|
ISO
|
Adenosine results in decreased expression of BCL2L1 mRNA; Adenosine results in decreased expression of BCL2L1 protein Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 protein]
|
CTD |
PMID:20063052 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
G
|
Birc2
|
baculoviral IAP repeat-containing 2
|
decreases expression
|
ISO
|
Adenosine results in decreased expression of BIRC2 mRNA; Adenosine results in decreased expression of BIRC2 protein
|
CTD |
PMID:20063052 |
|
NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911
|
|
G
|
Birc3
|
baculoviral IAP repeat-containing 3
|
decreases expression
|
ISO
|
Adenosine results in decreased expression of BIRC3 mRNA
|
CTD |
PMID:20063052 |
|
NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590
|
|
G
|
Bmp2
|
bone morphogenetic protein 2
|
increases expression
|
ISO
|
Adenosine results in increased expression of BMP2 mRNA
|
CTD |
PMID:34070360 |
|
NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760
|
|
G
|
Bmp4
|
bone morphogenetic protein 4
|
increases expression multiple interactions
|
ISO
|
Adenosine results in increased expression of BMP4 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA]; PSB603 inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA]; ZM 241385 inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA]
|
CTD |
PMID:34070360 |
|
NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172
|
|
G
|
Bmpr1a
|
bone morphogenetic protein receptor type 1A
|
increases expression
|
ISO
|
Adenosine results in increased expression of BMPR1A mRNA
|
CTD |
PMID:34070360 |
|
NCBI chr16:9,740,751...9,786,861
Ensembl chr16:9,742,875...9,786,861
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases activity
|
ISO EXP
|
Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP3 protein]; Thymidine inhibits the reaction [Adenosine results in increased activity of CASP3 protein]
|
CTD |
PMID:11570579 PMID:16469385 PMID:17303086 PMID:20063052 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases activity multiple interactions
|
ISO EXP
|
Adenosine results in increased activity of CASP8 protein Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP8 protein]
|
CTD |
PMID:16469385 PMID:17303086 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases activity multiple interactions
|
ISO EXP
|
Adenosine results in increased activity of CASP9 protein Thymidine inhibits the reaction [Adenosine results in increased activity of CASP9 protein]
|
CTD |
PMID:11570579 PMID:16469385 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Ccnb1
|
cyclin B1
|
affects expression
|
EXP
|
Adenosine affects the expression of CCNB1 protein
|
CTD |
PMID:19638569 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
G
|
Ccnd1
|
cyclin D1
|
increases expression
|
ISO EXP
|
Adenosine results in increased expression of CCND1 mRNA Adenosine results in increased expression of CCND1 protein
|
CTD |
PMID:19638569 PMID:34070360 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Ccne1
|
cyclin E1
|
increases expression
|
EXP
|
Adenosine results in increased expression of CCNE1 protein
|
CTD |
PMID:19638569 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822
|
|
G
|
Cd14
|
CD14 molecule
|
increases expression
|
ISO
|
Adenosine results in increased expression of CD14 mRNA
|
CTD |
PMID:21538184 |
|
NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292
|
|
G
|
Cflar
|
CASP8 and FADD-like apoptosis regulator
|
decreases expression multiple interactions
|
ISO
|
Adenosine results in decreased expression of CFLAR mRNA; Adenosine results in decreased expression of CFLAR mRNA alternative form; Adenosine results in decreased expression of CFLAR protein Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA alternative form]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR protein]
|
CTD |
PMID:17303086 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
increases activity multiple interactions
|
ISO
|
Adenosine results in increased activity of CFTR protein [Isoproterenol co-treated with Adenosine] results in increased activity of CFTR protein
|
CTD |
PMID:15039139 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Creb1
|
cAMP responsive element binding protein 1
|
increases expression multiple interactions
|
ISO
|
Adenosine results in increased expression of CREB1 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA]; PSB603 inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA]; ZM 241385 inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA]
|
CTD |
PMID:34070360 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339
|
|
G
|
Ctnnb1
|
catenin beta 1
|
increases expression
|
ISO
|
Adenosine results in increased expression of CTNNB1 mRNA
|
CTD |
PMID:34070360 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
G
|
Diablo
|
diablo, IAP-binding mitochondrial protein
|
increases expression multiple interactions
|
ISO
|
Adenosine results in increased expression of DIABLO mRNA; Adenosine results in increased expression of DIABLO protein Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO mRNA]; Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO protein]
|
CTD |
PMID:20063052 |
|
NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265
|
|
G
|
Dkk1
|
dickkopf WNT signaling pathway inhibitor 1
|
increases expression
|
ISO
|
Adenosine results in increased expression of DKK1 mRNA
|
CTD |
PMID:34070360 |
|
NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650
|
|
G
|
Dpp4
|
dipeptidylpeptidase 4
|
decreases expression multiple interactions
|
ISO
|
Adenosine results in decreased expression of DPP4 mRNA; Adenosine results in decreased expression of DPP4 protein [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 protein; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 protein
|
CTD |
PMID:16611738 |
|
NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422
|
|
G
|
E2f1
|
E2F transcription factor 1
|
affects expression
|
EXP
|
Adenosine affects the expression of E2F1 protein
|
CTD |
PMID:19638569 |
|
NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563
|
|
G
|
E2f3
|
E2F transcription factor 3
|
affects expression
|
EXP
|
Adenosine affects the expression of E2F3 protein
|
CTD |
PMID:19638569 |
|
NCBI chr17:34,810,355...34,887,725
Ensembl chr17:34,809,998...34,887,725
|
|
G
|
Egf
|
epidermal growth factor
|
increases expression multiple interactions
|
ISO
|
Adenosine results in increased expression of EGF mRNA Adenosine results in increased expression of and results in increased secretion of EGF protein
|
CTD |
PMID:34070360 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297
|
|
G
|
Esr1
|
estrogen receptor 1
|
increases expression
|
ISO
|
Adenosine results in increased expression of ESR1 protein
|
CTD |
PMID:29360751 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
G
|
Esr2
|
estrogen receptor 2
|
increases expression
|
ISO
|
Adenosine results in increased expression of ESR2 protein
|
CTD |
PMID:29360751 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709
|
|
G
|
Fadd
|
Fas associated via death domain
|
decreases expression multiple interactions
|
ISO
|
Adenosine results in decreased expression of FADD mRNA Dipyridamole inhibits the reaction [Adenosine results in decreased expression of FADD mRNA]
|
CTD |
PMID:17303086 |
|
NCBI chr 1:209,169,245...209,175,423
Ensembl chr 1:209,169,318...209,174,976
|
|
G
|
Faslg
|
Fas ligand
|
increases expression multiple interactions
|
ISO
|
Adenosine results in increased expression of FASLG protein [Adenosine co-treated with Coformycin] results in decreased expression of FASL mRNA
|
CTD |
PMID:11992407 PMID:16419169 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
Fgf6
|
fibroblast growth factor 6
|
multiple interactions
|
ISO
|
Adenosine results in increased expression of and results in increased secretion of FGF6 protein
|
CTD |
PMID:34070360 |
|
NCBI chr 4:161,541,089...161,549,624
Ensembl chr 4:161,541,089...161,553,521
|
|
G
|
Fshb
|
follicle stimulating hormone subunit beta
|
increases expression
|
ISO
|
Adenosine results in increased expression of FSHB protein
|
CTD |
PMID:29360751 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072
|
|
G
|
Fzd3
|
frizzled class receptor 3
|
increases expression
|
ISO
|
Adenosine results in increased expression of FZD3 mRNA
|
CTD |
PMID:34070360 |
|
NCBI chr15:43,596,962...43,664,047
Ensembl chr15:43,596,965...43,663,960
|
|
G
|
Fzd5
|
frizzled class receptor 5
|
increases expression
|
ISO
|
Adenosine results in increased expression of FZD5 mRNA
|
CTD |
PMID:34070360 |
|
NCBI chr 9:73,606,860...73,614,039
Ensembl chr 9:73,606,860...73,618,612
|
|
G
|
Gdnf
|
glial cell derived neurotrophic factor
|
increases secretion
|
ISO
|
Adenosine results in increased secretion of GDNF protein
|
CTD |
PMID:34070360 |
|
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240
|
|
G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
increases phosphorylation increases expression
|
ISO
|
Adenosine results in increased phosphorylation of GSK3B protein Adenosine results in increased expression of GSK3B mRNA
|
CTD |
PMID:34070360 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249
|
|
G
|
Gzmb
|
granzyme B
|
multiple interactions
|
ISO
|
[Adenosine co-treated with Coformycin] results in decreased expression of GZMB mRNA
|
CTD |
PMID:11992407 |
|
NCBI chr15:34,459,007...34,462,469
Ensembl chr15:34,459,007...34,462,469
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions
|
ISO
|
Adenosine promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]
|
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Hgf
|
hepatocyte growth factor
|
affects expression
|
EXP
|
Adenosine affects the expression of HGF protein
|
CTD |
PMID:19638569 |
|
NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
increases expression
|
ISO
|
Adenosine results in increased expression of HIF1A mRNA
|
CTD |
PMID:20067761 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
G
|
Idh2
|
isocitrate dehydrogenase (NADP(+)) 2
|
increases abundance multiple interactions
|
ISO
|
IDH2 protein mutant form results in increased abundance of Adenosine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine]
|
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
[Adenosine co-treated with Coformycin] results in decreased expression of IFNG protein
|
CTD |
PMID:11992407 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Igf1
|
insulin-like growth factor 1
|
affects expression multiple interactions
|
ISO
|
Adenosine affects the expression of IGF1 mRNA Adenosine results in increased expression of and results in increased secretion of IGF1 protein
|
CTD |
PMID:34070360 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764
|
|
G
|
Igf2
|
insulin-like growth factor 2
|
multiple interactions
|
ISO
|
Adenosine results in increased expression of and results in increased secretion of IGF2 protein
|
CTD |
PMID:34070360 |
|
NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions increases expression
|
ISO
|
Adenosine promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Adenosine results in increased expression of IL10 mRNA; Adenosine results in increased expression of IL10 protein
|
CTD |
PMID:11023991 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il12b
|
interleukin 12B
|
decreases expression multiple interactions
|
ISO
|
Adenosine results in decreased expression of IL12B protein Adenosine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]
|
CTD |
PMID:11023991 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
Adenosine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Adenosine inhibits the reaction [IL1B protein results in increased expression of IL1R1]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]
|
CTD |
PMID:24878381 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il1r1
|
interleukin 1 receptor type 1
|
multiple interactions
|
EXP
|
Adenosine inhibits the reaction [IL1B protein results in increased expression of IL1R1]
|
CTD |
PMID:24878381 |
|
NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579
|
|
G
|
Il2
|
interleukin 2
|
multiple interactions
|
ISO
|
[Adenosine co-treated with Coformycin] results in decreased expression of IL2 protein
|
CTD |
PMID:11992407 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672
|
|
G
|
Lef1
|
lymphoid enhancer binding factor 1
|
increases expression
|
ISO
|
Adenosine results in increased expression of LEF1 mRNA
|
CTD |
PMID:34070360 |
|
NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929
|
|
G
|
Ly96
|
lymphocyte antigen 96
|
increases expression
|
ISO
|
Adenosine results in increased expression of LY96 mRNA
|
CTD |
PMID:21538184 |
|
NCBI chr 5:7,365,536...7,397,864
Ensembl chr 5:7,365,557...7,395,816
|
|
G
|
Map2k1
|
mitogen activated protein kinase kinase 1
|
increases phosphorylation
|
ISO
|
Adenosine results in increased phosphorylation of MAP2K1 protein
|
CTD |
PMID:34070360 |
|
NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184
|
|
G
|
Map2k2
|
mitogen activated protein kinase kinase 2
|
increases phosphorylation
|
ISO
|
Adenosine results in increased phosphorylation of MAP2K2 protein
|
CTD |
PMID:34070360 |
|
NCBI chr 7:9,241,449...9,264,216
Ensembl chr 7:9,241,310...9,260,940
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions decreases phosphorylation
|
ISO
|
[Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 protein
|
CTD |
PMID:16611738 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
decreases phosphorylation multiple interactions
|
ISO
|
Adenosine results in decreased phosphorylation of MAPK3 protein [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 protein
|
CTD |
PMID:16611738 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Met
|
MET proto-oncogene, receptor tyrosine kinase
|
increases expression
|
EXP
|
Adenosine results in increased expression of MET protein
|
CTD |
PMID:19638569 |
|
NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821
|
|
G
|
Mki67
|
marker of proliferation Ki-67
|
affects expression increases expression
|
ISO EXP
|
Adenosine affects the expression of MKI67 mRNA Adenosine results in increased expression of MKI67 protein
|
CTD |
PMID:19638569 PMID:34070360 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
increases phosphorylation
|
ISO
|
Adenosine results in increased phosphorylation of MTOR protein
|
CTD |
PMID:34070360 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
decreases expression increases expression multiple interactions
|
ISO EXP
|
Adenosine results in decreased expression of MYC protein Adenosine results in increased expression of MYC protein Adenosine results in increased expression of MYC mRNA Thymidine inhibits the reaction [Adenosine results in decreased expression of MYC protein]; Uridine inhibits the reaction [Adenosine results in decreased expression of MYC protein]
|
CTD |
PMID:9808420 PMID:19638569 PMID:34070360 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO
|
[Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] results in decreased expression of NFKBIA mRNA
|
CTD |
PMID:24224954 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
decreases stability multiple interactions
|
EXP
|
Adenosine results in decreased stability of NOS2 mRNA Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]
|
CTD |
PMID:24878381 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nt5e
|
5' nucleotidase, ecto
|
multiple interactions
|
ISO
|
[alpha,beta-methyleneadenosine 5'-diphosphate results in decreased activity of NT5E protein] inhibits the reaction [Oxygen deficiency results in increased abundance of Adenosine]
|
CTD |
PMID:23437309 |
|
NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
increases expression
|
EXP
|
Adenosine results in increased expression of PCNA protein
|
CTD |
PMID:19638569 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pgf
|
placental growth factor
|
increases secretion
|
ISO
|
Adenosine results in increased secretion of PGF protein
|
CTD |
PMID:34070360 |
|
NCBI chr 6:110,547,165...110,557,747
Ensembl chr 6:110,547,153...110,557,747
|
|
G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
increases expression
|
ISO
|
Adenosine results in increased expression of PPARGC1A mRNA
|
CTD |
PMID:23056435 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213
|
|
G
|
Prf1
|
perforin 1
|
multiple interactions
|
ISO
|
[Adenosine co-treated with Coformycin] results in decreased expression of PRF1 mRNA
|
CTD |
PMID:11992407 |
|
NCBI chr20:29,789,040...29,794,550
Ensembl chr20:29,788,972...29,795,124
|
|
G
|
Ptgdr
|
prostaglandin D2 receptor
|
multiple interactions
|
ISO
|
[Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased metabolism of Adenosine; [Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased secretion of Adenosine
|
CTD |
PMID:11562489 |
|
NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO
|
[Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein]
|
CTD |
PMID:24224954 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Ren
|
renin
|
decreases secretion
|
EXP
|
Adenosine results in decreased secretion of REN protein
|
CTD |
PMID:3044993 |
|
NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543
|
|
G
|
Ripk1
|
receptor interacting serine/threonine kinase 1
|
multiple interactions
|
ISO
|
[Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein
|
CTD |
PMID:24224954 |
|
NCBI chr17:31,044,983...31,077,167
Ensembl chr17:31,044,994...31,077,167
|
|
G
|
Rps6kb1
|
ribosomal protein S6 kinase B1
|
increases phosphorylation
|
ISO
|
Adenosine results in increased phosphorylation of RPS6KB1 protein
|
CTD |
PMID:34070360 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238
|
|
G
|
Slc28a1
|
solute carrier family 28 member 1
|
affects transport multiple interactions
|
ISO
|
SLC28A1 protein affects the transport of Adenosine Adenosine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]
|
CTD |
PMID:9124315 |
|
NCBI chr 1:144,490,453...144,532,025
Ensembl chr 1:144,490,623...144,531,544
|
|
G
|
Slc28a2
|
solute carrier family 28 member 2
|
increases transport
|
ISO
|
SLC28A2 protein results in increased transport of Adenosine
|
CTD |
PMID:10087507 |
|
NCBI chr 3:129,778,425...129,841,292
Ensembl chr 3:129,807,537...129,841,291
|
|
G
|
Slc29a1
|
solute carrier family 29 member 1
|
multiple interactions increases uptake affects abundance
|
ISO EXP
|
4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; [4-nitrobenzylthioinosine results in decreased activity of SLC29A1 protein] inhibits the reaction [Oxygen deficiency results in increased abundance of Adenosine]; [SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine; Dipyridamole inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole promotes the reaction [[SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine] SLC29A1 protein alternative form results in increased uptake of Adenosine; SLC29A1 protein results in increased uptake of Adenosine cilostazol inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; draflazine inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Ethanol promotes the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Ethanol promotes the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Ticagrelor inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine] Adenosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] SLC29A1 affects the abundance of Adenosine
|
CTD |
PMID:9353301 PMID:9396714 PMID:11179696 PMID:21283641 PMID:21872611 PMID:23437309 PMID:28041785 More...
|
|
NCBI chr 9:22,897,099...22,911,640
Ensembl chr 9:22,902,471...22,914,620
|
|
G
|
Slc29a2
|
solute carrier family 29 member 2
|
increases uptake
|
ISO
|
SLC29A2 protein results in increased uptake of Adenosine
|
CTD |
PMID:9396714 |
|
NCBI chr 1:211,756,588...211,764,561
Ensembl chr 1:211,757,000...211,764,560
|
|
G
|
Slc29a3
|
solute carrier family 29 member 3
|
affects transport
|
ISO
|
SLC29A3 protein affects the transport of Adenosine
|
CTD |
PMID:19164483 |
|
NCBI chr20:29,191,086...29,228,299
Ensembl chr20:29,191,127...29,228,299
|
|
G
|
Slc5a5
|
solute carrier family 5 member 5
|
increases expression
|
EXP
|
Adenosine results in increased expression of SLC5A5 mRNA; Adenosine results in increased expression of SLC5A5 protein
|
CTD |
PMID:16954431 |
|
NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691
|
|
G
|
Tgfa
|
transforming growth factor alpha
|
increases secretion
|
ISO
|
Adenosine results in increased secretion of TGFA protein
|
CTD |
PMID:34070360 |
|
NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
increases expression
|
ISO
|
Adenosine results in increased expression of TGFB1 mRNA; Adenosine results in increased expression of TGFB1 protein
|
CTD |
PMID:34070360 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tgfb2
|
transforming growth factor, beta 2
|
increases expression multiple interactions
|
ISO
|
Adenosine results in increased expression of TGFB2 mRNA Adenosine results in increased expression of and results in increased secretion of TGFB2 protein
|
CTD |
PMID:34070360 |
|
NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856
|
|
G
|
Tlr4
|
toll-like receptor 4
|
increases expression affects localization multiple interactions
|
ISO
|
Adenosine results in increased expression of TLR4 mRNA Adenosine affects the localization of TLR4 protein Adenosine promotes the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of TLR4 protein]
|
CTD |
PMID:21538184 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions decreases expression
|
ISO
|
5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; [Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in increased susceptibility to TNF protein; Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF mRNA]; Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; ZM 241385 inhibits the reaction [Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]] Adenosine results in decreased expression of TNF protein
|
CTD |
PMID:11023991 PMID:21538184 PMID:24224954 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfaip3
|
TNF alpha induced protein 3
|
multiple interactions
|
ISO
|
[Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 mRNA; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 protein
|
CTD |
PMID:24224954 |
|
NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979
|
|
G
|
Tnfsf10
|
TNF superfamily member 10
|
multiple interactions
|
ISO
|
[Adenosine co-treated with Coformycin] results in decreased expression of TNFSF10 mRNA
|
CTD |
PMID:11992407 |
|
NCBI chr 2:112,136,550...112,155,903
|
|
G
|
Tp53bp1
|
tumor protein p53 binding protein 1
|
multiple interactions
|
ISO
|
Adenosine promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]
|
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747
|
|
G
|
Upp1
|
uridine phosphorylase 1
|
increases metabolic processing
|
ISO
|
UPP1 protein results in increased metabolism of Adenosine
|
CTD |
PMID:15772079 |
|
NCBI chr14:88,023,155...88,043,036
Ensembl chr14:88,023,351...88,043,034
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions increases expression increases secretion
|
ISO
|
Adenosine promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein]; Adenosine results in increased expression of and results in increased secretion of VEGFA protein Adenosine results in increased expression of VEGFA mRNA Adenosine results in increased secretion of VEGFA protein
|
CTD |
PMID:20067761 PMID:34070360 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
|
G
|
Sult1a1
|
sulfotransferase family 1A member 1
|
multiple interactions
|
EXP
|
Glutathione Disulfide affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]; Glutathione Disulfide affects the reaction [Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]]; Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]
|
CTD |
PMID:21130751 |
|
NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131
|
|
G
|
Sult1e1
|
sulfotransferase family 1E member 1
|
multiple interactions
|
ISO
|
[2,2',4,4'-tetrabromodiphenyl ether metabolite co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; Estradiol inhibits the reaction [[tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein]
|
CTD |
PMID:23959441 |
|
NCBI chr14:20,700,444...20,718,719
Ensembl chr14:20,700,292...20,718,716
|
|
G
|
Sult2a1
|
sulfotransferase family 2A member 1
|
affects binding multiple interactions
|
ISO
|
adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]; Dehydroepiandrosterone inhibits the reaction [Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]]
|
CTD |
PMID:24059442 |
|
NCBI chr 1:84,582,011...84,639,001
|
|
|
G
|
Nudt11
|
nudix hydrolase 11
|
multiple interactions
|
ISO
|
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate
|
CTD |
PMID:12121577 |
|
NCBI chr X:18,998,587...19,005,208
Ensembl chr X:18,998,461...19,005,208
|
|
|
G
|
Cd80
|
Cd80 molecule
|
increases expression
|
ISO
|
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD80 protein
|
CTD |
PMID:15944274 |
|
NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540
|
|
G
|
Cd86
|
CD86 molecule
|
increases expression
|
ISO
|
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD86 protein
|
CTD |
PMID:15944274 |
|
NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361
|
|
G
|
Il10
|
interleukin 10
|
decreases expression
|
ISO
|
adenosine 5'-O-(3-thiotriphosphate) results in decreased expression of IL10 protein
|
CTD |
PMID:15944274 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il12b
|
interleukin 12B
|
increases expression
|
ISO
|
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL12B protein
|
CTD |
PMID:15944274 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
G
|
Il1b
|
interleukin 1 beta
|
increases expression
|
ISO
|
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL1B protein
|
CTD |
PMID:15944274 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
P2rx7
|
purinergic receptor P2X 7
|
affects response to substance
|
ISO
|
P2RX7 protein affects the susceptibility to adenosine 5'-O-(3-thiotriphosphate)
|
CTD |
PMID:12873706 |
|
NCBI chr12:39,550,531...39,594,984
Ensembl chr12:39,540,567...39,595,193
|
|
G
|
Ptgdr
|
prostaglandin D2 receptor
|
multiple interactions
|
ISO
|
adenosine 5'-O-(3-thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]
|
CTD |
PMID:9579725 |
|
NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873
|
|
G
|
Trpv1
|
transient receptor potential cation channel, subfamily V, member 1
|
increases activity multiple interactions
|
EXP
|
adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein Capsaicin promotes the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein]; capsazepine inhibits the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein]
|
CTD |
PMID:11140687 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021
|
|
|
G
|
Abcc9
|
ATP binding cassette subfamily C member 9
|
multiple interactions
|
ISO
|
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]]
|
CTD |
PMID:11390963 |
|
NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:177,262,848...177,386,348
|
|
G
|
Aldh1a1
|
aldehyde dehydrogenase 1 family, member A1
|
multiple interactions
|
ISO
|
[4-dimethylaminocinnamaldehyde co-treated with Adenosine Monophosphate] binds to ALDH1A1 protein
|
CTD |
PMID:10609638 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500
|
|
G
|
Ercc6
|
ERCC excision repair 6, chromatin remodeling factor
|
increases abundance
|
ISO
|
ERCC6 gene mutant form results in increased abundance of Adenosine Monophosphate
|
CTD |
PMID:25440059 |
|
NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions
|
ISO
|
Adenosine Monophosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]
|
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Kcnj11
|
potassium inwardly-rectifying channel, subfamily J, member 11
|
multiple interactions
|
ISO
|
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]]
|
CTD |
PMID:11390963 |
|
NCBI chr 1:105,727,473...105,731,167
Ensembl chr 1:105,727,570...105,731,169
|
|
G
|
Nudt11
|
nudix hydrolase 11
|
multiple interactions
|
ISO
|
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate
|
CTD |
PMID:12121577 |
|
NCBI chr X:18,998,587...19,005,208
Ensembl chr X:18,998,461...19,005,208
|
|
G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
increases expression
|
ISO
|
Adenosine Monophosphate results in increased expression of PPARGC1A mRNA
|
CTD |
PMID:23056435 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213
|
|
G
|
Tp53bp1
|
tumor protein p53 binding protein 1
|
multiple interactions
|
ISO
|
Adenosine Monophosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]
|
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747
|
|
G
|
Tp73
|
tumor protein p73
|
affects abundance
|
ISO
|
TP73 protein affects the abundance of Adenosine Monophosphate
|
CTD |
PMID:25554796 |
|
NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:169,903,801...169,963,552
|
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
multiple interactions affects binding
|
ISO
|
estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein mutant form]; estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein]; Vanadates promotes the reaction [Adenosine Diphosphate binds to ABCC1 protein] Adenosine Diphosphate binds to ABCC1 protein; Adenosine Diphosphate binds to ABCC1 protein mutant form
|
CTD |
PMID:18336795 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions
|
EXP
|
Adenosine Diphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein]
|
CTD |
PMID:1848756 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Ak1
|
adenylate kinase 1
|
increases abundance
|
ISO
|
AK1 protein results in increased abundance of Adenosine Diphosphate
|
CTD |
PMID:11390963 |
|
NCBI chr 3:36,310,113...36,320,760
Ensembl chr 3:36,310,197...36,320,757
|
|
G
|
Alb
|
albumin
|
decreases secretion multiple interactions
|
ISO
|
Adenosine Diphosphate results in decreased secretion of ALB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of ALB protein]
|
CTD |
PMID:17303692 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
App
|
amyloid beta precursor protein
|
multiple interactions increases abundance
|
ISO
|
PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Adenosine Diphosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate]
|
CTD |
PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
G
|
Axl
|
Axl receptor tyrosine kinase
|
decreases response to substance
|
ISO
|
AXL protein results in decreased susceptibility to Adenosine Diphosphate
|
CTD |
PMID:15733062 |
|
NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:90,392,864...90,424,009
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein]
|
CTD |
PMID:16781456 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cd40lg
|
CD40 ligand
|
increases expression multiple interactions
|
ISO
|
Adenosine Diphosphate results in increased expression of CD40LG protein clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein]
|
CTD |
PMID:11297035 PMID:17043144 |
|
NCBI chr X:140,164,341...140,176,057
Ensembl chr X:140,164,302...140,176,475
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
multiple interactions
|
ISO
|
Adenosine Diphosphate binds to and results in decreased activity of CFTR protein; P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein]
|
CTD |
PMID:15684079 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Chordc1
|
cysteine and histidine rich domain containing 1
|
multiple interactions
|
ISO
|
Adenosine Diphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Diphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]
|
CTD |
PMID:23184943 |
|
NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
multiple interactions
|
ISO
|
CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid]
|
CTD |
PMID:16772608 PMID:18004210 PMID:18394438 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Dtymk
|
deoxythymidylate kinase
|
multiple interactions
|
ISO
|
DTYMK protein binds to [N1-(4-bis(pivaloyloxymethyl)phosphinylbuten-2-yl)thymine co-treated with Adenosine Diphosphate]
|
CTD |
PMID:21128666 |
|
NCBI chr 9:101,762,899...101,771,733
Ensembl chr 9:101,762,899...101,774,504
|
|
G
|
Dusp1
|
dual specificity phosphatase 1
|
multiple interactions
|
ISO
|
Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]]
|
CTD |
PMID:32941855 |
|
NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644
|
|
G
|
Dusp6
|
dual specificity phosphatase 6
|
multiple interactions
|
ISO
|
Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]]
|
CTD |
PMID:32941855 |
|
NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833
|
|
G
|
Epha4
|
Eph receptor A4
|
increases phosphorylation multiple interactions
|
ISO
|
Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein Benzoic Acid analog inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein]
|
CTD |
PMID:22273509 |
|
NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:86,263,982...86,406,755
|
|
G
|
Ern1
|
endoplasmic reticulum to nucleus signaling 1
|
multiple interactions decreases activity
|
ISO
|
Adenosine Diphosphate inhibits the reaction [ERN1 protein binds to ERN1 protein] Adenosine Diphosphate results in decreased activity of ERN1 protein
|
CTD |
PMID:25164867 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791
|
|
G
|
F2
|
coagulation factor II, thrombin
|
increases abundance multiple interactions
|
ISO
|
F2 protein results in increased abundance of Adenosine Diphosphate Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]; resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]
|
CTD |
PMID:15342215 |
|
NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246
|
|
G
|
Fga
|
fibrinogen alpha chain
|
multiple interactions increases secretion
|
ISO
|
Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGA protein]
|
CTD |
PMID:17303692 |
|
NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577
|
|
G
|
Fgb
|
fibrinogen beta chain
|
decreases secretion multiple interactions
|
ISO
|
Adenosine Diphosphate results in decreased secretion of FGB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of FGB protein]
|
CTD |
PMID:17303692 |
|
NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434
|
|
G
|
Fgg
|
fibrinogen gamma chain
|
increases secretion multiple interactions
|
ISO
|
Adenosine Diphosphate results in increased secretion of FGG protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGG protein]
|
CTD |
PMID:17303692 |
|
NCBI chr 2:170,652,929...170,660,372
Ensembl chr 2:170,652,234...170,661,170
|
|
G
|
Gapdh
|
glyceraldehyde-3-phosphate dehydrogenase
|
multiple interactions
|
ISO
|
Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
|
CTD |
PMID:15788719 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377
|
|
G
|
Gas6
|
growth arrest specific 6
|
increases response to substance
|
ISO
|
GAS6 protein results in increased susceptibility to Adenosine Diphosphate
|
CTD |
PMID:15733062 |
|
NCBI chr16:82,747,676...82,778,090
Ensembl chr16:82,747,345...82,778,088
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions
|
ISO
|
Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]
|
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Hras
|
HRas proto-oncogene, GTPase
|
multiple interactions
|
ISO
|
Adenosine Diphosphate binds to and affects the folding of HRAS protein
|
CTD |
PMID:16388579 |
|
NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590
|
|
G
|
Hsp90aa1
|
heat shock protein 90 alpha family class A member 1
|
multiple interactions
|
ISO
|
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]
|
CTD |
PMID:23184943 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499
|
|
G
|
Idh2
|
isocitrate dehydrogenase (NADP(+)) 2
|
multiple interactions increases abundance
|
ISO
|
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine Diphosphate]
|
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248
|
|
G
|
Il6
|
interleukin 6
|
increases expression multiple interactions
|
ISO
|
Adenosine Diphosphate results in increased expression of IL6 protein MRS 2211 inhibits the reaction [Adenosine Diphosphate results in increased expression of IL6 protein]
|
CTD |
PMID:24849676 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Itga2
|
integrin subunit alpha 2
|
multiple interactions
|
ISO
|
ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Adenosine Diphosphate]
|
CTD |
PMID:16214444 |
|
NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:48,253,412...48,354,509
|
|
G
|
Itga2b
|
integrin subunit alpha 2b
|
multiple interactions
|
ISO
|
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]
|
CTD |
PMID:18404433 |
|
NCBI chr10:87,908,697...87,926,225
Ensembl chr10:87,908,697...87,925,833
|
|
G
|
Itgb1bp2
|
integrin subunit beta 1 binding protein 2
|
multiple interactions
|
ISO
|
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]
|
CTD |
PMID:23184943 |
|
NCBI chr X:70,612,118...70,617,158
Ensembl chr X:70,612,521...70,617,158
|
|
G
|
Itgb3
|
integrin subunit beta 3
|
multiple interactions
|
ISO
|
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]
|
CTD |
PMID:18404433 |
|
NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation multiple interactions
|
ISO
|
Adenosine Diphosphate results in increased phosphorylation of MAPK1 protein Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]]
|
CTD |
PMID:15034929 PMID:32941855 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation multiple interactions
|
ISO
|
Adenosine Diphosphate results in increased phosphorylation of MAPK3 protein Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]]
|
CTD |
PMID:15034929 PMID:32941855 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
multiple interactions
|
ISO
|
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:24466103 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mapk9
|
mitogen-activated protein kinase 9
|
multiple interactions
|
ISO
|
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK9 protein]
|
CTD |
PMID:24466103 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228
|
|
G
|
Mapt
|
microtubule-associated protein tau
|
multiple interactions increases abundance
|
ISO
|
PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased abundance of Adenosine Diphosphate]
|
CTD |
PMID:39172838 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108
|
|
G
|
Mertk
|
MER proto-oncogene, tyrosine kinase
|
increases response to substance
|
ISO
|
MERTK protein results in increased susceptibility to Adenosine Diphosphate
|
CTD |
PMID:15733062 |
|
NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:136,383,560...136,500,192
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
NOS2 protein affects the susceptibility to [Phenylephrine co-treated with Adenosine Diphosphate]
|
CTD |
PMID:11498454 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nt5e
|
5' nucleotidase, ecto
|
decreases activity
|
ISO
|
Adenosine Diphosphate analog results in decreased activity of NT5E protein
|
CTD |
PMID:18404487 |
|
NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645
|
|
G
|
P2ry12
|
purinergic receptor P2Y12
|
affects response to substance increases response to substance multiple interactions
|
ISO EXP
|
P2RY12 gene polymorphism affects the susceptibility to Adenosine Diphosphate; P2RY12 protein affects the susceptibility to Adenosine Diphosphate P2RY12 protein results in increased susceptibility to Adenosine Diphosphate Epinephrine inhibits the reaction [P2RY12 gene mutant form results in decreased susceptibility to Adenosine Diphosphate] P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]
|
CTD |
PMID:11196645 PMID:11413167 PMID:18404433 PMID:23849096 |
|
NCBI chr 2:145,631,487...145,673,194
Ensembl chr 2:145,629,967...145,633,410
|
|
G
|
Pdgfb
|
platelet derived growth factor subunit B
|
increases secretion multiple interactions
|
ISO
|
Adenosine Diphosphate results in increased secretion of PDGFB protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of PDGFB protein]
|
CTD |
PMID:17303692 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343
|
|
G
|
Pf4
|
platelet factor 4
|
increases secretion multiple interactions
|
ISO
|
Adenosine Diphosphate results in increased secretion of PF4 protein silidianin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; Silybin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; silychristin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]
|
CTD |
PMID:19428933 PMID:29439388 |
|
NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,582,477...17,583,392
|
|
G
|
Pfkm
|
phosphofructokinase, muscle
|
multiple interactions
|
ISO
|
Adenosine Diphosphate inhibits the reaction [resveratrol results in decreased activity of PFKM protein]
|
CTD |
PMID:23454376 |
|
NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:131,100,753...131,138,248
|
|
G
|
Pgp
|
phosphoglycolate phosphatase
|
decreases phosphorylation
|
ISO
|
PGP protein results in decreased phosphorylation of Adenosine Diphosphate
|
CTD |
PMID:24338473 |
|
NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,999,331...14,002,408
|
|
G
|
Ppbp
|
pro-platelet basic protein
|
increases secretion
|
ISO
|
Adenosine Diphosphate results in increased secretion of PPBP protein
|
CTD |
PMID:19428933 |
|
NCBI chr14:17,586,495...17,587,299
Ensembl chr14:17,586,495...17,587,299
|
|
G
|
Ppp5c
|
protein phosphatase 5, catalytic subunit
|
multiple interactions
|
ISO
|
Adenosine Diphosphate binds to and affects the folding of PPP5C protein
|
CTD |
PMID:23184943 |
|
NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:86,818,297...86,842,950
|
|
G
|
Psen1
|
presenilin 1
|
multiple interactions
|
ISO
|
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate]
|
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189
|
|
G
|
Ptpn1
|
protein tyrosine phosphatase, non-receptor type 1
|
increases glutathionylation multiple interactions
|
EXP
|
Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein]
|
CTD |
PMID:16781456 |
|
NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:177,057,659...177,106,416
|
|
G
|
Selp
|
selectin P
|
multiple interactions increases expression
|
ISO
|
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; Heparin promotes the reaction [Adenosine Diphosphate affects the localization of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]; P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; Quercetin inhibits the reaction [Adenosine Diphosphate results in increased expression of SELP protein]
|
CTD |
PMID:9740346 PMID:18394438 PMID:18404433 PMID:23249183 |
|
NCBI chr13:79,009,379...79,044,994
Ensembl chr13:79,009,475...79,044,987
|
|
G
|
Sirt3
|
sirtuin 3
|
decreases abundance
|
ISO
|
SIRT3 protein results in decreased abundance of Adenosine Diphosphate
|
CTD |
PMID:23166782 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076
|
|
G
|
Taldo1
|
transaldolase 1
|
increases abundance
|
ISO
|
TALDO1 gene mutant form results in increased abundance of Adenosine Diphosphate
|
CTD |
PMID:19436114 |
|
NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535
|
|
G
|
Thbs1
|
thrombospondin 1
|
increases secretion
|
ISO
|
Adenosine Diphosphate results in increased secretion of THBS1 protein
|
CTD |
PMID:17303692 |
|
NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402
|
|
G
|
Tp53bp1
|
tumor protein p53 binding protein 1
|
multiple interactions
|
ISO
|
Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]
|
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747
|
|
G
|
Tyro3
|
TYRO3 protein tyrosine kinase
|
increases response to substance
|
ISO
|
TYRO3 protein results in increased susceptibility to Adenosine Diphosphate
|
CTD |
PMID:15733062 |
|
NCBI chr 3:127,231,468...127,254,806
Ensembl chr 3:127,231,903...127,250,943
|
|
G
|
Vasp
|
vasodilator-stimulated phosphoprotein
|
increases phosphorylation multiple interactions
|
ISO
|
Adenosine Diphosphate results in increased phosphorylation of VASP protein N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of VASP protein]
|
CTD |
PMID:25329809 |
|
NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:88,038,037...88,058,650
|
|
|
G
|
Adprh
|
ADP-ribosylarginine hydrolase
|
increases hydrolysis
|
ISO
|
ADPRH protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite
|
CTD |
PMID:21498885 |
|
NCBI chr11:75,805,347...75,811,686
Ensembl chr11:75,805,310...75,812,452
|
|
G
|
Adprs
|
ADP-ribosylserine hydrolase
|
increases hydrolysis multiple interactions
|
ISO
|
ADPRS protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite Adenosine Diphosphate Ribose inhibits the reaction [ADPRS protein results in increased hydrolysis of O-Acetyl-ADP-Ribose]
|
CTD |
PMID:21498885 |
|
NCBI chr 5:143,898,542...143,903,816
Ensembl chr 5:143,898,542...143,903,816
|
|
G
|
Nos1
|
nitric oxide synthase 1
|
multiple interactions
|
ISO
|
NOS1 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased ribosylation of Adenosine Diphosphate Ribose]
|
CTD |
PMID:10318960 |
|
NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837
|
|
G
|
Trpm2
|
transient receptor potential cation channel, subfamily M, member 2
|
multiple interactions increases activity
|
EXP ISO
|
Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]; Clotrimazole inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]; Flufenamic Acid inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]] Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein 2-aminoethoxydiphenyl borate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]]; Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Copper Sulfate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; ferrous chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; lead nitrate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Mercuric Chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Miconazole inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Selenium Oxides inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein] 4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; [Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein; Glutathione inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; Glutathione inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; TRPM2 protein promotes the reaction [Adenosine Diphosphate Ribose results in increased uptake of Calcium]
|
CTD |
PMID:18204483 PMID:20878536 PMID:21900507 PMID:22750002 PMID:33309544 PMID:35395232 More...
|
|
NCBI chr20:10,703,190...10,752,795
Ensembl chr20:10,704,482...10,752,802
|
|
|
G
|
Ager
|
advanced glycosylation end product-specific receptor
|
multiple interactions increases expression
|
ISO
|
[Ribose co-treated with Glucose] results in increased expression of AGER protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]] Ribose results in increased expression of AGER protein
|
CTD |
PMID:30101366 |
|
NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685
|
|
G
|
B2m
|
beta-2 microglobulin
|
increases glycation
|
ISO
|
Ribose results in increased glycation of B2M protein
|
CTD |
PMID:21864514 |
|
NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP
|
[Creatine co-treated with Ribose] results in decreased activity of CASP3 protein
|
CTD |
PMID:21220914 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Chuk
|
component of inhibitor of nuclear factor kappa B kinase complex
|
increases phosphorylation
|
ISO
|
Ribose results in increased phosphorylation of CHUK protein
|
CTD |
PMID:30101366 |
|
NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273
|
|
G
|
Ikbkb
|
inhibitor of nuclear factor kappa B kinase subunit beta
|
increases phosphorylation
|
ISO
|
Ribose results in increased phosphorylation of IKBKB protein
|
CTD |
PMID:30101366 |
|
NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911
|
|
G
|
Ins1
|
insulin 1
|
increases secretion
|
ISO
|
Ribose results in increased secretion of INS1 protein
|
CTD |
PMID:30101366 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions increases phosphorylation
|
ISO
|
[Ribose co-treated with Glucose] results in increased phosphorylation of NFKBIA protein Ribose results in increased phosphorylation of NFKBIA protein
|
CTD |
PMID:30101366 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Oat
|
ornithine aminotransferase
|
multiple interactions
|
EXP
|
Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]
|
CTD |
PMID:2827574 |
|
NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:196,777,975...196,797,754
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
increases phosphorylation multiple interactions
|
ISO
|
Ribose results in increased phosphorylation of RELA protein [Ribose co-treated with Glucose] affects the localization of RELA protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]]; Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]
|
CTD |
PMID:30101366 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions
|
EXP
|
Adenylyl Imidodiphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein]
|
CTD |
PMID:1848756 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
affects activity
|
ISO
|
Adenylyl Imidodiphosphate affects the activity of CFTR protein
|
CTD |
PMID:15657297 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Csnk2a1
|
casein kinase 2 alpha 1
|
affects binding
|
ISO
|
Adenylyl Imidodiphosphate binds to CSNK2A1 protein
|
CTD |
PMID:34344863 |
|
NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698
|
|
G
|
Ptgdr
|
prostaglandin D2 receptor
|
multiple interactions
|
ISO
|
Adenylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]
|
CTD |
PMID:9579725 |
|
NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873
|
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein
|
CTD |
PMID:11139385 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
|
G
|
Abca8
|
ATP binding cassette subfamily A member 8
|
multiple interactions
|
ISO
|
Adenosine Triphosphate affects the reaction [ABCA8 protein results in increased uptake of estradiol-17 beta-glucuronide]
|
CTD |
PMID:12379217 |
|
NCBI chr10:95,416,984...95,490,647
Ensembl chr10:95,416,205...95,490,452
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
multiple interactions
|
ISO EXP
|
Adenosine Triphosphate promotes the reaction [ABCB11 protein results in increased uptake of fexofenadine]
|
CTD |
PMID:18245269 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions affects binding increases hydrolysis
|
ISO EXP
|
[Cobalt results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Magnesium results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Manganese results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; ABCB1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; aurapten promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate] Adenosine Triphosphate binds to ABCB1 protein [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate
|
CTD |
PMID:2900677 PMID:14978246 PMID:18829547 PMID:18955043 PMID:22233293 PMID:23685082 PMID:32497533 More...
|
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
multiple interactions affects activity increases hydrolysis affects binding
|
ISO
|
[Adenosine Triphosphate affects the activity of ABCC1 protein] which results in increased transport of Acetaminophen metabolite; ABCC1 protein binds to and results in increased degradation of Adenosine Triphosphate; ABCC1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; ABCC1 protein mutant form binds to and results in increased hydrolysis of Adenosine Triphosphate; Adenosine Triphosphate binds to and affects the folding of ABCC1 protein; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Bilirubin]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of estradiol-17 beta-glucuronide]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Leukotriene C4]; daidzein promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Resveratrol promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Daunorubicin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Vanadates inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Adenosine Triphosphate binds to ABCC1 protein
|
CTD |
PMID:10856430 PMID:11278000 PMID:14978246 PMID:15245331 PMID:15355964 PMID:15459206 PMID:15737336 PMID:15838832 PMID:16156793 PMID:18336795 PMID:18955043 PMID:32472168 More...
|
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
multiple interactions affects activity affects metabolic processing
|
EXP ISO
|
Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased secretion of Fluo-3]; Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of temocaprilat] Adenosine Triphosphate affects the activity of ABCC2 protein [Adenosine Triphosphate affects the activity of ABCC2 protein] which results in increased transport of Acetaminophen metabolite; [Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide; Adenosine Triphosphate affects the reaction [ABCC2 protein results in increased transport of Mercury]; verlukast inhibits the reaction [[Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide] ABCC2 protein affects the metabolism of Adenosine Triphosphate Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of S-1,2-dichlorovinyl-N-acetylcysteine]
|
CTD |
PMID:9067317 PMID:9794919 PMID:20060011 PMID:22027652 PMID:24039982 PMID:32003934 PMID:32472168 More...
|
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
multiple interactions
|
ISO
|
Adenosine Triphosphate promotes the reaction [ABCC3 protein affects the transport of fexofenadine]
|
CTD |
PMID:18245269 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494
|
|
G
|
Abcc4
|
ATP binding cassette subfamily C member 4
|
multiple interactions affects activity increases hydrolysis
|
ISO
|
[Adenosine Triphosphate affects the activity of ABCC4 protein] which results in increased transport of Acetaminophen metabolite; ABCC4 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; daidzein promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]; Resveratrol promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]
|
CTD |
PMID:14978246 PMID:16156793 PMID:32472168 |
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375
|
|
G
|
Abcc6
|
ATP binding cassette subfamily C member 6
|
affects binding
|
ISO
|
Adenosine Triphosphate binds to ABCC6 protein
|
CTD |
PMID:11880368 |
|
NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895
|
|
G
|
Abcc8
|
ATP binding cassette subfamily C member 8
|
multiple interactions
|
EXP
|
Adenosine Triphosphate deficiency inhibits the reaction [Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein]]
|
CTD |
PMID:19095654 |
|
NCBI chr 1:105,734,992...105,816,272
Ensembl chr 1:105,734,992...105,815,982
|
|
G
|
Abcc9
|
ATP binding cassette subfamily C member 9
|
multiple interactions
|
EXP ISO
|
Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein] Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]]
|
CTD |
PMID:11390963 PMID:28842488 |
|
NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:177,262,848...177,386,348
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
increases hydrolysis multiple interactions
|
ISO
|
ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate; Lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]; Sulfasalazine inhibits the reaction [[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate]
|
CTD |
PMID:18829547 PMID:32003934 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Abl1
|
ABL proto-oncogene 1, non-receptor tyrosine kinase
|
multiple interactions increases chemical synthesis
|
ISO
|
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] ABL1 protein mutant form results in increased chemical synthesis of Adenosine Triphosphate
|
CTD |
PMID:19366808 PMID:33070465 |
|
NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:35,377,391...35,480,846
|
|
G
|
Acsl5
|
acyl-CoA synthetase long-chain family member 5
|
multiple interactions
|
ISO
|
[ACSL5 protein affects the susceptibility to Palmitic Acid] which affects the abundance of Adenosine Triphosphate
|
CTD |
PMID:32347412 |
|
NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
ISO
|
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]
|
CTD |
PMID:32721574 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Adcyap1
|
adenylate cyclase activating polypeptide 1
|
increases secretion
|
EXP
|
ADCYAP1 protein results in increased secretion of Adenosine Triphosphate
|
CTD |
PMID:18563302 |
|
NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383
|
|
G
|
Agtr1a
|
angiotensin II receptor, type 1a
|
multiple interactions decreases expression
|
EXP
|
Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein]; CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein]; Cyclosporine inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A protein]
|
CTD |
PMID:21464294 |
|
NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions
|
EXP
|
Adenosine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein]
|
CTD |
PMID:1848756 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
decreases activity multiple interactions
|
ISO
|
Adenosine Triphosphate results in decreased activity of AKT1 protein Alcohols inhibits the reaction [Adenosine Triphosphate results in decreased activity of AKT1 protein]
|
CTD |
PMID:24300283 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Aldh5a1
|
aldehyde dehydrogenase 5 family, member A1
|
increases abundance
|
ISO
|
ALDH5A1 gene mutant form results in increased abundance of Adenosine Triphosphate
|
CTD |
PMID:29031482 |
|
NCBI chr17:40,560,373...40,586,711
Ensembl chr17:40,558,347...40,586,714
|
|
G
|
Alk
|
ALK receptor tyrosine kinase
|
affects binding multiple interactions
|
ISO
|
ALK protein binds to Adenosine Triphosphate [ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]
|
CTD |
PMID:22072639 |
|
NCBI chr 6:28,631,431...29,351,321
Ensembl chr 6:28,632,197...29,349,721
|
|
G
|
Alpl
|
alkaline phosphatase, biomineralization associated
|
increases response to substance multiple interactions
|
ISO
|
ALPL gene mutant form results in increased susceptibility to Adenosine Triphosphate ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]
|
CTD |
PMID:27466191 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167
|
|
G
|
Anxa1
|
annexin A1
|
multiple interactions
|
EXP
|
[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein; arsenite affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Cadmium affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; chromium hexavalent ion affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Lead affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]
|
CTD |
PMID:20655937 |
|
NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831
|
|
G
|
App
|
amyloid beta precursor protein
|
multiple interactions increases secretion
|
ISO
|
Adenosine Triphosphate inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]; Adenosine Triphosphate inhibits the reaction [Rotenone results in decreased secretion of APP protein modified form]; Rotenone inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate]
|
CTD |
PMID:22906069 PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
G
|
Arrb2
|
arrestin, beta 2
|
multiple interactions
|
EXP
|
Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein]
|
CTD |
PMID:21464294 |
|
NCBI chr10:55,645,539...55,653,485
Ensembl chr10:55,645,357...55,653,487
|
|
G
|
Asic1
|
acid sensing ion channel subunit 1
|
multiple interactions
|
EXP
|
[Acids binds to and affects the activity of ASIC1 protein] which results in increased secretion of Adenosine Triphosphate
|
CTD |
PMID:19860742 |
|
NCBI chr 7:132,677,158...132,707,379
Ensembl chr 7:132,698,723...132,707,832
|
|
G
|
Asic2
|
acid sensing ion channel subunit 2
|
multiple interactions
|
EXP
|
[Acids binds to and affects the activity of ASIC2 protein] which results in increased secretion of Adenosine Triphosphate
|
CTD |
PMID:19860742 |
|
NCBI chr10:66,368,308...67,438,237
Ensembl chr10:66,368,310...66,636,245
|
|
G
|
Asic3
|
acid sensing ion channel subunit 3
|
multiple interactions
|
EXP
|
[Acids binds to and affects the activity of ASIC3 protein] which results in increased secretion of Adenosine Triphosphate
|
CTD |
PMID:19860742 |
|
NCBI chr 4:11,652,946...11,657,415
Ensembl chr 4:11,652,946...11,657,367
|
|
G
|
Atp7a
|
ATPase copper transporting alpha
|
multiple interactions
|
ISO
|
[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7A protein
|
CTD |
PMID:20964302 |
|
NCBI chr X:75,159,635...75,267,094
Ensembl chr X:75,159,782...75,267,093
|
|
G
|
Atp7b
|
ATPase copper transporting beta
|
multiple interactions increases phosphorylation
|
ISO
|
[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7B protein Adenosine Triphosphate results in increased phosphorylation of ATP7B protein
|
CTD |
PMID:19405516 PMID:20964302 |
|
NCBI chr16:76,654,725...76,726,092
Ensembl chr16:76,653,660...76,728,801
|
|
G
|
Atp8b1
|
ATPase phospholipid transporting 8B1
|
increases hydrolysis
|
EXP
|
ATP8B1 protein results in increased hydrolysis of Adenosine Triphosphate
|
CTD |
PMID:11584374 |
|
NCBI chr18:60,286,605...60,427,862
Ensembl chr18:60,288,464...60,427,027
|
|
G
|
Avp
|
arginine vasopressin
|
multiple interactions increases secretion
|
EXP
|
Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of AVP protein]; bisindolylmaleimide I inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; Dactinomycin inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of AVP protein]
|
CTD |
PMID:11102496 |
|
NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:138,246,554...138,248,522
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO
|
[Adenosine Triphosphate binds to P2RY11 protein] which results in decreased expression of BCL2 protein
|
CTD |
PMID:21503959 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcr
|
BCR activator of RhoGEF and GTPase
|
multiple interactions
|
ISO
|
[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
|
CTD |
PMID:19366808 |
|
NCBI chr20:13,468,732...13,596,333
Ensembl chr20:13,468,732...13,596,333
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
increases abundance
|
ISO
|
BIRC5 protein results in increased abundance of Adenosine Triphosphate
|
CTD |
PMID:32497533 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Cabin1
|
calcineurin binding protein 1
|
multiple interactions
|
EXP
|
CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein]
|
CTD |
PMID:21464294 |
|
NCBI chr20:12,892,750...13,014,801
Ensembl chr20:12,892,771...13,014,800
|
|
G
|
Calca
|
calcitonin-related polypeptide alpha
|
increases secretion multiple interactions
|
EXP
|
Adenosine Triphosphate results in increased secretion of CALCA protein Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]; Flurbiprofen inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]]; Suramin inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]]
|
CTD |
PMID:12044622 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529
|
|
G
|
Casp1
|
caspase 1
|
increases activity multiple interactions
|
EXP ISO
|
Adenosine Triphosphate results in increased activity of CASP1 mRNA; Adenosine Triphosphate results in increased activity of CASP1 protein [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein] [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; fraxinellone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of CASP1 protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Niclosamide co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CASP1 protein; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of CASP1 protein modified form]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; leojaponin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased activity of CASP1 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]
|
CTD |
PMID:18604214 PMID:19130485 PMID:21832250 PMID:23430110 PMID:24149798 PMID:25288807 PMID:25448682 PMID:26431797 PMID:26586371 PMID:29378952 PMID:32721574 PMID:33524445 PMID:33929904 PMID:34118343 PMID:34212273 PMID:34217685 PMID:34405489 PMID:35131329 PMID:35962723 PMID:36002070 PMID:36088791 PMID:36577999 PMID:36627344 PMID:36847822 PMID:37001609 PMID:38135199 PMID:38401882 More...
|
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
G
|
Casp3
|
caspase 3
|
increases expression multiple interactions
|
ISO
|
Adenosine Triphosphate results in increased expression of CASP3 Adenosine Triphosphate inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3]
|
CTD |
PMID:19448140 PMID:24732427 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp4
|
caspase 4
|
multiple interactions
|
ISO
|
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein] Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein]
|
CTD |
PMID:24149798 PMID:25288807 |
|
NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727
|
|
G
|
Cat
|
catalase
|
increases expression
|
ISO
|
Adenosine Triphosphate results in increased expression of CAT mRNA
|
CTD |
PMID:22129738 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccl3
|
C-C motif chemokine ligand 3
|
increases secretion multiple interactions
|
ISO
|
Adenosine Triphosphate results in increased secretion of CCL3 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CCL3 protein]
|
CTD |
PMID:26522449 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
multiple interactions
|
ISO
|
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides]]; [Phosphatidylinositol 4,5-Diphosphate co-treated with Adenosine Triphosphate] results in increased activity of CFTR protein; Adenosine Triphosphate affects the reaction [Curcumin results in increased activity of CFTR protein mutant form]; Adenosine Triphosphate binds to and results in increased activity of CFTR protein; Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides]
|
CTD |
PMID:14710196 PMID:15623556 PMID:17178710 PMID:20675434 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Chordc1
|
cysteine and histidine rich domain containing 1
|
multiple interactions
|
ISO
|
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein] Adenosine Triphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]
|
CTD |
PMID:23184943 |
|
NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
ISO
|
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]
|
CTD |
PMID:32721574 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Comt
|
catechol-O-methyltransferase
|
multiple interactions
|
ISO
|
[Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate
|
CTD |
PMID:14975680 |
|
NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533
|
|
G
|
Cpt2
|
carnitine palmitoyltransferase 2
|
multiple interactions
|
ISO
|
[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate; Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate]
|
CTD |
PMID:21816645 |
|
NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:127,893,207...127,910,818
|
|
G
|
Crkl
|
CRK like proto-oncogene, adaptor protein
|
multiple interactions
|
ISO
|
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; [BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
|
CTD |
PMID:19366808 |
|
NCBI chr11:97,033,033...97,067,457
Ensembl chr11:97,024,782...97,067,457
|
|
G
|
Csf2
|
colony stimulating factor 2
|
multiple interactions
|
ISO
|
[CSF2 protein affects the susceptibility to stearic acid] which affects the abundance of Adenosine Triphosphate
|
CTD |
PMID:32347412 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031
|
|
G
|
Csnk2a1
|
casein kinase 2 alpha 1
|
multiple interactions affects binding
|
ISO
|
silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]]
|
CTD |
PMID:21174434 |
|
NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698
|
|
G
|
Csnk2b
|
casein kinase 2 beta
|
multiple interactions affects binding
|
ISO
|
silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]]
|
CTD |
PMID:21174434 |
|
NCBI chr20:3,704,833...3,709,999
Ensembl chr20:3,704,904...3,710,525
|
|
G
|
Cstb
|
cystatin B
|
multiple interactions
|
ISO
|
Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein]
|
CTD |
PMID:25288807 |
|
NCBI chr20:10,245,157...10,247,199
Ensembl chr20:10,245,158...10,247,199
|
|
G
|
Ctsb
|
cathepsin B
|
increases activity multiple interactions
|
ISO
|
Adenosine Triphosphate results in increased activity of CTSB protein azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of CTSB protein]
|
CTD |
PMID:26522449 |
|
NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478
|
|
G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
increases secretion multiple interactions
|
ISO
|
Adenosine Triphosphate results in increased secretion of CXCL2 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CXCL2 protein]
|
CTD |
PMID:26522449 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
G
|
Dmd
|
dystrophin
|
increases secretion multiple interactions
|
ISO
|
DMD gene mutant form results in increased secretion of Adenosine Triphosphate Nifedipine inhibits the reaction [DMD gene mutant form results in increased secretion of Adenosine Triphosphate]
|
CTD |
PMID:24349043 |
|
NCBI chr X:51,070,098...53,437,845
Ensembl chr X:51,070,273...53,437,835
|
|
G
|
Dusp1
|
dual specificity phosphatase 1
|
multiple interactions
|
ISO
|
Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]]
|
CTD |
PMID:32941855 |
|
NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644
|
|
G
|
Dusp6
|
dual specificity phosphatase 6
|
multiple interactions
|
ISO
|
Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]]
|
CTD |
PMID:32941855 |
|
NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
multiple interactions increases phosphorylation
|
ISO
|
sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of EGFR protein]
|
CTD |
PMID:26104857 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Egr1
|
early growth response 1
|
multiple interactions increases expression
|
EXP
|
Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]
|
CTD |
PMID:10723097 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843
|
|
G
|
Enpp2
|
ectonucleotide pyrophosphatase/phosphodiesterase 2
|
multiple interactions
|
ISO
|
Adenosine Triphosphate promotes the reaction [Toluene 2,4-Diisocyanate results in increased expression of ENPP2 protein]
|
CTD |
PMID:26072274 |
|
NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957
|
|
G
|
Enpp7
|
ectonucleotide pyrophosphatase/phosphodiesterase 7
|
decreases activity
|
ISO
|
Adenosine Triphosphate results in decreased activity of ENPP7 protein
|
CTD |
PMID:12885774 |
|
NCBI chr10:104,740,763...104,745,760
Ensembl chr10:104,740,763...104,745,760
|
|
G
|
Ercc6
|
ERCC excision repair 6, chromatin remodeling factor
|
decreases abundance multiple interactions
|
ISO
|
ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]
|
CTD |
PMID:25440059 |
|
NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895
|
|
G
|
F2
|
coagulation factor II, thrombin
|
multiple interactions increases transport increases abundance increases secretion
|
ISO
|
2,4,3',5'-tetramethoxystilbene inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; [RWJ-56110 co-treated with 2,4,3',5'-tetramethoxystilbene] inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; calmidazolium affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Fendiline affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate]; Resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate] F2 protein results in increased transport of Adenosine Triphosphate STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate]
|
CTD |
PMID:2030746 PMID:15342215 PMID:30696774 PMID:35288162 |
|
NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246
|
|
G
|
Fasn
|
fatty acid synthase
|
multiple interactions decreases abundance
|
ISO
|
FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; Protein Kinase Inhibitors inhibits the reaction [FASN protein results in decreased abundance of Adenosine Triphosphate]
|
CTD |
PMID:26670611 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583
|
|
G
|
Fbp1
|
fructose-bisphosphatase 1
|
multiple interactions
|
ISO
|
[Enzyme Inhibitors results in decreased activity of FBP1 protein] which results in decreased abundance of Adenosine Triphosphate
|
CTD |
PMID:31974165 |
|
NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,213,492...2,235,746
|
|
G
|
Fbxo3
|
F-box protein 3
|
multiple interactions
|
EXP
|
FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]
|
CTD |
PMID:35962723 |
|
NCBI chr 3:110,872,185...110,904,479
Ensembl chr 3:110,872,220...110,904,479
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
increases expression multiple interactions
|
EXP ISO
|
Adenosine Triphosphate results in increased expression of FOS mRNA ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] [Phenylephrine co-treated with Adenosine Triphosphate] results in increased expression of FOS mRNA; Glucose affects the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]
|
CTD |
PMID:10723097 PMID:19463813 PMID:27466191 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Fscn1
|
fascin actin-bundling protein 1
|
increases expression multiple interactions
|
ISO
|
Adenosine Triphosphate results in increased expression of FSCN1 mRNA Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of FSCN1 mRNA]
|
CTD |
PMID:29733962 |
|
NCBI chr12:16,710,601...16,723,734
Ensembl chr12:16,710,601...16,723,734
|
|
G
|
Gapdh
|
glyceraldehyde-3-phosphate dehydrogenase
|
multiple interactions
|
ISO
|
Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
|
CTD |
PMID:15788719 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377
|
|
G
|
Gh1
|
growth hormone 1
|
multiple interactions increases secretion
|
ISO EXP
|
oxophenylarsine inhibits the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; Phosphatidylinositol 4,5-Diphosphate affects the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein] NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]]
|
CTD |
PMID:12471042 |
|
NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859
|
|
G
|
Gja1
|
gap junction protein, alpha 1
|
increases export
|
ISO
|
GJA1 protein mutant form results in increased export of Adenosine Triphosphate; GJA1 protein results in increased export of Adenosine Triphosphate
|
CTD |
PMID:17687502 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689
|
|
G
|
Gsdmd
|
gasdermin D
|
multiple interactions
|
ISO EXP
|
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein]
|
CTD |
PMID:33851234 PMID:34212273 PMID:34217685 PMID:35962723 PMID:36577999 PMID:37001609 More...
|
|
NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:109,422,910...109,430,722
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
multiple interactions
|
ISO
|
[GSTP1 protein co-treated with Glutathione] inhibits the reaction [[Adenosine Triphosphate results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct]; [GSTP1 protein co-treated with Glutathione] inhibits the reaction [Adenosine Triphosphate results in increased activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
|
CTD |
PMID:11196146 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions
|
ISO
|
Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]
|
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Hck
|
HCK proto-oncogene, Src family tyrosine kinase
|
multiple interactions affects binding
|
ISO
|
[Curcumin binds to 4-bis(2-chloroethyl)aminobenzaldehyde] inhibits the reaction [HCK protein binds to Adenosine Triphosphate]
|
CTD |
PMID:33617879 |
|
NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:162,031,817...162,074,935
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
multiple interactions
|
ISO
|
Adenosine Triphosphate inhibits the reaction [protoporphyrin IX results in decreased activity of HIF1A protein]
|
CTD |
PMID:23624237 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
G
|
Hk1
|
hexokinase 1
|
multiple interactions
|
ISO
|
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein]
|
CTD |
PMID:37001609 |
|
NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,773,220...30,874,814
|
|
G
|
Hk2
|
hexokinase 2
|
multiple interactions
|
ISO
|
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 protein
|
CTD |
PMID:36577999 |
|
NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:116,792,258...116,841,275
|
|
G
|
Hmgb1
|
high mobility group box 1
|
affects chemical synthesis multiple interactions
|
ISO
|
HMGB1 protein affects the chemical synthesis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; Adenosine Triphosphate promotes the reaction [fullerene C60 results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [graphene oxide results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [Nanotubes, Carbon results in increased secretion of HMGB1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein]
|
CTD |
PMID:21641551 PMID:31504961 PMID:34405489 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327 Ensembl chr12:39,039,050...39,041,327
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein]]
|
CTD |
PMID:34217685 PMID:38135199 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hsp90aa1
|
heat shock protein 90 alpha family class A member 1
|
multiple interactions
|
ISO
|
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]
|
CTD |
PMID:23184943 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
multiple interactions
|
ISO
|
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein]
|
CTD |
PMID:24149798 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Hspb1
|
heat shock protein family B (small) member 1
|
affects chemical synthesis
|
ISO
|
HSPB1 protein affects the chemical synthesis of Adenosine Triphosphate
|
CTD |
PMID:21641551 |
|
NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301
|
|
G
|
Hspd1
|
heat shock protein family D (Hsp60) member 1
|
multiple interactions increases expression
|
EXP
|
bisindolylmaleimide I inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; chelerythrine inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; Neomycin inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; resveratrol inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; tricyclodecane-9-yl-xanthogenate inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]
|
CTD |
PMID:16178011 |
|
NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:64,073,611...64,084,037
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions
|
ISO
|
Adenosine Triphosphate inhibits the reaction [Fructose results in increased expression of ICAM1 protein]
|
CTD |
PMID:18508964 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]
|
CTD |
PMID:14623498 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Il12b
|
interleukin 12B
|
multiple interactions
|
ISO
|
Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein]
|
CTD |
PMID:17707769 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
G
|
Il18
|
interleukin 18
|
multiple interactions increases secretion
|
ISO EXP
|
[Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL18 protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein] Adenosine Triphosphate results in increased secretion of IL18 protein 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA]
|
CTD |
PMID:17404311 PMID:24149798 PMID:26431797 PMID:27311643 PMID:29378952 PMID:31993881 PMID:33579316 PMID:33851234 PMID:34212273 PMID:34405489 PMID:35962723 PMID:36088791 PMID:36577999 PMID:36847822 More...
|
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
G
|
Il1a
|
interleukin 1 alpha
|
multiple interactions
|
ISO
|
(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein]]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein]
|
CTD |
PMID:26068648 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases expression increases secretion decreases abundance
|
EXP ISO
|
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; Enzyme Inhibitors inhibits the reaction [IL1B protein results in decreased abundance of Adenosine Triphosphate]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]] Adenosine Triphosphate results in increased expression of IL1B protein Adenosine Triphosphate results in increased secretion of IL1B protein (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; [[Air Pollutants results in increased abundance of Particulate Matter] results in increased susceptibility to [Dietary Fats co-treated with Lipopolysaccharides co-treated with Adenosine Triphosphate]] which results in increased secretion of IL1B protein; [[Air Pollutants results in increased abundance of Particulate Matter] results in increased susceptibility to [Lipopolysaccharides co-treated with Adenosine Triphosphate]] which results in increased secretion of IL1B protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; leojaponin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and affects the cleavage of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; Okadaic Acid inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; tabersonine inhibits the reaction [Adenosine Triphosphate results in increased expression of IL1B protein]; zinc chloride inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]] 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein; Apigenin inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; flavone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; L 709049 inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; MitoTEMPO inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]]; tyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]
|
CTD |
PMID:10365824 PMID:14623498 PMID:17404311 PMID:18604214 PMID:19130485 PMID:22221676 PMID:23430110 PMID:24149798 PMID:24158569 PMID:24685903 PMID:26068648 PMID:26086368 PMID:26431797 PMID:26586371 PMID:26819091 PMID:26968431 PMID:27311643 PMID:29378952 PMID:29960001 PMID:31993881 PMID:32721574 PMID:33050067 PMID:33524445 PMID:33579316 PMID:33851234 PMID:33929904 PMID:34118343 PMID:34212273 PMID:34217685 PMID:34405489 PMID:35962723 PMID:36002070 PMID:36088791 PMID:36577999 PMID:36627344 PMID:36847822 PMID:37001609 PMID:37062408 PMID:37544346 PMID:38135199 PMID:38401882 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions increases expression
|
ISO EXP
|
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein]; NF157 compound inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein] Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; resveratrol inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]] [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; MRS 2211 inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]
|
CTD |
PMID:17707769 PMID:24793913 PMID:24849676 PMID:25348860 PMID:26104857 PMID:26522449 PMID:33851234 PMID:37001609 PMID:37544346 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Ins1
|
insulin 1
|
multiple interactions increases secretion
|
ISO EXP
|
Adenosine Triphosphate inhibits the reaction [Glucose results in increased secretion of INS1 protein] Adenosine Triphosphate results in increased secretion of INS1 protein [[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]
|
CTD |
PMID:10535451 PMID:10780946 PMID:16366736 PMID:22221676 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
G
|
Ins2
|
insulin 2
|
multiple interactions
|
ISO
|
[ammonium ferrous sulfate results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; [chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; INS protein inhibits the reaction [Acetaminophen results in decreased abundance of Adenosine Triphosphate]; Mannose inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate]; Phloretin inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate]
|
CTD |
PMID:17965850 PMID:26739624 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805
|
|
G
|
Irf2
|
interferon regulatory factor 2
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA]
|
CTD |
PMID:34212273 |
|
NCBI chr16:52,171,855...52,283,620
Ensembl chr16:52,164,442...52,282,627
|
|
G
|
Itgb1bp2
|
integrin subunit beta 1 binding protein 2
|
multiple interactions
|
ISO
|
Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]] Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]
|
CTD |
PMID:23184943 |
|
NCBI chr X:70,612,118...70,617,158
Ensembl chr X:70,612,521...70,617,158
|
|
G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
ISO
|
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein]
|
CTD |
PMID:24149798 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
G
|
Kcnd2
|
potassium voltage-gated channel subfamily D member 2
|
multiple interactions increases abundance
|
ISO
|
[[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased abundance of Adenosine Triphosphate; [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate KCND2 protein results in increased abundance of Adenosine Triphosphate
|
CTD |
PMID:34418280 |
|
NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:50,742,839...51,243,522
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
decreases activity
|
ISO
|
Adenosine Triphosphate deficiency results in decreased activity of KCNH2 protein
|
CTD |
PMID:12531891 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
G
|
Kcnj11
|
potassium inwardly-rectifying channel, subfamily J, member 11
|
multiple interactions decreases response to substance
|
ISO
|
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] KCNJ11 protein mutant form results in decreased susceptibility to Adenosine Triphosphate
|
CTD |
PMID:11390963 PMID:28842488 |
|
NCBI chr 1:105,727,473...105,731,167
Ensembl chr 1:105,727,570...105,731,169
|
|
G
|
Kcnj15
|
potassium inwardly-rectifying channel, subfamily J, member 15
|
increases activity
|
ISO
|
Adenosine Triphosphate results in increased activity of KCNJ15 protein
|
CTD |
PMID:15328350 |
|
NCBI chr11:48,046,953...48,091,285
Ensembl chr11:48,035,655...48,092,457
|
|
G
|
Kcnj8
|
potassium inwardly-rectifying channel, subfamily J, member 8
|
multiple interactions decreases response to substance
|
EXP
|
Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein] KCNJ8 protein mutant form results in decreased susceptibility to Adenosine Triphosphate
|
CTD |
PMID:28842488 |
|
NCBI chr 4:177,240,692...177,246,548
Ensembl chr 4:177,239,908...177,246,531
|
|
G
|
Khk
|
ketohexokinase
|
multiple interactions
|
ISO
|
KHK protein promotes the reaction [Fructose results in decreased abundance of Adenosine Triphosphate]
|
CTD |
PMID:19158351 |
|
NCBI chr 6:31,165,246...31,175,779
Ensembl chr 6:31,165,248...31,175,481
|
|
G
|
Kif5a
|
kinesin family member 5A
|
multiple interactions increases hydrolysis
|
ISO
|
Adenosine Triphosphate inhibits the reaction [zinc chloride results in decreased activity of KIF5A protein]; Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]; Egtazic Acid inhibits the reaction [Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]]
|
CTD |
PMID:24239783 PMID:28122263 |
|
NCBI chr 7:64,937,210...64,974,339
Ensembl chr 7:64,934,740...64,978,272
|
|
G
|
Lep
|
leptin
|
multiple interactions
|
EXP
|
[[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] which results in decreased secretion of LEP protein
|
CTD |
PMID:10780946 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
G
|
Lipe
|
lipase E, hormone sensitive type
|
increases activity
|
ISO
|
Adenosine Triphosphate results in increased activity of LIPE protein
|
CTD |
PMID:7155675 |
|
NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:90,093,433...90,112,117
|
|
G
|
Lpl
|
lipoprotein lipase
|
affects response to substance
|
ISO
|
LPL protein affects the susceptibility to Adenosine Triphosphate
|
CTD |
PMID:11786490 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107
|
|
G
|
Map2k1
|
mitogen activated protein kinase kinase 1
|
affects binding
|
ISO
|
Adenosine Triphosphate binds to MAP2K1 protein
|
CTD |
PMID:17693661 |
|
NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases phosphorylation increases activity
|
ISO EXP
|
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK1 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:12513686 PMID:15034929 PMID:21503959 PMID:24300283 PMID:26104857 PMID:26522449 PMID:30502331 PMID:32941855 PMID:34405489 More...
|
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions increases phosphorylation increases activity
|
ISO EXP
|
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK3 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK3 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:12513686 PMID:15034929 PMID:21503959 PMID:24300283 PMID:26104857 PMID:26522449 PMID:30502331 PMID:32941855 PMID:34405489 More...
|
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapt
|
microtubule-associated protein tau
|
multiple interactions decreases abundance
|
EXP ISO
|
[annonacin results in decreased abundance of Adenosine Triphosphate] which affects the localization of MAPT protein MAPT protein mutant form results in decreased abundance of Adenosine Triphosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Adenosine Triphosphate]
|
CTD |
PMID:17634376 PMID:39172838 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108
|
|
G
|
Metrnl
|
meteorin-like, glial cell differentiation regulator
|
multiple interactions
|
ISO
|
METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Adenosine Triphosphate]
|
CTD |
PMID:30213948 |
|
NCBI chr10:107,462,148...107,476,143
Ensembl chr10:107,462,109...107,476,135
|
|
G
|
Mfn2
|
mitofusin 2
|
decreases response to substance multiple interactions increases chemical synthesis
|
ISO EXP
|
MFN2 results in decreased susceptibility to Adenosine Triphosphate deficiency MFN2 protein inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate] MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate] MFN2 protein results in increased chemical synthesis of Adenosine Triphosphate
|
CTD |
PMID:22292091 PMID:24898700 PMID:25416777 |
|
NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:163,587,463...163,618,495
|
|
G
|
Mir219a1
|
microRNA 219a-1
|
multiple interactions
|
EXP
|
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of MIR219A1 mRNA; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]
|
CTD |
PMID:35962723 |
|
NCBI chr20:4,831,580...4,831,689
Ensembl chr20:4,831,580...4,831,689
|
|
G
|
Mir23b
|
microRNA 23b
|
multiple interactions decreases abundance
|
ISO
|
[[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate MIR23B mRNA results in decreased abundance of Adenosine Triphosphate
|
CTD |
PMID:34418280 |
|
NCBI chr17:1,819,386...1,819,482
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA]
|
CTD |
PMID:36847822 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions increases activity increases secretion
|
EXP ISO
|
1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; SB 3CT compound inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; wortmannin inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of MMP9 protein] Adenosine Triphosphate results in increased secretion of MMP9 protein
|
CTD |
PMID:20195827 PMID:26522449 PMID:36847822 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mt-atp6
|
mitochondrially encoded ATP synthase membrane subunit 6
|
affects abundance
|
EXP
|
ATP6 protein affects the abundance of Adenosine Triphosphate
|
CTD |
PMID:18273840 |
|
NCBI chr MT:7,919...8,599
Ensembl chr MT:7,904...8,584
|
|
G
|
Mt-co3
|
mitochondrially encoded cytochrome c oxidase III
|
increases abundance
|
ISO
|
COX3 protein results in increased abundance of Adenosine Triphosphate
|
CTD |
PMID:17428446 |
|
NCBI chr MT:8,599...9,382
Ensembl chr MT:8,584...9,367
|
|
G
|
Mvd
|
mevalonate diphosphate decarboxylase
|
increases hydrolysis
|
ISO
|
MVD protein results in increased hydrolysis of Adenosine Triphosphate
|
CTD |
PMID:9392419 |
|
NCBI chr19:67,404,911...67,414,974
Ensembl chr19:67,404,911...67,422,366
|
|
G
|
Mvk
|
mevalonate kinase
|
increases hydrolysis multiple interactions
|
ISO
|
MVK protein results in increased hydrolysis of Adenosine Triphosphate 3,3-dimethylallyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; dolichol monophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; Farnesol inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; farnesyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranyl diphosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranylgeranyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; isopentenyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]
|
CTD |
PMID:9392419 |
|
NCBI chr12:47,802,002...47,819,503
Ensembl chr12:47,802,002...47,819,503
|
|
G
|
Myd88
|
MYD88, innate immune signal transduction adaptor
|
multiple interactions
|
ISO
|
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein]
|
CTD |
PMID:34405489 PMID:37544346 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230
|
|
G
|
Myh7
|
myosin heavy chain 7
|
increases abundance
|
ISO
|
MYH7 gene mutant form results in increased abundance of Adenosine Triphosphate
|
CTD |
PMID:29741611 |
|
NCBI chr15:32,416,525...32,439,851
Ensembl chr15:32,416,527...32,438,194
|
|
G
|
Nadsyn1
|
NAD synthetase 1
|
multiple interactions
|
ISO
|
[Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased activity of NADSYN1 protein; [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD
|
CTD |
PMID:12547821 |
|
NCBI chr 1:208,410,914...208,439,242
Ensembl chr 1:208,410,914...208,439,207
|
|
G
|
Ncs1
|
neuronal calcium sensor 1
|
multiple interactions increases response to substance
|
EXP
|
NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]] NCS1 protein results in increased susceptibility to Adenosine Triphosphate
|
CTD |
PMID:12471042 |
|
NCBI chr 3:34,920,949...34,966,554
Ensembl chr 3:34,920,971...34,968,711
|
|
G
|
Nek7
|
NIMA-related kinase 7
|
multiple interactions
|
ISO
|
[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to NEK7 protein]
|
CTD |
PMID:36627344 |
|
NCBI chr13:52,573,730...52,700,869
Ensembl chr13:52,573,730...52,700,823
|
|
G
|
Nfatc1
|
nuclear factor of activated T-cells 1
|
affects localization multiple interactions
|
EXP ISO
|
Adenosine Triphosphate affects the localization of NFATC1 protein azetidine analog inhibits the reaction [Adenosine Triphosphate affects the localization of NFATC1 protein]
|
CTD |
PMID:21464294 PMID:26522449 |
|
NCBI chr18:76,321,386...76,430,997
Ensembl chr18:76,321,386...76,430,990
|
|
G
|
Nfatc3
|
nuclear factor of activated T-cells 3
|
affects localization
|
EXP
|
Adenosine Triphosphate affects the localization of NFATC3 protein
|
CTD |
PMID:21464294 |
|
NCBI chr19:50,870,464...50,944,992
Ensembl chr19:50,870,489...50,944,992
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein]]
|
CTD |
PMID:34217685 PMID:38135199 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
EXP ISO
|
Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]] [Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein]
|
CTD |
PMID:21464294 PMID:24149798 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Ngf
|
nerve growth factor
|
multiple interactions
|
EXP
|
[NGF protein co-treated with Adenosine Triphosphate] results in increased uptake of Calcium
|
CTD |
PMID:1374475 |
|
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834
|
|
G
|
Nlrp1a
|
NLR family, pyrin domain containing 1A
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with resveratrol] results in increased expression of NLRP1 mRNA
|
CTD |
PMID:24149798 |
|
NCBI chr10:56,277,134...56,332,229
Ensembl chr10:56,277,134...56,323,880
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions
|
ISO EXP
|
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to NEK7 protein]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased activity of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased activity of NLRP3 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein] 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased activity of NLRP3 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with Resveratrol] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]
|
CTD |
PMID:18604214 PMID:23430110 PMID:24149798 PMID:26086368 PMID:26586371 PMID:29378952 PMID:32721574 PMID:33524445 PMID:34217685 PMID:34405489 PMID:35131329 PMID:35962723 PMID:36088791 PMID:36627344 PMID:36847822 PMID:37001609 PMID:37544346 PMID:38135199 PMID:38401882 More...
|
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
G
|
Nolc1
|
nucleolar and coiled-body phosphoprotein 1
|
multiple interactions
|
ISO
|
Adenosine Triphosphate affects the reaction [Doxorubicin binds to NOLC1 protein]
|
CTD |
PMID:17129415 |
|
NCBI chr 1:254,870,195...254,881,070
Ensembl chr 1:254,870,319...254,881,069
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions increases expression
|
ISO EXP
|
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein] [Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased abundance of Nitric Oxide]
|
CTD |
PMID:21464294 PMID:26522449 PMID:36847822 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nos3
|
nitric oxide synthase 3
|
multiple interactions
|
ISO
|
Adenosine Triphosphate affects the reaction [Alcohols affects the phosphorylation of NOS3 protein]; Adenosine Triphosphate inhibits the reaction [Alcohols results in decreased expression of NOS3 protein]
|
CTD |
PMID:24300283 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
G
|
Npy
|
neuropeptide Y
|
affects response to substance
|
ISO
|
NPY protein affects the susceptibility to Adenosine Triphosphate
|
CTD |
PMID:15003356 |
|
NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310
|
|
G
|
Nr4a1
|
nuclear receptor subfamily 4, group A, member 1
|
increases expression
|
EXP
|
Adenosine Triphosphate results in increased expression of NR4A1 mRNA
|
CTD |
PMID:10723097 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041
|
|
G
|
Oas1a
|
2'-5' oligoadenylate synthetase 1A
|
multiple interactions
|
ISO
|
[OAS1 protein results in increased metabolism of Adenosine Triphosphate] which results in increased chemical synthesis of 2',5'-oligoadenylate
|
CTD |
PMID:15732009 |
|
NCBI chr12:41,330,423...41,341,130
Ensembl chr12:41,285,211...41,341,128
|
|
G
|
Oxt
|
oxytocin/neurophysin I prepropeptide
|
multiple interactions increases secretion
|
EXP
|
Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of OXT protein]
|
CTD |
PMID:11102496 |
|
NCBI chr 3:138,235,754...138,236,594
Ensembl chr 3:138,235,754...138,236,594
|
|
G
|
P2rx1
|
purinergic receptor P2X 1
|
multiple interactions affects binding
|
EXP
|
geldanamycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; herbimycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; monorden promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1] ATP binds to P2rx1 protein
|
CTD RGD |
PMID:11930156 PMID:12237343 |
RGD:727431 |
NCBI chr10:58,117,107...58,132,167
Ensembl chr10:58,117,088...58,132,164
|
|
G
|
P2rx2
|
purinergic receptor P2X 2
|
multiple interactions affects activity increases activity affects response to substance
|
EXP ISO
|
1-amino-4-(3-(4,6-dichloro(1,3,5)triazine-2-ylamino)phenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Acetylcysteine inhibits the reaction [Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Cadmium Chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cobaltous chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Copper promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cupric chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Dithiothreitol inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercuric Chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; methyl methanethiosulfonate inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; methyl methanethiosulfonate inhibits the reaction [Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; myxothiazol promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; nickel chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; palladium chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; zinc chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein] ATP affects activity of rat P2x2 receptor in transfected glial cells P2RX2 protein affects the susceptibility to Adenosine Triphosphate
|
CTD RGD |
PMID:15081800 PMID:16190872 PMID:19793987 PMID:21207957 PMID:16388598 |
RGD:1642662 |
NCBI chr12:51,999,107...52,002,627
Ensembl chr12:51,999,372...52,002,627
|
|
G
|
P2rx3
|
purinergic receptor P2X 3
|
multiple interactions increases activity affects activity
|
EXP
|
Eugenol inhibits the reaction [P2RX3 protein affects the activity of Adenosine Triphosphate] Adenosine Triphosphate results in increased activity of P2RX3 protein
|
CTD |
PMID:19967073 PMID:27481062 |
|
NCBI chr 3:90,487,506...90,531,315
Ensembl chr 3:90,487,506...90,531,794
|
|
G
|
P2rx4
|
purinergic receptor P2X 4
|
multiple interactions increases activity
|
EXP ISO
|
[Cadmium co-treated with Zinc] promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [Mercury co-treated with Copper] inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cadmium promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cobalt promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]]; Mercury inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro(3,2-e)-1,4-diazepin-2-one inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [ginsenoside compound K co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 mRNA; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 protein; ginsenoside compound K promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Ivermectin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]
|
CTD |
PMID:10737610 PMID:15629187 PMID:19793987 PMID:21638035 PMID:24149798 PMID:27481062 PMID:30545933 More...
|
|
NCBI chr12:39,505,438...39,523,349
Ensembl chr12:39,505,438...39,523,094
|
|
G
|
P2rx5
|
purinergic receptor P2X 5
|
affects transport
|
EXP
|
ATP affects transport ion flux of P2rx5 receptor
|
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:58,276,329...58,291,108
Ensembl chr10:58,276,257...58,287,935
|
|
G
|
P2rx7
|
purinergic receptor P2X 7
|
multiple interactions increases response to substance increases expression decreases response to substance increases activity
|
ISO EXP
|
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein; Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein; AZ 11645373 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; calmidazolium inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; KN 62 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased transport of Barium]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein]; ZINC58368839 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein] P2RX7 protein results in increased susceptibility to Adenosine Triphosphate Adenosine Triphosphate results in increased expression of P2RX7 protein P2RX7 gene mutant form results in decreased susceptibility to Adenosine Triphosphate 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]
|
CTD |
PMID:11003599 PMID:17728465 PMID:19023039 PMID:21638035 PMID:23565201 PMID:24101734 PMID:24149798 PMID:26522449 PMID:27466191 PMID:27481062 PMID:30545933 PMID:31263019 PMID:31504961 More...
|
|
NCBI chr12:39,550,531...39,594,984
Ensembl chr12:39,540,567...39,595,193
|
|
G
|
P2ry1
|
purinergic receptor P2Y1
|
multiple interactions affects activity
|
ISO EXP
|
[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium] [N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate binds to and results in decreased activity of P2RY1 protein] inhibits the reaction [Adenosine Triphosphate results in increased uptake of Calcium] Adenosine Triphosphate affects the activity of P2RY1 protein
|
CTD |
PMID:12694404 PMID:15243297 PMID:16973929 PMID:22129738 |
|
NCBI chr 2:147,391,661...147,397,870
Ensembl chr 2:147,390,681...147,398,027
|
|
G
|
P2ry13
|
purinergic receptor P2Y13
|
multiple interactions
|
ISO
|
MRS 2211 inhibits the reaction [P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]
|
CTD |
PMID:22129738 |
|
NCBI chr 2:145,620,321...145,624,730
Ensembl chr 2:145,619,655...145,622,787
|
|
G
|
P2ry2
|
purinergic receptor P2Y2
|
multiple interactions affects activity increases activity
|
ISO EXP
|
[Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Calcium [Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased uptake of Calcium Adenosine Triphosphate affects the activity of P2RY2 protein
|
CTD |
PMID:11527950 PMID:15243297 PMID:17003265 |
|
NCBI chr 1:164,764,119...164,779,578
Ensembl chr 1:164,759,213...164,781,852
|
|
G
|
P2ry4
|
pyrimidinergic receptor P2Y4
|
multiple interactions
|
ISO
|
[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium]
|
CTD |
PMID:12694404 |
|
NCBI chr X:69,722,604...69,757,726
Ensembl chr X:69,721,753...69,753,510
|
|
G
|
P2ry6
|
pyrimidinergic receptor P2Y6
|
multiple interactions
|
ISO
|
N,N''-1,4-butanediylbis(N'-(3-isothiocyanatophenyl))thiourea inhibits the reaction [P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]
|
CTD |
PMID:22129738 |
|
NCBI chr 1:164,707,188...164,742,689
Ensembl chr 1:164,706,116...164,743,588
|
|
G
|
Panx1
|
Pannexin 1
|
decreases activity multiple interactions increases export
|
ISO
|
Adenosine Triphosphate results in decreased activity of PANX1 protein Carbenoxolone inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate]; Probenecid inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate]
|
CTD |
PMID:19023039 PMID:19213873 |
|
NCBI chr 8:20,128,783...20,171,200
Ensembl chr 8:20,132,165...20,171,200
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions increases expression
|
ISO
|
PARP1 mutant form inhibits the reaction [Cadmium results in decreased abundance of Adenosine Triphosphate] PARP1 protein affects the reaction [pyrithione zinc results in decreased abundance of Adenosine Triphosphate]; PARP1 protein affects the reaction [Zinc results in decreased abundance of Adenosine Triphosphate] Adenosine Triphosphate results in increased expression of PARP1 protein
|
CTD |
PMID:17728843 PMID:19809895 PMID:21767558 PMID:22253048 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pdk1
|
pyruvate dehydrogenase kinase 1
|
multiple interactions affects response to substance
|
ISO
|
[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium; Adenosine Triphosphate promotes the reaction [PDK1 protein affects the abundance of Calcium]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium]
|
CTD |
PMID:28887310 |
|
NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145
|
|
G
|
Pfkm
|
phosphofructokinase, muscle
|
multiple interactions
|
ISO
|
Adenosine Triphosphate promotes the reaction [resveratrol results in decreased activity of PFKM protein]
|
CTD |
PMID:23454376 |
|
NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:131,100,753...131,138,248
|
|
G
|
Pgp
|
phosphoglycolate phosphatase
|
decreases phosphorylation
|
ISO
|
PGP protein results in decreased phosphorylation of Adenosine Triphosphate
|
CTD |
PMID:24338473 |
|
NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,999,331...14,002,408
|
|
G
|
Pik3ca
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha
|
multiple interactions affects binding
|
ISO
|
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [Adenosine Triphosphate binds to PIK3CA protein]; Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]]
|
CTD |
PMID:17550345 PMID:18754654 |
|
NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:117,143,468...117,177,411
|
|
G
|
Pik3r1
|
phosphoinositide-3-kinase regulatory subunit 1
|
multiple interactions
|
ISO
|
Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]]
|
CTD |
PMID:17550345 |
|
NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347
|
|
G
|
Pla2g4a
|
phospholipase A2 group 4A
|
increases activity
|
ISO
|
Adenosine Triphosphate results in increased activity of PLA2G4A protein
|
CTD |
PMID:10535451 |
|
NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641
|
|
G
|
Plau
|
plasminogen activator, urokinase
|
increases secretion
|
ISO
|
Adenosine Triphosphate results in increased secretion of PLAU protein
|
CTD |
PMID:20177776 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030
|
|
G
|
Plpp3
|
phospholipid phosphatase 3
|
decreases chemical synthesis
|
ISO
|
PLPP3 gene mutant form results in decreased chemical synthesis of Adenosine Triphosphate
|
CTD |
PMID:28982073 |
|
NCBI chr 5:125,156,000...125,231,119
Ensembl chr 5:125,155,945...125,235,667
|
|
G
|
Pml
|
PML nuclear body scaffold
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PML protein; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased abundance of Reactive Oxygen Species]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]
|
CTD |
PMID:23430110 |
|
NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:67,523,164...67,576,083
|
|
G
|
Pmvk
|
phosphomevalonate kinase
|
increases hydrolysis
|
ISO
|
PMVK protein results in increased hydrolysis of Adenosine Triphosphate
|
CTD |
PMID:9392419 |
|
NCBI chr 2:177,174,344...177,184,076
Ensembl chr 2:177,174,335...177,184,080
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
[Fenofibrate results in increased activity of PPARA protein] which results in decreased abundance of Adenosine Triphosphate
|
CTD |
PMID:19593819 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions decreases abundance
|
ISO
|
FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]] PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate; PPARG protein results in decreased abundance of Adenosine Triphosphate
|
CTD |
PMID:26670611 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PPARGC1A protein; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PPARGC1A protein]
|
CTD |
PMID:38135199 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213
|
|
G
|
Ppp5c
|
protein phosphatase 5, catalytic subunit
|
multiple interactions
|
ISO
|
Adenosine Triphosphate binds to and affects the folding of PPP5C protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein]
|
CTD |
PMID:23184943 |
|
NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:86,818,297...86,842,950
|
|
G
|
Prdx2
|
peroxiredoxin 2
|
increases expression
|
EXP
|
Adenosine Triphosphate results in increased expression of PRDX2 protein modified form
|
CTD |
PMID:16178011 |
|
NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006
|
|
G
|
Prkaa1
|
protein kinase AMP-activated catalytic subunit alpha 1
|
multiple interactions
|
ISO
|
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate
|
CTD |
PMID:31974165 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450
|
|
G
|
Prkaa2
|
protein kinase AMP-activated catalytic subunit alpha 2
|
multiple interactions
|
ISO
|
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate
|
CTD |
PMID:31974165 |
|
NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:125,042,179...125,108,324
|
|
G
|
Prkca
|
protein kinase C, alpha
|
multiple interactions
|
ISO
|
[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin
|
CTD |
PMID:16087181 |
|
NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572
|
|
G
|
Psen1
|
presenilin 1
|
multiple interactions
|
ISO
|
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate]
|
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]
|
CTD |
PMID:24149798 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Pycard
|
PYD and CARD domain containing
|
multiple interactions
|
ISO EXP
|
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased polymerization of PYCARD protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PYCARD gene mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of G(M3) Ganglioside]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased polymerization of PYCARD protein]
|
CTD |
PMID:18604214 PMID:23430110 PMID:24149798 PMID:24475307 PMID:29378952 PMID:32721574 PMID:34405489 PMID:35962723 PMID:36577999 PMID:36627344 PMID:38135199 PMID:38401882 More...
|
|
NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419
|
|
G
|
Ralbp1
|
ralA binding protein 1
|
multiple interactions
|
ISO
|
[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin; Adenosine Triphosphate promotes the reaction [RALBP1 protein affects the transport of Leukotriene C4]
|
CTD |
PMID:15386349 PMID:16087181 |
|
NCBI chr 9:112,903,289...112,940,093
Ensembl chr 9:112,903,302...112,939,659
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP ISO
|
[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein; [mitochondrial uncoupler BAM15 co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein] [Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; Resveratrol promotes the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein]; S-Nitrosoglutathione promotes the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]
|
CTD |
PMID:21464294 PMID:24149798 PMID:33524445 PMID:34217685 PMID:34405489 PMID:37544346 More...
|
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Rhof
|
ras homolog family member F, filopodia associated
|
multiple interactions increases expression
|
ISO
|
Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of RHOF mRNA]
|
CTD |
PMID:29733962 |
|
NCBI chr12:39,082,413...39,107,528
Ensembl chr12:39,091,979...39,107,528
|
|
G
|
S100a10
|
S100 calcium binding protein A10
|
increases expression
|
ISO
|
Adenosine Triphosphate results in increased expression of S100A10 mRNA
|
CTD |
PMID:29733962 |
|
NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:181,904,261...181,913,103
|
|
G
|
S100a11
|
S100 calcium binding protein A11
|
increases expression
|
ISO
|
Adenosine Triphosphate results in increased expression of S100A11 mRNA
|
CTD |
PMID:29733962 |
|
NCBI chr 2:181,875,132...181,880,542
Ensembl chr 2:181,875,130...181,880,541
|
|
G
|
S100a4
|
S100 calcium-binding protein A4
|
multiple interactions increases expression
|
ISO
|
Adenosine Triphosphate results in increased expression of and results in increased secretion of S100A4 protein; Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of S100A4 protein] Adenosine Triphosphate results in increased expression of S100A4 mRNA
|
CTD |
PMID:29733962 |
|
NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837
|
|
G
|
S100a6
|
S100 calcium binding protein A6
|
increases expression
|
ISO
|
Adenosine Triphosphate results in increased expression of S100A6 mRNA
|
CTD |
PMID:29733962 |
|
NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:178,398,481...178,399,762
|
|
G
|
Sell
|
selectin L
|
multiple interactions
|
ISO
|
P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein]
|
CTD |
PMID:11003599 |
|
NCBI chr13:78,950,100...78,969,604
Ensembl chr13:78,950,015...78,969,600
|
|
G
|
Sftpa1
|
surfactant protein A1
|
multiple interactions
|
ISO
|
[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]
|
CTD |
PMID:15065867 |
|
NCBI chr16:17,042,264...17,045,770
Ensembl chr16:17,042,255...17,045,769
|
|
G
|
Sftpb
|
surfactant protein B
|
increases secretion multiple interactions
|
ISO EXP
|
Adenosine Triphosphate results in increased secretion of SFTPB protein Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPB protein]
|
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:105,917,578...105,927,646
|
|
G
|
Sftpc
|
surfactant protein C
|
increases secretion multiple interactions
|
EXP ISO
|
Adenosine Triphosphate results in increased secretion of SFTPC protein Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPC protein]
|
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr15:52,006,274...52,009,324
Ensembl chr15:52,006,283...52,009,475
|
|
G
|
Sirt1
|
sirtuin 1
|
multiple interactions
|
EXP ISO
|
[SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]; SIRT1 protein promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate] [STK11 protein co-treated with Adenosine Triphosphate] results in increased activity of and results in increased phosphorylation of SIRT1 protein
|
CTD |
PMID:16366736 PMID:34216621 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
G
|
Sirt3
|
sirtuin 3
|
multiple interactions
|
ISO
|
SIRT3 protein inhibits the reaction [Metformin results in decreased abundance of Adenosine Triphosphate]
|
CTD |
PMID:23166782 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076
|
|
G
|
Slc25a14
|
solute carrier family 25 member 14
|
decreases chemical synthesis
|
ISO
|
SLC25A14 protein results in decreased chemical synthesis of Adenosine Triphosphate
|
CTD |
PMID:20600837 |
|
NCBI chr X:132,685,518...132,723,705
Ensembl chr X:132,676,818...132,723,703
|
|
G
|
Slc2a1
|
solute carrier family 2 member 1
|
decreases stability
|
ISO
|
Adenosine Triphosphate results in decreased stability of SLC2A1 protein
|
CTD |
PMID:11420438 |
|
NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742
|
|
G
|
Slc2a4
|
solute carrier family 2 member 4
|
increases abundance
|
ISO
|
SLC2A4 protein results in increased abundance of Adenosine Triphosphate
|
CTD |
PMID:34904774 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270
|
|
G
|
Slc46a1
|
solute carrier family 46 member 1
|
multiple interactions
|
ISO
|
[SLC46A1 protein results in increased susceptibility to N-((5-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo(2,3-d)pyrimidin-6-yl)propyl)thiophen-2-yl)carbonyl)glutamic acid] which results in decreased chemical synthesis of Adenosine Triphosphate
|
CTD |
PMID:21879757 |
|
NCBI chr10:63,859,551...63,865,987
Ensembl chr10:63,859,504...63,866,869
|
|
G
|
Slc5a5
|
solute carrier family 5 member 5
|
multiple interactions
|
ISO
|
Adenosine Triphosphate inhibits the reaction [TSHB protein results in increased expression of SLC5A5 protein]
|
CTD |
PMID:16439463 |
|
NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691
|
|
G
|
Snca
|
synuclein alpha
|
multiple interactions decreases abundance
|
ISO
|
GW8510 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate]; SB 216763 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate]
|
CTD |
PMID:24989254 |
|
NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:91,026,474...91,126,315
|
|
G
|
Sod1
|
superoxide dismutase 1
|
increases expression
|
EXP ISO
|
Adenosine Triphosphate results in increased expression of SOD1 protein
|
CTD |
PMID:16178011 PMID:22129738 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sod2
|
superoxide dismutase 2
|
affects chemical synthesis decreases abundance multiple interactions
|
ISO
|
SOD2 protein affects the chemical synthesis of Adenosine Triphosphate SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate MK-886 promotes the reaction [SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate]
|
CTD |
PMID:20638473 PMID:25362851 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Srr
|
serine racemase
|
multiple interactions
|
ISO
|
Adenosine Triphosphate inhibits the reaction [Edetic Acid inhibits the reaction [SRR protein results in increased abundance of D-Aspartic Acid]]; Adenosine Triphosphate promotes the reaction [SRR protein results in increased abundance of D-Aspartic Acid]
|
CTD |
PMID:27387750 |
|
NCBI chr10:60,267,936...60,285,094
Ensembl chr10:60,268,859...60,285,100
|
|
G
|
Stk11
|
serine/threonine kinase 11
|
multiple interactions
|
ISO
|
[STK11 protein co-treated with Adenosine Triphosphate] results in increased activity of and results in increased phosphorylation of SIRT1 protein
|
CTD |
PMID:34216621 |
|
NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:10,225,204...10,241,965
|
|
G
|
Stxbp2
|
syntaxin binding protein 2
|
multiple interactions
|
ISO
|
STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate]
|
CTD |
PMID:30696774 |
|
NCBI chr12:6,487,265...6,498,351
Ensembl chr12:6,487,297...6,504,212
|
|
G
|
Sugt1
|
SGT1 homolog, MIS12 kinetochore complex assembly cochaperone
|
multiple interactions
|
ISO
|
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]]
|
CTD |
PMID:23184943 |
|
NCBI chr15:61,400,478...61,441,303
Ensembl chr15:61,400,004...61,468,852
|
|
G
|
Syn2
|
synapsin II
|
multiple interactions
|
ISO
|
SYN2 mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of Calcium]
|
CTD |
PMID:18701217 |
|
NCBI chr 4:149,858,919...150,016,845
Ensembl chr 4:149,851,520...150,019,650
|
|
G
|
Tac1
|
tachykinin, precursor 1
|
increases secretion multiple interactions
|
EXP
|
Adenosine Triphosphate results in increased secretion of TAC1 protein Iloprost promotes the reaction [Adenosine Triphosphate results in increased secretion of TAC1 protein]
|
CTD |
PMID:16039053 |
|
NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546
|
|
G
|
Taldo1
|
transaldolase 1
|
increases abundance
|
ISO
|
TALDO1 gene mutant form results in increased abundance of Adenosine Triphosphate
|
CTD |
PMID:19436114 |
|
NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535
|
|
G
|
Tas2r145
|
taste receptor, type 2, member 145
|
increases activity
|
ISO
|
Adenosine Triphosphate results in increased activity of TAS2R131 protein
|
CTD |
PMID:29347925 |
|
NCBI chr 4:167,869,406...167,870,356
Ensembl chr 4:167,869,358...167,870,544
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
[Dimethyl Sulfoxide co-treated with TGFB1 protein] results in decreased abundance of Adenosine Triphosphate
|
CTD |
PMID:35366062 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Timm17a
|
translocase of inner mitochondrial membrane 17A
|
multiple interactions decreases expression
|
ISO
|
1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in decreased expression of TIMM17A protein]
|
CTD |
PMID:24315374 |
|
NCBI chr13:49,282,918...49,296,363
Ensembl chr13:49,282,918...49,307,904
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
decreases secretion multiple interactions
|
ISO
|
Adenosine Triphosphate results in decreased secretion of TIMP1 protein azetidine analog inhibits the reaction [Adenosine Triphosphate results in decreased secretion of TIMP1 protein]
|
CTD |
PMID:26522449 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions
|
ISO
|
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein]
|
CTD |
PMID:34405489 PMID:37544346 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions decreases chemical synthesis
|
ISO EXP
|
[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Chlorides]; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Potassium]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased secretion of TNF protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA] Adenosine Triphosphate inhibits the reaction [Sunitinib results in increased expression of TNF protein]; TNF protein promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate] TNF protein results in decreased chemical synthesis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein; [Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein]; MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Rosiglitazone inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Vitamin K 3 promotes the reaction [[Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate]
|
CTD |
PMID:8817062 PMID:10783394 PMID:14623498 PMID:17707769 PMID:23430110 PMID:24898700 PMID:26522449 PMID:29378952 PMID:32131635 PMID:33050067 PMID:33524445 PMID:33851234 PMID:36577999 PMID:37001609 PMID:37544346 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfsf11
|
TNF superfamily member 11
|
increases abundance
|
ISO
|
TNFSF11 protein results in increased abundance of Adenosine Triphosphate
|
CTD |
PMID:26287518 |
|
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
multiple interactions increases hydrolysis
|
ISO
|
Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; copper-thiosemicarbazone complex analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Dithiothreitol inhibits the reaction [Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]]; Emodin inhibits the reaction [TOP2A results in increased hydrolysis of Adenosine Triphosphate]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Thiosemicarbazones analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate] TOP2A protein results in increased hydrolysis of Adenosine Triphosphate; TOP2A results in increased hydrolysis of Adenosine Triphosphate
|
CTD |
PMID:20855424 PMID:26982206 PMID:27533850 PMID:29272108 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
G
|
Top2b
|
DNA topoisomerase II beta
|
increases hydrolysis multiple interactions
|
ISO
|
TOP2B protein results in increased hydrolysis of Adenosine Triphosphate cannabidiol hydroxyquinone inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate]; Cannabidiol metabolite inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate]
|
CTD |
PMID:29272108 |
|
NCBI chr15:11,482,089...11,542,464
Ensembl chr15:11,482,089...11,542,464
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions increases abundance
|
ISO
|
TP53 protein inhibits the reaction [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] TP53 gene mutant form results in increased abundance of Adenosine Triphosphate
|
CTD |
PMID:21042727 PMID:33070465 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tp53bp1
|
tumor protein p53 binding protein 1
|
multiple interactions
|
ISO
|
Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]
|
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747
|
|
G
|
Trpc3
|
transient receptor potential cation channel, subfamily C, member 3
|
multiple interactions increases activity
|
ISO
|
ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate inhibits the reaction [Adenosine Triphosphate results in increased activity of TRPC3 protein]
|
CTD |
PMID:19289841 |
|
NCBI chr 2:121,409,436...121,487,095
Ensembl chr 2:121,409,436...121,475,823
|
|
G
|
Trpc5
|
transient receptor potential cation channel, subfamily C, member 5
|
increases activity
|
ISO
|
Adenosine Triphosphate results in increased activity of TRPC5 protein
|
CTD |
PMID:19289841 |
|
NCBI chr X:112,742,828...113,027,638
Ensembl chr X:112,742,828...113,027,638
|
|
G
|
Trpc6
|
transient receptor potential cation channel, subfamily C, member 6
|
increases activity
|
ISO
|
Adenosine Triphosphate results in increased activity of TRPC6 protein
|
CTD |
PMID:19289841 |
|
NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304
|
|
G
|
Trpc7
|
transient receptor potential cation channel, subfamily C, member 7
|
increases activity
|
ISO
|
Adenosine Triphosphate results in increased activity of TRPC7 protein
|
CTD |
PMID:19289841 |
|
NCBI chr17:7,707,954...7,839,064
Ensembl chr17:7,714,505...7,838,745
|
|
G
|
Trpm4
|
transient receptor potential cation channel, subfamily M, member 4
|
decreases activity
|
ISO EXP
|
Adenosine Triphosphate results in decreased activity of TRPM4 protein
|
CTD |
PMID:16966582 PMID:17188667 |
|
NCBI chr 1:104,918,462...104,949,453
Ensembl chr 1:104,918,462...104,948,653
|
|
G
|
Trpv1
|
transient receptor potential cation channel, subfamily V, member 1
|
multiple interactions
|
EXP
|
[Capsaicin binds to and affects the activity of TRPV1 protein] which results in increased secretion of Adenosine Triphosphate
|
CTD |
PMID:19860742 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021
|
|
G
|
Tshb
|
thyroid stimulating hormone subunit beta
|
multiple interactions
|
ISO
|
Adenosine Triphosphate inhibits the reaction [TSHB protein results in increased expression of SLC5A5 protein]
|
CTD |
PMID:16439463 |
|
NCBI chr 2:192,913,171...192,918,054
Ensembl chr 2:192,913,171...192,942,984
|
|
G
|
Txn1
|
thioredoxin 1
|
increases expression
|
ISO
|
Adenosine Triphosphate results in increased expression of TXN protein
|
CTD |
PMID:22129738 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307
|
|
G
|
Txnip
|
thioredoxin interacting protein
|
increases activity
|
EXP
|
Adenosine Triphosphate results in increased activity of TXNIP mRNA
|
CTD |
PMID:21832250 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731
|
|
G
|
Ucp1
|
uncoupling protein 1
|
multiple interactions decreases abundance
|
EXP ISO
|
Adenosine Triphosphate inhibits the reaction [UCP1 protein results in increased transport of Protons] UCP1 results in decreased abundance of Adenosine Triphosphate UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]
|
CTD |
PMID:12734183 PMID:26670611 |
|
NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420
|
|
G
|
Ucp2
|
uncoupling protein 2
|
multiple interactions
|
ISO EXP
|
Adenosine Triphosphate inhibits the reaction [UCP2 protein results in increased transport of Protons] [SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]
|
CTD |
PMID:12734183 PMID:16366736 |
|
NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:164,251,373...164,257,743
|
|
G
|
Ucp3
|
uncoupling protein 3
|
multiple interactions
|
ISO
|
Adenosine Triphosphate inhibits the reaction [UCP3 protein results in increased transport of Protons]
|
CTD |
PMID:12734183 |
|
NCBI chr 1:164,227,910...164,240,893
Ensembl chr 1:164,227,882...164,241,210
|
|
G
|
Vdac1
|
voltage-dependent anion channel 1
|
multiple interactions
|
ISO
|
VDAC1 mutant form inhibits the reaction [chromium hexavalent ion results in decreased abundance of Adenosine Triphosphate]
|
CTD |
PMID:22858589 |
|
NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541
|
|
G
|
Xrcc1
|
X-ray repair cross complementing 1
|
multiple interactions increases abundance decreases abundance
|
ISO
|
Acetylcysteine inhibits the reaction [XRCC1 gene mutant form results in decreased abundance of Adenosine Triphosphate]; Acetylcysteine promotes the reaction [XRCC1 protein results in increased abundance of Adenosine Triphosphate]
|
CTD |
PMID:30998386 |
|
NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613
|
|
|
G
|
Kat2b
|
lysine acetyltransferase 2B
|
affects binding
|
ISO
|
butyryl-coenzyme A binds to KAT2B protein
|
CTD |
PMID:28077572 |
|
NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616
|
|
|
G
|
F3
|
coagulation factor III, tissue factor
|
multiple interactions
|
ISO
|
cangrelor results in decreased expression of and results in decreased activity of F3 protein; Indomethacin promotes the reaction [cangrelor results in decreased expression of and results in decreased activity of F3 protein]
|
CTD |
PMID:20200314 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369
|
|
G
|
Gpr17
|
G protein-coupled receptor 17
|
multiple interactions
|
ISO
|
cangrelor inhibits the reaction [Uridine Diphosphate results in increased activity of GPR17 protein]
|
CTD |
PMID:18974869 |
|
NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702
|
|
G
|
Itga2b
|
integrin subunit alpha 2b
|
multiple interactions
|
ISO
|
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]
|
CTD |
PMID:18404433 |
|
NCBI chr10:87,908,697...87,926,225
Ensembl chr10:87,908,697...87,925,833
|
|
G
|
Itgb3
|
integrin subunit beta 3
|
multiple interactions
|
ISO
|
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]
|
CTD |
PMID:18404433 |
|
NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800
|
|
G
|
P2ry12
|
purinergic receptor P2Y12
|
multiple interactions decreases activity affects response to substance
|
ISO
|
[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased abundance of phosphatidylinositol 3,4,5-triphosphate; [cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein cangrelor results in decreased activity of P2RY12 protein P2RY12 gene polymorphism affects the susceptibility to cangrelor
|
CTD |
PMID:12606772 PMID:20126830 PMID:22273509 |
|
NCBI chr 2:145,631,487...145,673,194
Ensembl chr 2:145,629,967...145,633,410
|
|
G
|
Pf4
|
platelet factor 4
|
multiple interactions
|
ISO
|
cangrelor inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased secretion of PF4 protein]
|
CTD |
PMID:22273509 |
|
NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,582,477...17,583,392
|
|
G
|
Selp
|
selectin P
|
multiple interactions
|
ISO
|
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]
|
CTD |
PMID:18404433 |
|
NCBI chr13:79,009,379...79,044,994
Ensembl chr13:79,009,475...79,044,987
|
|
G
|
Syk
|
spleen associated tyrosine kinase
|
multiple interactions
|
ISO
|
[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein
|
CTD |
PMID:12606772 |
|
NCBI chr17:12,756,493...12,830,927
Ensembl chr17:12,756,493...12,813,278
|
|
|
G
|
Adcy5
|
adenylate cyclase 5
|
increases response to substance multiple interactions
|
ISO
|
ADCY5 protein results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine ADCY5 protein results in increased susceptibility to [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with Quinpirole]
|
CTD |
PMID:12223546 |
|
NCBI chr11:78,976,861...79,123,343
Ensembl chr11:78,976,861...79,123,343
|
|
G
|
Adora2a
|
adenosine A2a receptor
|
increases response to substance multiple interactions
|
ISO EXP
|
ADORA2A protein results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of ADORA2A mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of ADORA2A protein]; 8-(3-chlorostyryl)caffeine inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A mRNA]]; 8-(3-chlorostyryl)caffeine inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]]; PRKCZ protein affects the reaction [[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein] which results in decreased expression of VEGFA mRNA] 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of ADORA2A mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of ADORA2A protein]
|
CTD |
PMID:11172060 PMID:12590138 PMID:15452191 PMID:19749167 PMID:19966059 PMID:26367767 PMID:27289578 PMID:30555576 More...
|
|
NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,270...13,332,802
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
multiple interactions
|
EXP
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of BDNF mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of BDNF protein]
|
CTD |
PMID:35917217 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Becn1
|
beclin 1
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of BECN1 protein]
|
CTD |
PMID:30555576 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002
|
|
G
|
Bmal1
|
basic helix-loop-helix ARNT like 1
|
increases expression multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of BMAL1 mRNA [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in increased expression of BMAL1 mRNA
|
CTD |
PMID:22923002 |
|
NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]
|
CTD |
PMID:30555576 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Clock
|
clock circadian regulator
|
increases expression
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of CLOCK mRNA
|
CTD |
PMID:22923002 |
|
NCBI chr14:32,262,747...32,346,872
Ensembl chr14:32,262,750...32,346,872
|
|
G
|
Col3a1
|
collagen type III alpha 1 chain
|
increases expression multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of COL3A1 protein CTNNB1 protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of COL3A1 protein]
|
CTD |
PMID:27595240 |
|
NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232
|
|
G
|
Creb1
|
cAMP responsive element binding protein 1
|
multiple interactions
|
EXP
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of CREB1 mRNA]
|
CTD |
PMID:35917217 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339
|
|
G
|
Ctnnb1
|
catenin beta 1
|
affects localization multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine affects the localization of CTNNB1 protein modified form 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of and affects the phosphorylation of CTNNB1 protein; CTNNB1 protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of COL3A1 protein]
|
CTD |
PMID:27595240 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
G
|
Cyp27a1
|
cytochrome P450, family 27, subfamily a, polypeptide 1
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 protein]
|
CTD |
PMID:19035488 |
|
NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215
|
|
G
|
Edn1
|
endothelin 1
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of EDN1 protein]
|
CTD |
PMID:39332792 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
G
|
Ednra
|
endothelin receptor type A
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of EDNRA protein]
|
CTD |
PMID:39332792 |
|
NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284
|
|
G
|
Ednrb
|
endothelin receptor type B
|
multiple interactions
|
ISO
|
[Phosphorus, Dietary co-treated with Cisplatin co-treated with 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine] results in increased expression of EDNRB protein
|
CTD |
PMID:39332792 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765
|
|
G
|
Ephx2
|
epoxide hydrolase 2
|
multiple interactions increases response to substance decreases response to substance
|
ISO
|
12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [EPHX2 gene results in decreased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine]; 14,15-eicosa-5-enoic acid inhibits the reaction [EPHX2 gene mutant form results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine]; 4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid inhibits the reaction [EPHX2 gene results in decreased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine]; T 0070907 inhibits the reaction [EPHX2 gene mutant form results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine]
|
CTD |
PMID:23152114 |
|
NCBI chr15:44,465,447...44,503,157
Ensembl chr15:44,465,448...44,503,160
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
EXP
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of FOS mRNA]
|
CTD |
PMID:15452191 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Havcr1
|
hepatitis A virus cellular receptor 1
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of HAVCR1 protein]
|
CTD |
PMID:39332792 |
|
NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268
|
|
G
|
Hmgcr
|
3-hydroxy-3-methylglutaryl-CoA reductase
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of HMGCR mRNA]
|
CTD |
PMID:30825513 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533
|
|
G
|
Hmgcs1
|
3-hydroxy-3-methylglutaryl-CoA synthase 1
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of HMGCS1 mRNA]
|
CTD |
PMID:30825513 |
|
NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [TNF protein results in increased expression of IL10 mRNA]
|
CTD |
PMID:22923002 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il12a
|
interleukin 12A
|
multiple interactions
|
ISO
|
[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in decreased expression of IL12A mRNA
|
CTD |
PMID:22923002 |
|
NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997
|
|
G
|
Lep
|
leptin
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of LEP mRNA]
|
CTD |
PMID:26367767 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
G
|
Map1lc3b
|
microtubule-associated protein 1 light chain 3 beta
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]
|
CTD |
PMID:30555576 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358 Ensembl chr16:66,574,407...66,584,358
|
|
G
|
Mmp14
|
matrix metallopeptidase 14
|
decreases activity
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased activity of MMP14 protein
|
CTD |
PMID:16783407 |
|
NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
decreases activity
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased activity of MMP2 protein
|
CTD |
PMID:16783407 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
decreases activity decreases expression
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased activity of MMP9 protein 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of MMP9 mRNA
|
CTD |
PMID:16783407 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of NOS2 protein]
|
CTD |
PMID:39332792 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nos3
|
nitric oxide synthase 3
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in decreased expression of NOS3 protein]
|
CTD |
PMID:39332792 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
G
|
Nppa
|
natriuretic peptide A
|
multiple interactions
|
EXP
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; Caffeine analog inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]]
|
CTD |
PMID:15452191 PMID:19966059 |
|
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493
|
|
G
|
Nr1d1
|
nuclear receptor subfamily 1, group D, member 1
|
increases expression
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of NR1D1 mRNA
|
CTD |
PMID:22923002 |
|
NCBI chr10:84,224,599...84,231,812
Ensembl chr10:84,224,540...84,231,812
|
|
G
|
Ntrk2
|
neurotrophic receptor tyrosine kinase 2
|
multiple interactions increases expression
|
EXP
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of NTRK2 mRNA] 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of NTRK2 mRNA
|
CTD |
PMID:35917217 |
|
NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,564,570...5,874,628
|
|
G
|
Per2
|
period circadian regulator 2
|
decreases expression
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of PER2 mRNA
|
CTD |
PMID:22923002 |
|
NCBI chr 9:99,454,828...99,497,069
Ensembl chr 9:99,454,830...99,496,993
|
|
G
|
Prkce
|
protein kinase C, epsilon
|
multiple interactions
|
EXP
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine affects the localization of and results in increased activity of PRKCE protein
|
CTD |
PMID:12590138 |
|
NCBI chr 6:13,718,050...14,204,931
Ensembl chr 6:13,718,050...14,204,288
|
|
G
|
Prkcz
|
protein kinase C, zeta
|
multiple interactions
|
EXP
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine affects the localization of and results in increased activity of PRKCZ protein; PRKCZ protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of VEGFA mRNA]; PRKCZ protein affects the reaction [[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein] which results in decreased expression of VEGFA mRNA]
|
CTD |
PMID:12590138 |
|
NCBI chr 5:171,101,774...171,212,694
Ensembl chr 5:171,101,774...171,212,674
|
|
G
|
Ren
|
renin
|
multiple interactions increases expression
|
EXP
|
Atenolol inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of REN protein]
|
CTD |
PMID:9300315 |
|
NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543
|
|
G
|
Rgs2
|
regulator of G-protein signaling 2
|
multiple interactions
|
EXP
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of RGS2 mRNA]
|
CTD |
PMID:15452191 |
|
NCBI chr13:58,350,063...58,352,666
Ensembl chr13:58,349,163...58,352,697
|
|
G
|
Sirt1
|
sirtuin 1
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of SIRT1 mRNA]
|
CTD |
PMID:30825513 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
G
|
Sirt3
|
sirtuin 3
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in decreased expression of SIRT3 protein]]
|
CTD |
PMID:30555576 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076
|
|
G
|
Slc9a1
|
solute carrier family 9 member A1
|
multiple interactions
|
EXP
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of SLC9A1 protein]
|
CTD |
PMID:15452191 |
|
NCBI chr 5:150,859,412...150,913,525
Ensembl chr 5:150,860,228...150,913,517
|
|
G
|
Smad3
|
SMAD family member 3
|
multiple interactions
|
EXP
|
8-(4-methoxyphenyl)-4-oxo-4,6,7,8-tetrahydroimidazo(2,1-c)(1,2,4)triazine-3-carbohydrazide inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of SMAD3 protein]
|
CTD |
PMID:22063920 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
|
|
G
|
Socs3
|
suppressor of cytokine signaling 3
|
multiple interactions
|
EXP
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of SOCS3 mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of SOCS3 protein]
|
CTD |
PMID:27289578 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825
|
|
G
|
Srebf2
|
sterol regulatory element binding transcription factor 2
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of SREBF2 mRNA]
|
CTD |
PMID:30825513 |
|
NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:115,543,290...115,600,943
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of TGFB1 protein]
|
CTD |
PMID:39332792 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [TNF protein results in increased expression of IL10 mRNA]; [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in decreased expression of IL12A mRNA; [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in increased expression of BMAL1 mRNA 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of TNF protein]
|
CTD |
PMID:21538184 PMID:22923002 PMID:39332792 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions
|
ISO
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]]
|
CTD |
PMID:30555576 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
increases secretion decreases expression multiple interactions
|
ISO EXP
|
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased secretion of VEGFA protein 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of VEGFA mRNA 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; PRKCZ protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of VEGFA mRNA]; PRKCZ protein affects the reaction [[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein] which results in decreased expression of VEGFA mRNA]
|
CTD |
PMID:12590138 PMID:20067761 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
|
G
|
Acot8
|
acyl-CoA thioesterase 8
|
affects hydrolysis
|
ISO
|
ACOT8 protein affects the hydrolysis of Coenzyme A analog
|
CTD |
PMID:16141203 |
|
NCBI chr 3:173,950,530...173,962,188
Ensembl chr 3:173,950,531...173,962,570
|
|
G
|
Kat2b
|
lysine acetyltransferase 2B
|
affects binding
|
ISO
|
Coenzyme A binds to KAT2B protein
|
CTD |
PMID:28077572 |
|
NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616
|
|
|
G
|
Cd38
|
CD38 molecule
|
decreases abundance
|
ISO
|
CD38 gene mutant form results in decreased abundance of Cyclic ADP-Ribose
|
CTD |
PMID:23343681 |
|
NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505
|
|
G
|
Homer1
|
homer scaffold protein 1
|
multiple interactions
|
EXP
|
HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]]
|
CTD |
PMID:12887973 |
|
NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:26,278,105...26,381,657
|
|
G
|
Ryr2
|
ryanodine receptor 2
|
multiple interactions
|
EXP
|
HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]]
|
CTD |
PMID:12887973 |
|
NCBI chr17:63,081,527...63,667,141
Ensembl chr17:63,081,527...63,666,705
|
|
|
G
|
Ager
|
advanced glycosylation end product-specific receptor
|
multiple interactions increases expression
|
ISO
|
[Ribose co-treated with Glucose] results in increased expression of AGER protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]] Ribose results in increased expression of AGER protein
|
CTD |
PMID:30101366 |
|
NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685
|
|
G
|
B2m
|
beta-2 microglobulin
|
increases glycation
|
ISO
|
Ribose results in increased glycation of B2M protein
|
CTD |
PMID:21864514 |
|
NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP
|
[Creatine co-treated with Ribose] results in decreased activity of CASP3 protein
|
CTD |
PMID:21220914 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Chuk
|
component of inhibitor of nuclear factor kappa B kinase complex
|
increases phosphorylation
|
ISO
|
Ribose results in increased phosphorylation of CHUK protein
|
CTD |
PMID:30101366 |
|
NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273
|
|
G
|
Ikbkb
|
inhibitor of nuclear factor kappa B kinase subunit beta
|
increases phosphorylation
|
ISO
|
Ribose results in increased phosphorylation of IKBKB protein
|
CTD |
PMID:30101366 |
|
NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911
|
|
G
|
Ins1
|
insulin 1
|
increases secretion
|
ISO
|
Ribose results in increased secretion of INS1 protein
|
CTD |
PMID:30101366 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
increases phosphorylation multiple interactions
|
ISO
|
Ribose results in increased phosphorylation of NFKBIA protein [Ribose co-treated with Glucose] results in increased phosphorylation of NFKBIA protein
|
CTD |
PMID:30101366 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Oat
|
ornithine aminotransferase
|
multiple interactions
|
EXP
|
Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]
|
CTD |
PMID:2827574 |
|
NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:196,777,975...196,797,754
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions increases phosphorylation
|
ISO
|
[Ribose co-treated with Glucose] affects the localization of RELA protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]]; Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein] Ribose results in increased phosphorylation of RELA protein
|
CTD |
PMID:30101366 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
|
G
|
Taldo1
|
transaldolase 1
|
increases abundance
|
ISO
|
TALDO1 gene mutant form results in increased abundance of ribose-5-phosphate
|
CTD |
PMID:19436114 |
|
NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535
|
|
|
G
|
Hsdl2
|
hydroxysteroid dehydrogenase like 2
|
multiple interactions
|
ISO
|
[decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein
|
CTD |
PMID:25526675 |
|
NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798
|
|
G
|
Pecr
|
peroxisomal trans-2-enoyl-CoA reductase
|
multiple interactions
|
ISO
|
[decanoyl-coenzyme A co-treated with NADP] binds to PECR protein
|
CTD |
PMID:25526675 |
|
NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:81,347,173...81,375,806
|
|
|
G
|
Acot4
|
acyl-CoA thioesterase 4
|
affects hydrolysis
|
ISO
|
ACOT4 protein affects the hydrolysis of glutaryl-coenzyme A
|
CTD |
PMID:16141203 |
|
NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:109,399,578...109,405,138
|
|
G
|
Acot8
|
acyl-CoA thioesterase 8
|
affects hydrolysis
|
ISO
|
ACOT8 protein affects the hydrolysis of glutaryl-coenzyme A
|
CTD |
PMID:16141203 |
|
NCBI chr 3:173,950,530...173,962,188
Ensembl chr 3:173,950,531...173,962,570
|
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP
|
Guanosine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]
|
CTD |
PMID:25174304 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Eif4e
|
eukaryotic translation initiation factor 4E
|
affects binding multiple interactions
|
ISO
|
Guanosine analog binds to EIF4E protein Guanosine analog inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Guanosine analog inhibits the reaction [RNA Caps binds to EIF4E protein]
|
CTD |
PMID:27592390 |
|
NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105
|
|
G
|
Glul
|
glutamate-ammonia ligase
|
multiple interactions
|
ISO
|
[Guanosine co-treated with Ketamine] results in increased activity of GLUL protein
|
CTD |
PMID:36878458 |
|
NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions
|
ISO
|
Guanosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]
|
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Impdh2
|
inosine monophosphate dehydrogenase 2
|
decreases expression
|
EXP
|
Guanosine results in decreased expression of IMPDH2 mRNA
|
CTD |
PMID:11145582 |
|
NCBI chr 8:118,135,204...118,139,892
Ensembl chr 8:118,135,262...118,139,873
|
|
G
|
Kras
|
KRAS proto-oncogene, GTPase
|
multiple interactions
|
ISO
|
Guanosine inhibits the reaction [tiazofurin results in decreased expression of KRAS]
|
CTD |
PMID:9381980 |
|
NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
Guanosine results in increased phosphorylation of and results in increased activity of MAPK1 protein
|
CTD |
PMID:18456249 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO
|
Guanosine results in increased phosphorylation of and results in increased activity of MAPK3 protein
|
CTD |
PMID:18456249 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions
|
ISO
|
Guanosine inhibits the reaction [tiazofurin results in decreased expression of MYC]
|
CTD |
PMID:9381980 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Slc1a2
|
solute carrier family 1 member 2
|
multiple interactions
|
ISO
|
[Guanosine co-treated with Ketamine] results in increased expression of SLC1A2 protein
|
CTD |
PMID:36878458 |
|
NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249
|
|
G
|
Slc29a1
|
solute carrier family 29 member 1
|
multiple interactions
|
ISO EXP
|
Guanosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]
|
CTD |
PMID:9353301 PMID:11085929 |
|
NCBI chr 9:22,897,099...22,911,640
Ensembl chr 9:22,902,471...22,914,620
|
|
G
|
Slc29a2
|
solute carrier family 29 member 2
|
multiple interactions
|
ISO
|
Guanosine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine]
|
CTD |
PMID:11085929 |
|
NCBI chr 1:211,756,588...211,764,561
Ensembl chr 1:211,757,000...211,764,560
|
|
G
|
Slc29a3
|
solute carrier family 29 member 3
|
affects transport
|
ISO
|
SLC29A3 protein affects the transport of Guanosine
|
CTD |
PMID:19164483 |
|
NCBI chr20:29,191,086...29,228,299
Ensembl chr20:29,191,127...29,228,299
|
|
G
|
Tp53bp1
|
tumor protein p53 binding protein 1
|
multiple interactions
|
ISO
|
Guanosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]
|
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747
|
|
G
|
Upp1
|
uridine phosphorylase 1
|
increases metabolic processing
|
ISO
|
UPP1 protein results in increased metabolism of Guanosine
|
CTD |
PMID:15772079 |
|
NCBI chr14:88,023,155...88,043,036
Ensembl chr14:88,023,351...88,043,034
|
|
|
G
|
Pecr
|
peroxisomal trans-2-enoyl-CoA reductase
|
multiple interactions
|
ISO
|
[hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein
|
CTD |
PMID:25526675 |
|
NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:81,347,173...81,375,806
|
|
|
G
|
Ada
|
adenosine deaminase
|
decreases abundance increases abundance
|
ISO
|
ADA alternative form results in decreased abundance of Inosine ADA protein results in increased abundance of Inosine
|
CTD |
PMID:16221767 |
|
NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293
|
|
G
|
App
|
amyloid beta precursor protein
|
multiple interactions
|
ISO
|
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine]
|
CTD |
PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
G
|
Faslg
|
Fas ligand
|
increases expression
|
ISO
|
Inosine results in increased expression of FASLG protein
|
CTD |
PMID:16419169 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions
|
ISO
|
Inosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]
|
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Psen1
|
presenilin 1
|
multiple interactions
|
ISO
|
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine]
|
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189
|
|
G
|
Slc29a1
|
solute carrier family 29 member 1
|
multiple interactions
|
ISO EXP
|
Inosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]
|
CTD |
PMID:9353301 PMID:11085929 |
|
NCBI chr 9:22,897,099...22,911,640
Ensembl chr 9:22,902,471...22,914,620
|
|
G
|
Slc29a2
|
solute carrier family 29 member 2
|
multiple interactions
|
ISO
|
Inosine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine]
|
CTD |
PMID:11085929 |
|
NCBI chr 1:211,756,588...211,764,561
Ensembl chr 1:211,757,000...211,764,560
|
|
G
|
Tp53bp1
|
tumor protein p53 binding protein 1
|
multiple interactions
|
ISO
|
Inosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]
|
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747
|
|
|
G
|
Kat2b
|
lysine acetyltransferase 2B
|
affects binding
|
ISO
|
isobutyryl-coenzyme A binds to KAT2B protein
|
CTD |
PMID:28077572 |
|
NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616
|
|
|
G
|
Gsta1
|
glutathione S-transferase alpha 1
|
multiple interactions
|
ISO
|
lauroyl-coenzyme A binds to and results in decreased activity of GSTA1 protein
|
CTD |
PMID:10542059 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528
|
|
G
|
Hsdl2
|
hydroxysteroid dehydrogenase like 2
|
multiple interactions
|
ISO
|
[lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein
|
CTD |
PMID:25526675 |
|
NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798
|
|
G
|
Pecr
|
peroxisomal trans-2-enoyl-CoA reductase
|
multiple interactions
|
ISO
|
[lauroyl-coenzyme A co-treated with NADP] binds to PECR protein
|
CTD |
PMID:25526675 |
|
NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:81,347,173...81,375,806
|
|
|
G
|
Mlycd
|
malonyl-CoA decarboxylase
|
multiple interactions
|
ISO
|
PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A]
|
CTD |
PMID:14641110 |
|
NCBI chr19:64,356,582...64,372,447
Ensembl chr19:64,356,223...64,372,446
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A]
|
CTD |
PMID:14641110 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
|
G
|
Echs1
|
enoyl-CoA hydratase, short chain 1
|
increases abundance
|
ISO
|
ECHS1 gene mutant form results in increased abundance of methacrylyl-coenzyme A
|
CTD |
PMID:25125611 |
|
NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506
|
|
G
|
Hibch
|
3-hydroxyisobutyryl-CoA hydrolase
|
increases abundance
|
ISO
|
HIBCH gene mutant form results in increased abundance of methacrylyl-coenzyme A
|
CTD |
PMID:25125611 |
|
NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:56,082,091...56,161,886
|
|
|
G
|
Dbi
|
diazepam binding inhibitor
|
affects binding
|
ISO
|
S-tetradecanoyl-coenzyme A binds to DBI protein
|
CTD |
PMID:17044054 |
|
NCBI chr13:33,794,231...33,802,632
Ensembl chr13:33,759,845...33,821,450
|
|
G
|
Gsta1
|
glutathione S-transferase alpha 1
|
multiple interactions
|
ISO
|
S-tetradecanoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein
|
CTD |
PMID:10542059 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
S-tetradecanoyl-coenzyme A binds to and results in increased activity of PPARA protein
|
CTD |
PMID:11139385 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
|
G
|
Adam17
|
ADAM metallopeptidase domain 17
|
decreases expression multiple interactions
|
ISO
|
N(6),N(6)-dimethyladenosine results in decreased expression of ADAM17 protein N(6),N(6)-dimethyladenosine inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein]
|
CTD |
PMID:36558177 |
|
NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:46,601,583...46,649,344
|
|
G
|
Bsg
|
basigin
|
decreases expression
|
ISO
|
N(6),N(6)-dimethyladenosine results in decreased expression of BSG protein
|
CTD |
PMID:36574092 |
|
NCBI chr 7:10,643,788...10,651,005
Ensembl chr 7:10,643,789...10,651,005
|
|
|
G
|
Adora2b
|
adenosine A2B receptor
|
affects response to substance
|
ISO
|
ADORA2B protein affects the susceptibility to Adenosine-5'-(N-ethylcarboxamide)
|
CTD |
PMID:16920807 |
|
NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091
|
|
G
|
Adora3
|
adenosine A3 receptor
|
affects binding
|
ISO
|
Adenosine-5'-(N-ethylcarboxamide) binds to ADORA3 protein
|
CTD |
PMID:21186795 |
|
NCBI chr 2:196,077,042...196,080,686
Ensembl chr 2:196,077,042...196,080,686
|
|
G
|
Casp1
|
caspase 1
|
increases activity
|
EXP
|
Adenosine-5'-(N-ethylcarboxamide) results in increased activity of CASP1 mRNA; Adenosine-5'-(N-ethylcarboxamide) results in increased activity of CASP1 protein
|
CTD |
PMID:21832250 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
increases secretion
|
ISO
|
Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of CCL2 protein
|
CTD |
PMID:17696452 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ephx2
|
epoxide hydrolase 2
|
increases response to substance
|
ISO
|
EPHX2 gene mutant form results in increased susceptibility to Adenosine-5'-(N-ethylcarboxamide)
|
CTD |
PMID:23152114 |
|
NCBI chr15:44,465,447...44,503,157
Ensembl chr15:44,465,448...44,503,160
|
|
G
|
Gna11
|
G protein subunit alpha 11
|
decreases expression multiple interactions
|
EXP
|
Adenosine-5'-(N-ethylcarboxamide) results in decreased expression of GNA11 protein Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Fluoxetine results in decreased expression of GNA11 protein]
|
CTD |
PMID:21712787 |
|
NCBI chr 7:8,814,285...8,828,628
Ensembl chr 7:8,814,327...8,830,558
|
|
G
|
Gnaq
|
G protein subunit alpha q
|
decreases expression multiple interactions
|
EXP
|
Adenosine-5'-(N-ethylcarboxamide) results in decreased expression of GNAQ protein Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Fluoxetine results in decreased expression of GNAQ protein]
|
CTD |
PMID:21712787 |
|
NCBI chr 1:222,852,453...223,098,754
Ensembl chr 1:222,852,097...223,126,742
|
|
G
|
Il13
|
interleukin 13
|
increases secretion
|
ISO
|
Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of IL13 protein
|
CTD |
PMID:17696452 |
|
NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483
|
|
G
|
Sftpb
|
surfactant protein B
|
increases secretion multiple interactions
|
EXP ISO
|
Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPB protein Ro 31-8220 inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPB protein]
|
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:105,917,578...105,927,646
|
|
G
|
Sftpc
|
surfactant protein C
|
increases secretion multiple interactions
|
ISO EXP
|
Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPC protein Ro 31-8220 inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPC protein]
|
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr15:52,006,274...52,009,324
Ensembl chr15:52,006,283...52,009,475
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; ZM 241385 inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]
|
CTD |
PMID:21538184 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfsf11
|
TNF superfamily member 11
|
increases expression
|
EXP
|
Adenosine-5'-(N-ethylcarboxamide) results in increased expression of TNFSF11 mRNA; Adenosine-5'-(N-ethylcarboxamide) results in increased expression of TNFSF11 protein
|
CTD |
PMID:29649498 |
|
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479
|
|
G
|
Txnip
|
thioredoxin interacting protein
|
increases activity
|
EXP
|
Adenosine-5'-(N-ethylcarboxamide) results in increased activity of TXNIP mRNA
|
CTD |
PMID:21832250 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions
|
ISO
|
Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA mRNA]; Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA protein]; N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA mRNA]]; N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA protein]]
|
CTD |
PMID:26311998 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
|
G
|
Gsta1
|
glutathione S-transferase alpha 1
|
multiple interactions
|
ISO
|
oleoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein
|
CTD |
PMID:10542059 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
oleoyl-coenzyme A binds to and results in increased activity of PPARA protein
|
CTD |
PMID:11139385 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
ISO
|
oleoyl-coenzyme A binds to and results in increased activity of PPARG protein
|
CTD |
PMID:11139385 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP
|
diadenosine tetraphosphate inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]
|
CTD |
PMID:19442829 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Nudt2
|
nudix hydrolase 2
|
increases hydrolysis
|
ISO
|
NUDT2 protein results in increased hydrolysis of diadenosine tetraphosphate
|
CTD |
PMID:20533549 |
|
NCBI chr 5:61,424,176...61,439,018
Ensembl chr 5:61,424,053...61,439,015
|
|
G
|
Th
|
tyrosine hydroxylase
|
multiple interactions
|
EXP
|
diadenosine tetraphosphate inhibits the reaction [Methamphetamine results in decreased expression of TH protein]
|
CTD |
PMID:19442829 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227
|
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
multiple interactions
|
ISO
|
P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein]
|
CTD |
PMID:15684079 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Nudt11
|
nudix hydrolase 11
|
multiple interactions increases metabolic processing
|
ISO
|
[NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of adenosine 5'-tetraphosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; manganese chloride promotes the reaction [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate]
|
CTD |
PMID:12121577 |
|
NCBI chr X:18,998,587...19,005,208
Ensembl chr X:18,998,461...19,005,208
|
|
G
|
Sirt1
|
sirtuin 1
|
multiple interactions
|
EXP
|
P(1),P(5)-di(adenosine-5'-)pentaphosphate analog inhibits the reaction [[Nitrites co-treated with Oxygen deficiency] results in increased expression of SIRT1 mRNA]
|
CTD |
PMID:22892143 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
|
G
|
Nudt11
|
nudix hydrolase 11
|
multiple interactions increases metabolic processing
|
ISO
|
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate; [NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate
|
CTD |
PMID:12121577 |
|
NCBI chr X:18,998,587...19,005,208
Ensembl chr X:18,998,461...19,005,208
|
|
|
G
|
Acox1
|
acyl-CoA oxidase 1
|
increases metabolic processing multiple interactions
|
ISO
|
ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A [ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide; benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Dehydroepiandrosterone promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Tetrachlorodibenzodioxin promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]
|
CTD |
PMID:10497882 |
|
NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,905,083...101,930,136
|
|
G
|
Ces1d
|
carboxylesterase 1D
|
increases hydrolysis
|
EXP
|
CES1 protein results in increased hydrolysis of Palmitoyl Coenzyme A
|
CTD |
PMID:8611161 |
|
NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449
|
|
G
|
Cpt1a
|
carnitine palmitoyltransferase 1A
|
multiple interactions
|
EXP
|
valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Palmitoyl Coenzyme A]
|
CTD |
PMID:19854160 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326
|
|
G
|
Dgat1
|
diacylglycerol O-acyltransferase 1
|
multiple interactions
|
ISO
|
DGAT1 protein results in increased metabolism of [Palmitoyl Coenzyme A co-treated with Vitamin A]
|
CTD |
PMID:16214399 |
|
NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016
|
|
G
|
Gsta1
|
glutathione S-transferase alpha 1
|
multiple interactions
|
ISO
|
Palmitoyl Coenzyme A binds to and results in decreased activity of GSTA1 protein
|
CTD |
PMID:10542059 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528
|
|
G
|
Hnf4a
|
hepatocyte nuclear factor 4, alpha
|
decreases expression
|
ISO
|
Palmitoyl Coenzyme A results in decreased expression of HNF4A mRNA; Palmitoyl Coenzyme A results in decreased expression of HNF4A protein
|
CTD |
PMID:17992261 |
|
NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:172,606,220...172,667,758
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
Palmitoyl Coenzyme A binds to and results in increased activity of PPARA protein Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
|
CTD |
PMID:11139385 PMID:18812576 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
ISO
|
Palmitoyl Coenzyme A binds to and results in increased activity of PPARG protein
|
CTD |
PMID:11139385 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Shbg
|
sex hormone binding globulin
|
decreases expression
|
ISO
|
Palmitoyl Coenzyme A results in decreased expression of SHBG mRNA; Palmitoyl Coenzyme A results in decreased expression of SHBG protein
|
CTD |
PMID:17992261 |
|
NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,831,718...54,838,760
|
|
|
G
|
Gsta1
|
glutathione S-transferase alpha 1
|
multiple interactions
|
ISO
|
stearoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein
|
CTD |
PMID:10542059 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
stearoyl-coenzyme A binds to and results in increased activity of PPARA protein
|
CTD |
PMID:11139385 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
ISO
|
stearoyl-coenzyme A binds to and results in increased activity of PPARG protein
|
CTD |
PMID:11139385 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
|
G
|
Acot4
|
acyl-CoA thioesterase 4
|
affects hydrolysis
|
ISO
|
ACOT4 protein affects the hydrolysis of succinyl-coenzyme A
|
CTD |
PMID:16141203 |
|
NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:109,399,578...109,405,138
|
|
|
G
|
Kras
|
KRAS proto-oncogene, GTPase
|
multiple interactions decreases expression
|
ISO
|
Guanosine inhibits the reaction [tiazofurin results in decreased expression of KRAS]
|
CTD |
PMID:9381980 |
|
NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
decreases expression multiple interactions
|
ISO
|
tiazofurin results in decreased expression of MYC Guanosine inhibits the reaction [tiazofurin results in decreased expression of MYC]
|
CTD |
PMID:9381980 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
|
G
|
P2rx1
|
purinergic receptor P2X 1
|
affects binding
|
EXP
|
TNP-ATP binds to P2rx1 protein
|
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:58,117,107...58,132,167
Ensembl chr10:58,117,088...58,132,164
|
|
G
|
P2rx2
|
purinergic receptor P2X 2
|
multiple interactions
|
EXP
|
TNP-ATP binds to P2rx2 protein; TNP-ATP inhibits the reaction [ATP binds to P2rx2 protein] in transfected glial cells
|
RGD |
PMID:16388598 |
RGD:1642662 |
NCBI chr12:51,999,107...52,002,627
Ensembl chr12:51,999,372...52,002,627
|
|
G
|
P2rx5
|
purinergic receptor P2X 5
|
affects transport
|
EXP
|
TNP-ATP affects transport ion flux of P2rx5 receptor
|
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:58,276,329...58,291,108
Ensembl chr10:58,276,257...58,287,935
|
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
EXP
|
xanthosine inhibits the reaction [Palmitates results in decreased phosphorylation of AKT1 protein]
|
CTD |
PMID:36627075 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Foxo1
|
forkhead box O1
|
multiple interactions
|
EXP
|
xanthosine inhibits the reaction [Palmitates results in decreased phosphorylation of FOXO1 protein]
|
CTD |
PMID:36627075 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419
|
|
G
|
G6pc1
|
glucose-6-phosphatase catalytic subunit 1
|
multiple interactions
|
EXP
|
xanthosine inhibits the reaction [Palmitates results in increased expression of G6PC1 protein]
|
CTD |
PMID:36627075 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033
|
|
G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
multiple interactions
|
EXP
|
xanthosine inhibits the reaction [Palmitates results in decreased phosphorylation of GSK3B protein]
|
CTD |
PMID:36627075 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249
|
|
G
|
Gys1
|
glycogen synthase 1
|
multiple interactions
|
EXP
|
xanthosine inhibits the reaction [Palmitates results in increased phosphorylation of GYS1 protein]
|
CTD |
PMID:36627075 |
|
NCBI chr 1:105,051,916...105,071,763
Ensembl chr 1:105,051,961...105,072,419
|
|
G
|
Pck2
|
phosphoenolpyruvate carboxykinase 2 (mitochondrial)
|
multiple interactions
|
EXP
|
xanthosine inhibits the reaction [Palmitates results in increased expression of PCK2 protein]
|
CTD |
PMID:36627075 |
|
NCBI chr15:32,997,853...33,006,691
Ensembl chr15:32,997,834...33,016,864
|
|